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Cellular Plasticity And Heterogeneity: Implications In Tumor Cell Invasion And 
Metastasis 
Abstract 
The existence of heterogenous subpopulations of cells in cancer has been shown to arise via natural 
evolution or through movement between cellular states collectively known as “cellular plasticity.” This 
heterogeneity and plasticity are critical drivers of phenotypic diversity culminating in many facets of 
disease progression, such as metastasis. While the existence of heterogeneity and cellular plasticity are 
well accepted, the molecular underpinnings and functional outcomes, such as metastasis, of these 
populations remains limited. Here, we first investigated a form of cellular plasticity known as epithelial-to-
mesenchymal transition (EMT) and dissect the molecular mechanisms of a recently described partial 
EMT (P-EMT) state operating in vivo in a mouse model of pancreatic ductal adenocarcinoma (PDAC), 
whereby tumor cells lose their epithelial state through a post-translational mechanism. This is distinct 
from complete EMT (C-EMT), which achieves the transition transcriptionally, through regulation of a 
complex hierarchy of EMT transcription factors (EMT-TFs). We report that prolonged calcium signaling in 
carcinoma cells induces a P-EMT phenotype characterized by the internalization of membranous E-
cadherin (ECAD) and an increase in cellular migration and invasion. These effects can be recapitulated by 
signaling through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through the 
downstream activation of calmodulin. These results implicate calcium signaling as a potent driver of 
epithelial-mesenchymal plasticity in cancer cells that may be important for the metastatic cascade. We 
subsequently investigated other potential mechanisms of metastasis that may occur as tumors evolve de 
novo. Specifically, we analyzed paired primary tumors and metastases using a multi-fluorescent lineage-
labeled mouse model of PDAC. Genomic and transcriptomic analysis revealed, for the first time, an 
association between metastatic burden and amplification of MYC. Mechanistically, we found that MYC 
promotes metastasis by recruiting tumor associated macrophages (TAMs), leading to greater 
bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was 
associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically 
in metastatic patients. These results implicate MYC activity as a major determinant of metastatic burden 
in advanced PDAC. Thus, using novel mouse models of PDAC, we identified key pathways, genetic and 
non-genetic, that regulate cellular plasticity and lead to increased invasion and metastatic spread. The 
identification of these pathways and regulators represent an avenue for combating the most lethal 
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CELLULAR PLASTICITY AND HETEROGENEITY: IMPLICATIONS IN TUMOR CELL 
INVASION AND METASTASIS 
 
Robert J. Norgard 
Ben Z. Stanger 
 
The existence of heterogenous subpopulations of cells in cancer has been shown to arise 
via natural evolution or through movement between cellular states collectively known as “cellular 
plasticity.” This heterogeneity and plasticity are critical drivers of phenotypic diversity culminating 
in many facets of disease progression, such as metastasis. While the existence of heterogeneity 
and cellular plasticity are well accepted, the molecular underpinnings and functional outcomes, 
such as metastasis, of these populations remains limited. Here, we first investigated a form of 
cellular plasticity known as epithelial-to-mesenchymal transition (EMT) and dissect the molecular 
mechanisms of a recently described partial EMT (P-EMT) state operating in vivo in a mouse model 
of pancreatic ductal adenocarcinoma (PDAC), whereby tumor cells lose their epithelial state 
through a post-translational mechanism. This is distinct from complete EMT (C-EMT), which 
achieves the transition transcriptionally, through regulation of a complex hierarchy of EMT 
transcription factors (EMT-TFs). We report that prolonged calcium signaling in carcinoma cells 
induces a P-EMT phenotype characterized by the internalization of membranous E-cadherin 
(ECAD) and an increase in cellular migration and invasion. These effects can be recapitulated by 
signaling through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through 
the downstream activation of calmodulin. These results implicate calcium signaling as a potent 
driver of epithelial-mesenchymal plasticity in cancer cells that may be important for the metastatic 
cascade. We subsequently investigated other potential mechanisms of metastasis that may occur 
as tumors evolve de novo. Specifically, we analyzed paired primary tumors and metastases using 
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a multi-fluorescent lineage-labeled mouse model of PDAC. Genomic and transcriptomic analysis 
revealed, for the first time, an association between metastatic burden and amplification of MYC. 
Mechanistically, we found that MYC promotes metastasis by recruiting tumor associated 
macrophages (TAMs), leading to greater bloodstream intravasation. Consistent with these findings, 
metastatic progression in human PDAC was associated with activation of MYC signaling pathways 
and enrichment for MYC amplifications specifically in metastatic patients. These results implicate 
MYC activity as a major determinant of metastatic burden in advanced PDAC.  Thus, using novel 
mouse models of PDAC, we identified key pathways, genetic and non-genetic, that regulate cellular 
plasticity and lead to increased invasion and metastatic spread. The identification of these 
pathways and regulators represent an avenue for combating the most lethal aspects of tumor 
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CHAPTER 1: INTRODUCTION 
 
Tumor cell plasticity and epithelial to mesenchymal transition (EMT) 
 
Tumors are complex, ever changing and evolving ecosystems. Tumor cells are 
exposed to diverse metabolic conditions, signaling molecules, stromal elements, and 
therapeutic agents, which collectively form a volatile microenvironment that can fuel 
changes in the cellular phenotype. Such changes may involve genetic alterations, but they 
more commonly involve transcriptional, proteomic, or epigenetic fluctuations. The 
resulting pliability in cell state, referred to as plasticity, can facilitate multiple aspects of 
tumor progression, including tumor initiation and metastasis, immune evasion, and 
chemoresistance (Yuan et al, 2019). Consequently, elucidating the mechanisms by which 
cancer cells exploit plasticity to cope with selective pressures may lead to novel 
therapeutic opportunities. 
One of the most well-well-known examples of cellular plasticity that occurs in 
normal development is a process known as epithelial-to-mesenchymal transition (EMT) – 
or the reverse mesenchymal-to-epithelial transition (MET). In development, EMT can be 
induced by any of several pleiotropic and evolutionarily conserved signaling factors (e.g., 
TGFβ, EGF, HGF, NOTCH, FGF, and WNT ligands), which initiate a signaling cascade 
leading to the expression of one or more so-called EMT transcription factors (EMT-TFs). 
These EMT-TFs—which include SNAIL, TWIST, ZEB, and PRRX family members—
function as transcriptional activators and repressors, whose principal function is the 
repression of genes whose products are necessary for maintenance of the epithelial state 
(i.e., proteins comprising junctional complexes and epithelial intermediate filaments). Loss 
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of E-cadherin, a key component of epithelial adherens junctions, is considered a hallmark 
of EMT. In parallel, EMT involves the induction of genes associated with the mesenchymal 
state, including the mesenchymal intermediate filament protein vimentin and components 
of the extracellular matrix (ECM) (Lamouille et al, 2014). 
While critical for normal embryonic development, EMT is also frequently observed 
in many cancers and has been associated with invasion, metastasis, and poorer prognosis. 
In carcinomas (cancers that arise from cells of epithelial origin), the manifestation of an 
EMT program is reflected in a tumor's grade. High-grade disease is aggressive and 
marked by an obliteration of normal tissue structure and architecture. Such tumors—often 
referred to as “poorly differentiated”—bear the histopathologic and molecular hallmarks of 
EMT. By contrast, low-grade disease is characterized by a “moderately-to-well-
differentiated” histology that reflects the cancer cells' retention of an epithelial phenotype. 
Across human cancer, high-grade (poorly differentiated) tumors carry a worse prognosis 
than low-grade (well-differentiated) tumors. Importantly, such grading schemes describe 
the dominant cellular phenotype within a tumor and thus fail to capture the dynamic 
plasticity that exists. Rather than being wholly comprised of cancer cells with either a 
mesenchymal or an epithelial phenotype, most tumor cells exist in equilibrium between 
the two states. In poorly differentiated tumors, this equilibrium is shifted to the 
mesenchymal state, whereas in well-differentiated tumors it is shifted to the epithelial state. 
Thus, it is the relative abundance of cells in either state that dictates tumor grade. Although 
the determinants of “equilibrium constants” governing epithelial–mesenchymal plasticity 
in tumors are unknown, it is likely that genetic and epigenetic factors existing before or 
acquired during tumor progression are responsible. It has also been shown that the “cell 
of origin” from which a tumor arises plays an important role in shaping tumor histology, 
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and it likely also influences the epithelial–mesenchymal “set point” of a tumor (Latil et al, 
2017). 
Although most studies of EMT mechanisms have focused on transcriptional 
regulatory programs, post-transcriptional programs also regulate the epithelial phenotype. 
During development, the abundance or localization of E-cadherin—a critical component 
of epithelial adherens junctions—can be lost through one of several post-transcriptional 
mechanisms. These include p38-mediated regulation of E-cadherin protein levels during 
mouse gastrulation (Zohn et al, 2006; Hirano et al, 2008; Lee et al, 2007), EGF-mediated 
endocytosis of E-cadherin during zebrafish epiboly (Song et al, 2013), and transcription-
independent regulation of E-cadherin by the GATA factor Serpent 
during Drosophila endoderm development (Campbell et al, 2011). As I will show later in 
my thesis, post-transcriptional programs can also mediate cancer-associated EMT, where 
a significant percentage of carcinoma cells lose their epithelial phenotype through 
internalization of epithelial proteins rather than transcriptional repression (Aiello et al, 
2018). 
EMT is rarely observed in adult tissues under homeostatic conditions, but it can 
emerge upon injury or stress and is a common feature of malignancy. Many of the factors 
shown to induce EMT during embryogenesis or under in vitro settings are present in 
tumors, including a variety of soluble growth factors and matrix components, hypoxia, 
inflammation, and increased tissue stiffness (Lamouille et al, 2014). The best studied of 
these inducers is TGFβ, which can induce EMT in a wide assortment of cultured 
carcinoma cells. TGFβ signaling induces the formation of an active SMAD complex, which 
partners with other DNA binding proteins to induce the transcription of EMT-TFs such as 
SNAIL, TWIST, and ZEB (Xu et al, 2009). But what particular (or culmination of) factors 
remain important to induce EMT in vivo remains unknown. 
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Importantly, EMT likely does not represent a single defined program. Rather, it 
encompasses a phenotypic spectrum characterized by different degrees of epithelial and 
mesenchymal features, involving a range of mechanisms. Hence, definitions of EMT have 
evolved over time to accommodate a variety of phenotypic transitions that involve some 
measurable changes in the epithelial or mesenchymal features of a cell (Nieto et al, 2016b; 
Klymkowsky & Savagner, 2009). This conceptual flexibility has also led to the recognition 
that cells having intermediate epithelial–mesenchymal phenotype—occupying a hybrid or 
“partial EMT” (P-EMT) state—have properties distinguishing them from cells with a purely 
epithelial or mesenchymal phenotype (Yang et al, 2020). Cells residing in such P-EMT 
states may simultaneously express epithelial and mesenchymal features or may have lost 
their epithelial characteristics without acquiring mesenchymal traits. Still unresolved is 
whether these intermediate states are “metastable,” suggesting an incomplete or 
intermediate step as cells transition, or whether P-EMT represents a stable state of its 
own (Jolly et al, 2016). Such partial states may facilitate the collective cell migration of 
tumor cells (Aiello et al, 2018; Lecharpentier et al, 2011; Armstrong et al, 2011), leading 
to the formation of highly metastatic circulating tumor cell clusters (Aceto et al, 2014; 
Maddipati & Stanger, 2015). For this reason, and the greater cellular plasticity possibly 
afforded by partial EMT, P-EMT states are thought to confer carcinoma cells with a higher 
degree of metastatic competence as compared with complete EMT programs (Bierie et al, 
2017), making them of great interest to study. 
Most molecular studies of epithelial–mesenchymal plasticity in the last decade 
were conducted through in vitro manipulation of cultured carcinoma cells. Thus, the 
mechanisms underlying EMT in vivo, and the functional role(s) of epithelial–mesenchymal 
plasticity as tumors evolve have been hard to pin down. One challenge impeding in 
vivo studies was the difficulty in distinguishing carcinoma cells that have undergone an 
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EMT (and hence exhibit a mesenchymal phenotype) from fibroblasts or other 
mesenchymal cells that normally populate the tumor stroma. In addition, most metastatic 
lesions were known to exhibit epithelial features, an observation that on face value 
seemed at odds with a role for EMT in metastasis (discussed below). Thus, despite long-
standing evidence for epithelial–mesenchymal plasticity in tumors (Brabletz et al, 2001; 
Savagner, 2001), the importance of EMT in cancer biology—and even its very existence—
has long been questioned (Tarin, 2005). With more recent advances in lineage-tracing 
techniques and intravital imaging, however, it has become widely accepted that cancer 
cells acquire a variety of EMT-like phenotypes during tumor progression in both model 
systems and patients with cancer (Lecharpentier et al, 2011; Rhim et al, 2012; Yu et al, 
2013; Dongre & Weinberg, 2019). 
While the existence of EMT is no longer highly disputed, the debate over EMT in 
vivo has been particularly contentious regarding metastasis. When carcinomas spread, 
they lose contact with neighboring epithelial cells. The acquisition of invasive behavior 
thus requires (by definition) that carcinoma cells remodel the tight junctions, adherens 
junctions, and other complexes that mediate their intimate intercellular connections. 
Because EMT involves a loss of epithelial characteristics and/or an acquisition of 
mesenchymal characteristics, it has emerged as the most straightforward mechanism to 
account for cancer cell invasion. Indeed, gain-of-function approaches have clearly shown 
that EMT is sufficient to enhance invasion and metastasis. For example, overexpression 
of certain EMT-TFs (e.g., SNAIL1, TWIST1, ZEB1) in epithelial carcinoma cells promotes 
the loss of E-cadherin, acquisition of a spindle-like mesenchymal morphology, and 
enhanced migratory and invasive behavior in vitro (Cano et al, 2000; Batlle et al, 2000; 
Yang et al, 2004). By contrast, loss-of-function studies have been more difficult to interpret 
and suggest that tissue- and context-dependent differences dictate the molecular 
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mechanisms underlying EMT in a given tumor (Ye et al, 2015). For example, deleting 
either SNAIL1 or TWIST1 in a spontaneous mouse model of PDAC had minimal effect on 
metastasis (Zheng et al, 2015), whereas ZEB1 ablation in a similar model drastically 
reduced colonization, invasion, and metastasis (Krebs et al, 2017). Taken together, these 
results suggest that distinct and overlapping EMT inducers—including both transcriptional 
and posttranscriptional mechanisms—play distinct roles in metastatic spread. 
 
Tumor cell heterogeneity and the potential for subclones to acquire metastatic 
capabilities 
 
With advances in molecular diagnostics and sequencing techniques, the genetic 
make-up of tumors has been unraveled. The process from normal to malignant is 
understood to occur through sequential acquisitions of mutations or alterations that lead 
to uncontrolled proliferation, circumvention of growth suppressors and death programs, 
and evasion of the immune system—ultimately culminating in programs leading to 
invasion and metastasis (Hanahan & Weinberg, 2011). Although portrayed to occur in a 
step wise fashion, the actual events that occur are rather stochastic and can occur in a 
variety of scenarios. And even after cancers arise, this process continues to flourish as 
tumor cells begin to experience certain limitations and are forced to adapt to situations 
such as lack of nutrients and therapy. 
Tumor heterogeneity can be divided into two categories: intertumoral and 
intratumoral heterogeneity.  Intertumoral heterogeneity refers to differences in tumors of 
the same histological type between different patients. This is typically thought to arise from 
patient variations that occur due to germline mutations, somatic mutations, and 
environmental factors. The idea of personalized medicine has really shaped our 
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appreciation for intertumoral heterogeneity. For example, this can be exemplified in 
patients with oncogenic drivers such as BRCA mutations that are sensitive to PARP 
inhibitors (Farmer et al, 2005). Intratumoral heterogeneity refers to difference within a 
patient and can occur as spatial heterogeneity, where different subpopulations of tumors 
exist across a tumor, or temporal heterogeneity, where tumor cells change over time 
(either genetically or non-genetically). Temporal heterogeneity occurs as tumor cells 
become plastic either as a result of a natural progression or a result of a selective pressure 
that targets only a small subset of tumor cells. The result can be a highly aggressive 
subpopulation of tumors that either is resistant to therapies or has acquired the ability to 
metastasize (Dagogo-Jack & Shaw, 2018). 
Metastasis is the hallmark of cancer that constitutes the primary cause of death 
for >90% of cancer patients (Steeg, 2006). The metastatic process and the development 
of metastases is a highly inefficient process. It requires cancer cells to leave their primary 
site, survive circulation in the bloodstream, exit the bloodstream, acclimate to a foreign 
environment and begin to grow. Only a select number of cells are capable of migrating out 
from the primary tumor and the ones that make it into circulation are now exposed to harsh 
conditions while in circulation. While this is well known, what drives these select cancer 
cells to metastasize and the potential mechanisms employed by tumor cells to survive 
metastasize remains poorly understood (Mehlen & Puisieux, 2006). In their seminal 
perspective, Hanahan and Weinberg specify that “activating invasion and metastasis” is a 
hallmark of cancer (Hanahan & Weinberg, 2011). But how this comes about in tumors is 
rather unknown. One idea is that some tumor cells themselves exhibit genome 
instability(Hanahan & Weinberg, 2011; Carter et al, 2006; Waddell et al, 2015). This can 
range from either single base pair substitutions to entire genome amplifications and is 
thought to be critical to the progression of cancers. The source of this instability is thought 
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to occur from something as simple as errors occurring under unregulated growth to 
exposure to mutagens to mistakes made during DNA repair processes. Regardless of the 
how the instability transpires, this genome instability results in the formation of clonally 
diverse tumor cells potentially leading to the emergence of more competitive sub-
clones(De Bruin et al, 2014; Campbell et al, 2010). 
This idea of clonal evolution or the selective hypothesis was first postulated by 
Peter Nowell and is based on the idea that a mutation initiates malignancy which confers 
an initial growth advantage (Nowell, 1976). As expanding cells continue, genome 
instability creates additional subclones that begin to become subjected to pressures 
creating a survival of the fittest scenario and resulting in genetically heterogenous 
subpopulations. However, the notion that clonal populations must always be in competition 
has been challenged by suggesting that there is a cooperation and possible necessity for 
different subclones during tumor progression and metastasis. Nonetheless, genomic 
instability is thought to eventually lead to the presence of a subclone with the inherent 
ability to metastasize (Cleary et al, 2014; Maddipati & Stanger, 2015). 
In tumors, genome studies have comprehensively catalogued key mutations that 
are responsible for tumor development. For example, in pancreatic ductal 
adenocarcinoma (PDAC), KRAS, TRP53, CDKN2A, and SMAD4 are suggested to play a 
role in tumor development, paving the path for genomic investigations of metastatic 
disease and the potential identification of metastasis promoting alterations (Kleeff et al, 
2016). Indeed, recent sequencing studies and functional experiments in mouse models 
have found genomic amplifications in KRAS to be associated with the development from 
non-metastatic to metastatic disease (Chan-Seng-Yue et al, 2020; Mueller et al, 2018). 
Other studies using mouse models of various cancers suggest that other genes are 
metastatic drivers (e.g. MYC, GATAD2B, BLIMP1) (Chiou et al, 2017; Grzeskowiak et al, 
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2018; Wolfer & Ramaswamy, 2011; Rapp et al, 2009)  adding to an increasing growing 
list of putative driver genes identified from massive sequencing efforts (Jamal-Hanjani et 
al, 2017; Bailey et al, 2018). 
Although these studies have suggested the potential for genetic drivers of 
metastasis, and from a genetic point of view, it would seem plausible that sequential 
additional mutations would lead to metastasis, extensive studies have not been able to 
explicitly define evidence for driver mutations. In addition, heterogeneity has been 
observed in metastatic lesions suggesting that many types of cells are capable of 
metastasis, leaving further doubt. Recent endeavors have thus focused on studying 
putative epigenetic drivers and the outcomes from active signaling pathways on 
rearranging a more permissive tumor microenvironment for metastasis. In fact, several 
studies have indicated that the presence of a certain cell type, (neutrophils, macrophages, 
etc) can strongly influence metastatic behavior (Wculek & Malanchi, 2015; Harney et al, 
2015). Thus, understanding the interplay between genetic alterations that influence 
metastatic behavior and the tumor biology that promotes it – in a cell autonomous and/or 
non-cell autonomous manner – is crucial for understanding metastasis and critical for the 
development of more effective treatments. 
 
Pancreatic cancer, invasion, metastasis and the problem 
 
Pancreatic cancer is a uniformly lethal disease with a dismal overall prognosis that 
has not significantly changed for many decades (five-year survival rate of less than 10%). 
It is predicted to soon be the second leading cause of cancer related death in the USA 
(Rahib et al, 2014). The reasons for this poor prognosis are multifactorial. It is usually 
diagnosed at advanced stages, often resulting from a lack of specific symptoms and 
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difficulties in non-invasive imaging for detection. Pancreatic cancer is aggressive, with 
local and distant invasion and metastasis present, impeding curative surgical resection in 
the majority of patients. Underlying this disease are few prevalent genetic mutations (the 
most common are KRAS, TRP53, CDKN2A, and SMAD4), none of which are currently 
targetable (Kleeff et al, 2016). The treatments that are available are rather ineffective since 
pancreatic cancers are complex at the genome, epigenetic, and metabolic levels. 
Furthermore, a complex interplay between tumor cells and the normal infiltrating tumor 
cells further inhibits therapeutic intervention. Thus, pancreatic cancer is a disease needed 
of further understanding. 
Metastasis remains the main reason for death across cancer types and pancreatic 
cancer is no exception with nearly 80% of patients presenting with metastasis (Lambert et 
al, 2017). While metastasis is classically thought to be a late event in tumor progression, 
brought on by increasing mutations, the use of genetically engineered mouse models has 
questioned this dogma. These models have revealed that pancreatic cancer readily 
undergoes EMT, dissemination and metastasis during neoplastic transformation, 
surprisingly well before the transition to invasive carcinoma (Rhim et al, 2012). These 
studies truly highlighted the importance and relevance of the existence of EMT tumor cells 
since they are nearly impossible to distinguish from normal fibroblasts that infiltrate in 
tumor development. This is known as the desmoplastic response and in some 
instances >90% of PDAC tumors are composed of normal cells that have infiltrated. 
As mentioned above, recent studies have investigated the molecular mechanisms 
and clinical significance of EMT in vivo particularly in PDAC. While deletion of EMT-TF 
SNAIL1 or TWIST1 failed to reduce metastasis in mouse models of PDAC, the lack of 
these factors greatly impacted the response to chemotherapy (Zheng et al, 2015). In a 
different study, deletion of ZEB1, drastically reduced colonization, invasion, and 
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metastasis revealing that different transcription factors may play differing roles in EMT and 
chemoresistance in PDAC (Krebs et al, 2017). Furthermore, our sequencing effort, 
presented in chapter 2, to unbiasedly identify the underpinnings of EMT in PDAC revealed 
that a post-translational mechanism may be the main mechanism by which PDAC cells 
undergo EMT (Aiello et al, 2018), adding another level of complexity to EMT regulation in 
PDAC, warranting further investigation. 
Although EMT presents a major concern for the treatment of PDAC patients, the 
mutational landscapes and subtype heterogeneity adds to this complexity. It is now well 
accepted that histo-pathologically indistinguishable tumors often harbor substantial 
molecular differences. While the molecular pathology of pancreatic cancer is dominated 
by KRAS, TRP53, CDKN2A, and SMAD4, new sequencing efforts have brought to light 
the prevalence of other genes that are mutated at much lower rates (KDM6A, BCORL1, 
RBM10, MLL3, ARID1A, and TGFBR2 are the among the highest mutated) (refer to 
Collisson et al, 2019). The identification of these mutated genes has been useful in 
understanding tumor biology and guiding clinical decisions. For example, patients with 
BRCA1/2 mutations, that occur frequently in ovarian cancer patients but are rare in PDAC, 
have been shown to respond to PARP inhibitors, prolonging progression free survival 
(Golan et al, 2019). But in addition to genomic aberrations, transcriptional subtypes have 
also been identified. Three seminal papers (Bailey et al, 2016b; Collisson et al, 2011; 
Moffitt et al, 2015) have identified three predominate transcriptional subtypes that exist in 
PDAC: a pancreatic progenitor subtype, a squamous more aggressive subtype, and an 
immunogenic, activated stroma subtype indicative of the stroma present in the tumor. The 
existence of these subtypes has identified clear opportunities to advance therapeutic 
development being associated with different prognoses and mutations in specific genetic 
pathways. Yet, how these subtypes arise, how many exist in a given tumor and whether 
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selective pressures from treatment may alter the molecular composition seen in other 
tumors remains unknown. It is also likely that these subtypes exist in metastasis, and 
ongoing work attempts to understand this heterogeneity in metastasis. 
Based on the above introduction, this thesis aims to understand how plasticity and 
heterogeneity impact tumor cell migration, invasion and metastasis by (i) understanding 
the molecular changes that occur in epithelial plasticity in an unbiased fashion, (ii) 
determining the molecular mechanisms of the partial EMT state, and (iii) modeling 
metastatic heterogeneity found in human patients and dissect molecular and cellular 
features contributing to metastasis. The ultimate goal of this project is to vastly improve 
our understanding of basic biological processes in tumor cell plasticity and heterogeneity, 
critical for the development of tractable therapeutics for cancer patients. While the majority 
of this work is focused on pancreatic cancer, we believe that the themes and discoveries 












Chapter 1 Acknowledgements: Excerpts within chapter one are used from: Yuan S*, 
Norgard RJ*, and Stanger BZ. Cellular Plasticity in Cancer. Cancer Discovery. 2018. A 
special thanks to Salina Yuan for help writing that review.  
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CHAPTER 2: EMT SUBTYPE INFLUENCES EPITHELIAL 




Metastasis is responsible for most cancer-related deaths, and yet the cellular and 
molecular mechanisms underlying tumor cell spread remain obscure. One attractive 
model for metastatic dissemination involves epithelial-to-mesenchymal transition (EMT) 
(Ye et al, 2015). EMT has traditionally been viewed as a binary process involving a 
complete conversion from epithelial to mesenchymal state. However, it has been 
increasingly recognized that EMT also encompasses a range of hybrid states, a 
phenotype that has been referred to “partial EMT” (P-EMT). Because P-EMT is not well 
defined in molecular terms (Savagner, 2015), it is unknown whether this hybrid status 
signifies an intermediate phase during a mesenchymal transition or represents its own 
end-state. Likewise, it is unclear whether the same mechanisms of transcriptional 
repression that drive a “complete EMT” also operate during P-EMT. 
While EMT involving classical (transcription-dependent) mechanisms can give rise 
to single cells capable of crossing basement membranes and invading blood vessels, 
many tumors have been noted to exhibit “collective” migratory patterns whereby cells 
retain cell-cell contacts and activate mesenchymal programs, resulting in dissemination of 
multi-cellular tumor cell clusters (Cheung & Ewald, 2016; Friedl et al, 2012). While both 
phenomena have been observed in mouse models and clinical specimens ((Aceto et al, 
2014; Maddipati & Stanger, 2015; Jolly et al, 2017), the programs underlying these 
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differences in epithelial plasticity and cell migration – and the extent to which P-EMT 
contributes to either phenotype – remain unclear. 
In this chapter, we explore the relationship between EMT, tumor subtype, and 
invasive phenotype in vivo. We show that in a widely-used mouse model of pancreatic 
ductal adenocarcinoma (PDAC), individual tumors utilize different plasticity programs – a 
complete EMT program involving transcriptional repression and an alternative program in 
which the epithelial phenotype is lost post-transcriptionally. Tumors utilizing these 
programs are phenotypically distinguishable at a histological and transcriptional level in a 
manner that correlates with the major subtypes of human PDAC. Moreover, these 
divergent plasticity programs are associated with either single cell invasion or collective 
migration. Finally, we provide evidence that the alternative program observed in PDAC 
governs EMT in other tumor types as well. Our findings thus suggest that the mechanisms 
driving EMT in vivo may differ from the classically described transcriptional programs 
studied in vitro and indicate a link between the broad transcriptional programs that define 





KPCY tumors exhibit two distinct EMT programs 
To study the mechanism of EMT in vivo, we used the LSL-KrasG12D; P53loxP/+; Pdx1-cre; 
LSL-Rosa26YFP/YFP (KPCY) mouse model of PDAC. In KPCY mice, pancreas-specific Cre 
recombinase (Cre) activity triggers expression of a mutant KrasG12D and deletes a single 
p53 allele, leading to tumor formation over a period of 14-20 weeks. In parallel, Cre 
activates a yellow fluorescent protein (YFP) lineage label expressed in all mutated 
pancreatic epithelial cells, enabling tracking of their contribution to all stages of tumor 
progression(Rhim et al, 2012). 
Loss of the adherens junction protein E-cadherin (ECAD) is considered a hallmark 
of EMT. To assess the EMT state of KPCY tumors, we used the YFP lineage label to 
distinguish between stromal cells (which are YFP-) and tumor cells (which are YFP+) and 
looked for histological features of EMT including separation from a lumen-associated 
structure and a change in cellular architecture from a cuboidal to a spindle or fibroblast-
like morphology. As expected, most tumor cells (89% ± 11.9; mean ± SD) exhibiting 
morphological features of EMT lacked membrane ECAD staining (Chapter 2 Figure 1A). 
In addition, co-staining experiments revealed a tight correlation between the loss of 
membrane ECAD staining and the loss of staining for the tight junction protein Claudin-7 
(CLDN7) and the epithelial cell adhesion molecule (EPCAM) on YFP+ tumor cells 
(Chapter 2 Figure S1A,B). These results indicate that loss of surface E-cadherin identifies 
most tumor cells undergoing EMT in this model. 
Because EMT is typically associated with both gain of mesenchymal features and 
loss of epithelial features, we examined the ability of a series of mesenchymal markers to 
detect EMT in KPCY tumors. Using ECAD as an “anchor” epithelial marker, we co-stained 
sections for ECAD and the mesenchymal markers Zinc-finger E-box homeobox 1 (ZEB1), 
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SLUG (SNAI2), Vimentin (VIM), and Fibroblast-specific protein 1 (FSP1). Staining for 
these proteins was uncommon in YFP+ECAD+ cells (Chapter 2 Figure S1C-J), suggesting 
that loss of membranous ECAD (M-ECAD) precedes a gain of mesenchymal markers in 
most tumor cells undergoing EMT. By contrast, positive staining for these mesenchymal 
markers was observed in a third to a half of YFP+ECAD- tumor cells, although this staining 
showed a high degree of variability from tumor to tumor (Chapter 2 Figure S1C-J). Based 
on these findings, we concluded that loss of M-ECAD, rather than the gain of any single 
mesenchymal marker, would result in the identification of most cells exhibiting 
morphological features of EMT in this model. 
We used fluorescence-activated cell sorting (FACS) to isolate M-ECAD+ 
(epithelial) and M-ECAD- (mesenchymal) YFP+ cancer cells from 11 primary KPCY tumors 
for RNA sequencing (Chapter 2 Figures 1B and S2A). We confirmed accurate sorting by 
visual inspection and ruled out contamination of non-tumor cells by performing qPCR for 
Cd45 and YFP (Chapter 2 Figure S2B-D). Unsupervised hierarchical clustering and 
principal component analysis identified two subgroups organized independently of E-
cadherin status (Chapter 2 Figure 1C,D). Instead, tumor pairs (matched M-ECAD+ and 
M-ECAD- samples) tended to cluster together, with three tumors comprising one group 
(Cluster 1) and eight comprising another (Cluster 2). To examine how EMT may be 
regulated in these two clusters, we examined the transcription of epithelial and 
mesenchymal genes previously implicated in EMT by comparing M-ECAD- and M-ECAD+ 
cells. In the smaller tumor subgroup (Cluster 1; 3/11), EMT was associated with robust 
downregulation of mRNAs for Ecad, EpCAM, Claudin-7, and other epithelial genes, as 
predicted from standard EMT models (Chapter 2 Figure 1E,F). Surprisingly, EMT in the 
larger subgroup (Cluster 2; 8/11) was associated with stable levels of mRNA for Ecad and 
other epithelial genes (Chapter 2 Figure 1E,F) when M-ECAD+ and M-ECAD- cells were 
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compared. Thus, loss of the epithelial program occurs in the absence of Ecad 
transcriptional repression in the majority of KPCY tumors evaluated. 
To distinguish between these phenotypes, we applied the term “complete EMT” 
(C-EMT) to refer to Cluster 1 tumors, in which induction of a mesenchymal phenotype was 
accompanied by transcriptional repression of the epithelial program, and the term “partial 
EMT” (P-EMT) to refer to Cluster 2 tumors, in which tumor cells retained epithelial 
transcripts during the mesenchymal transition. Tumors in both subgroups exhibited robust 
upregulation of mesenchymal-related transcripts within the M-ECAD- population (Chapter 
2 Figure 1F), and gene set enrichment analysis (GSEA) of both C- and P-EMT samples 
confirmed that M-ECAD- transcriptomes correlated strongly with published EMT datasets 
(Chapter 2 Figure S3A). Notably, C-EMT tumors had markedly higher expression of 
several EMT-associated transcription factors (Etv1, Prrx1, Zeb1, Twist1, Snai1, Snai2, 
and Zeb2) compared to P-EMT tumors regardless of whether M-ECAD+ or M-ECAD- cells 
were examined (Chapter 2 Figure S3B,C). Thus, tumors characterized as either C-EMT 
or P-EMT exhibit overlapping mesenchymal programs during EMT despite repressing their 
epithelial programs by distinct means. 
 
EMT programs are correlated with tumor differentiation and PDAC subtypes 
Histological examination of the KPCY tumors profiled in Figure 1 revealed a striking 
dissimilarity between the histology of C-EMT (Chapter 2 Figure S4A) and P-EMT (Chapter 
2 Figure S4B) tumors. Specifically, C-EMT tumors exhibited a poorly differentiated 
histology while P-EMT tumors exhibited a moderately- to well-differentiated histology 
(Table S1). We thus hypothesized that C-EMT and P-EMT programs might be associated 
with distinct tumor subtypes. To test this, we compared our KPCY tumor transcriptomes 
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to published signatures for human PDAC subtypes (Bailey et al, 2016b; Collisson et al, 
2011; Moffitt et al, 2015) (Chapter 2 Figure S5). In all cases, C-EMT tumors were strongly 
associated with poorly-differentiated transcriptional subtypes (quasi-mesenchymal 
(Collisson et al, 2011)), squamous (Bailey et al, 2016b), and basal-like (Moffitt et al, 2015) 
while P-EMT tumors were associated with well-differentiated transcriptional subtypes 
(classical/exocrine-like (Collisson et al, 2011) pancreatic progenitor/ADEX (Bailey et al, 
2016b),  and classical (Moffitt et al, 2015) (Chapter 2 Table S2). Hence, the mode by which 
the epithelial phenotype is lost in murine PDAC correlates with distinct histological and 
transcriptional subtypes of human PDAC. 
 
The P-EMT program is mediated by protein re-localization 
To understand how the epithelial program is repressed in different tumor subtypes, we 
derived a panel of non-clonal, cell lines from poorly- and well-differentiated KPCY tumors. 
To determine whether the EMT phenotypes of the cells in vitro matched their behavior in 
vivo, we used FACS to separate cell lines based on surface or membranous ECAD (M-
ECAD) staining and then performed qPCR for Ecad mRNA (Chapter 2 Figure 2A). Some 
cell lines (those derived from poorly-differentiated tumors) exhibited a robust down-
regulation of Ecad mRNA when comparing M-ECAD- cells to M-ECAD+ cells (Chapter 2 
Figure 2B). By contrast, other cell lines (those derived from moderately- or well-
differentiated tumors) exhibited comparable levels of Ecad mRNA in M-ECAD- versus M-
ECAD+ cells (Chapter 2 Figure 2B). Thus, cell lines derived from KPCY tumors retain the 
distinct EMT programs observed in vivo. Henceforth, we refer to cell lines in which EMT 
is associated with transcriptional repression of Ecad as “C-EMT lines” and to those cell 
lines in which EMT is associated with stable levels of Ecad mRNA as “P-EMT lines.” 
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The persistence of epithelial gene transcription in M-ECAD- negative cancer cells 
suggested that the epithelial program is regulated post-transcriptionally in tumor cells 
undergoing P-EMT. To address this possibility, we sorted KPCY cell lines into epithelial 
(M-ECAD+) and mesenchymal (M-ECAD-) fractions and compared levels of several 
epithelial proteins in whole cell lysates. As expected, the M-ECAD- fractions from C-EMT 
lines – harboring low levels of Ecad mRNA – had no detectable ECAD protein (Chapter 2 
Figure 2C). By contrast, ECAD protein was abundant in the M-ECAD- fractions from P-
EMT lines, at levels comparable to their E+ counterparts. Other epithelial proteins, 
including CLDN7 and EPCAM also persisted in whole cell lysates in P-EMT cell lines that 
had lost M-ECAD (Chapter 2 Figure 2C). Interestingly, levels of p120-catenin (p120), an 
ECAD interactor (Ireton et al, 2002; Stairs et al, 2011),did not vary between M-ECAD+ 
and M-ECAD- in either C- or P-EMT cell lines. Nevertheless, P-EMT cell lines expressed 
both the 1A (mesenchymal) and 3A (epithelial) p120 isoforms (Pieters et al, 2012) while 
C-EMT cell lines expressed only the 1A isoform. These data suggest that P-EMT cells 
continue to express components of the epithelial program at the protein level following 
EMT, while C-EMT cells lack both RNA and protein components of the epithelial program 
following EMT. 
We reasoned that intracellular sequestration might account for the lack of 
membranous ECAD in P-EMT tumors and cell lines. To test this, we performed dual 
antibody immunofluorescence by first staining live cells for ECAD using the fluorophore 
Brilliant Violet 421 (to detect membrane-associated ECAD; M-ECAD) followed by fixation, 
permeabilization, and a second round of ECAD staining using the fluorophore APC (to 
detect intracellular ECAD; I-ECAD) (Chapter 2 Figure 2D and Figure S6). As expected, C-
EMT cells lacking membranous ECAD also lacked intracellular ECAD, consistent with the 
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loss of Ecad mRNA and protein (Chapter 2 Figure 2E). By contrast, most P-EMT cells 
lacking membranous ECAD were positive for intracellular ECAD (Chapter 2 Figure 2E). 
The relocalization of ECAD was confirmed in tissue sections from KPCY mice, where 
intracellular ECAD staining was observed exclusively in P-EMT tumors (Chapter 2 Figure 
2F,G; epithelial cells for comparison, Chapter 2 Figure 2H,I). Similar patterns were 
observed in sections from human PDAC tissue sections (Chapter 2 Figure 2J,K; epithelial 
cells for comparison, Chapter 2 Figure 2L,M). Staining for other epithelial proteins, 
including b-catenin, Claudin-7, and EpCAM, revealed a punctate intracellular pattern 
similar to that of ECAD (Chapter 2 Figure 2O-Q). Taken together, these results suggest 
that cells undergoing a P-EMT program retain epithelial proteins intracellularly both in vitro 
and in vivo. 
 
P-EMT is associated with ECAD localization in late recycling vesicles 
Turnover and endocytic regulation of surface epithelial proteins is critical to both 
maintenance of epithelial cell homeostasis and cell migration during EMT (Brüser & 
Bogdan, 2017; Corallino et al, 2015). This process is regulated by the Rab subfamily of 
GTPases, which mark internalized proteins for recycling or degradation following 
sequestration into endosomes (Delva & Kowalczyk, 2009). To further understand the 
mechanism of ECAD absence from the cell surface, we stained cultured P-EMT cells and 
found that ECAD protein was confined to intracellular foci in delaminated cells exhibiting 
a mesenchymal morphology (Chapter 2 Figure 3A), suggestive of storage in endocytic 
complexes. To examine whether Rab family members are differentially expressed in 
tumors belonging to the two EMT subtypes, we measured the relative abundance of 
mRNAs encoding the major endocytic proteins Rab5, Rab7, and Rab11 in our tumor panel 
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from Chapter 2 Figure 1. In comparison to C-EMT tumors, P-EMT tumors had higher 
mRNA levels for the late recycling endosome protein Rab11, which is associated with 
storage and recycling of epithelial proteins back to the cell surface (Chapter 2 Figure 3B). 
By contrast, mRNAs for Rab7, which marks endosomes targeted for lysosomal fusion and 
protein degradation, were more abundant in C-EMT tumors as compared to P-EMT tumors 
(Chapter 2 Figure 3B). 
To further examine the localization of internalized ECAD during P-EMT, we co-
stained P-EMT cells for ECAD and Rab5, Rab7, or Rab11 (Chapter 2 Figure 3C-E). In 
cells that had undergone P-EMT (delaminated spindle shaped cells) we observed rare co-
localization of ECAD with Rab5 or Rab7 (Pearson’s correlation coefficients of 0.18 and 
0.19, respectively) (Chapter 2 Figure 3C ,D). By contrast, we observed prominent co-
localization of ECAD with Rab11 (Pearson’s correlation coefficient of 0.70) in virtually all 
cells exhibiting a mesenchymal morphology (Chapter 2 Figure 3E). These results suggest 
that turnover of surface ECAD during P-EMT is associated with storage in recycling 
endocytic vesicles. 
 
Plasticity between epithelial and mesenchymal states is determined by EMT 
subtype 
Epithelial-mesenchymal plasticity – both EMT and the reverse process of mesenchymal-
epithelial transition (MET) – is thought to play a role in tumor cell invasion and metastasis 
(Nieto et al. 2016). Thus, we sought to determine whether different EMT subtypes (C-EMT 
vs. P-EMT) are associated with differences in cellular plasticity during EMT in vitro and in 
vivo. To assess the capacity of cells from either C-EMT or P-EMT cell lines to undergo 
EMT, we sorted M-ECAD- cells from several cell lines and monitored them for the re-
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expression of surface ECAD by FACS. Following re-plating of cells from P-EMT lines, 
most cells re-expressed M-ECAD over a period of 6-9 days (Chapter 2 Figure 4A, green 
curves), consistent with their derivation from well-differentiated tumors. Likewise, a 
measurable (albeit smaller) fraction of cells from C-EMT lines also became positive for M-
ECAD (Chapter 2 Figure 4A, orange curves). As expected, mRNA levels for ECAD 
changed minimally over this timeframe in P-EMT cell lines (Chapter 2 Figure 4A). By 
contrast, mRNAs for mesenchymal genes including CDH11, COLA8A2, PDGFRB, and 
SNAIL were downregulated as C-EMT tumor cells became positive for M-ECAD (Chapter 
2 Figure 4B). These results suggest that PDAC cells are competent to undergo MET 
regardless of which program they use to shed their epithelial program during EMT. 
To assess the plasticity of epithelial and mesenchymal cells in vivo, we FACS 
sorted M-ECAD+ and M-ECAD- populations from murine C- and P-EMT cell lines and 
injected them subcutaneously into NOD.SCID mice (Chapter 2 Figure 4C). After tumors 
reached 1cm in size, YFP+ tumor cells were assessed for M-ECAD expression. Sorted M-
ECAD+ P-EMT cells (P E+) and M-ECAD- P-EMT cells (P E-) both gave rise to well-
differentiated tumors with a comparably high frequency of ECAD+ tumor cells, 
recapitulating the phenotype of tumors derived from parental (unsorted) P-EMT cells 
(Chapter 2 Figure 4C). Conversely, sorted M-ECAD+ C-EMT cells (C E+) and M-ECAD- 
C-EMT cells (C E-) gave rise to poorly-differentiated tumors with a comparably low 
frequency of M-ECAD+ cells, recapitulating the phenotype of tumors derived from parental 
(unsorted) C-EMT cells (Chapter 2 Figure 4C). These results indicate that all cell lines 
tested exhibit robust plasticity between the epithelial and mesenchymal states, with an 
equilibrium governed by cell line-specific “set points.” In P-EMT cell lines (which have an 
epithelial phenotype at a population level), this equilibrium is skewed to the epithelial state, 
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whereas in C-EMT cell lines (which have a mesenchymal phenotype at a population level) 
this equilibrium is skewed towards a mesenchymal state (Chapter 2 Figure 4D). 
 
TGFb treatment induces a C-EMT phenotype 
EMT is often induced experimentally by exposing cultured cells to exogenous 
growth factors – most commonly TGFβ – resulting in the downregulation of transcripts for 
Ecad and other epithelial genes across a variety of tumor types (Zavadil & Böttinger, 
2005). However, our data suggested that in the autochthonous setting, well-differentiated 
tumor cells undergo EMT via post-transcriptional regulation of epithelial proteins without 
repression of epithelial gene expression. To examine how P-EMT tumor cells respond to 
TGFβ stimulation, we treated two P-EMT cell lines (PD7591 and PD798) with TGFβ for a 
period of 5 days. This treatment resulted in morphological changes (Chapter 2 Figure 4E) 
and robust down-regulation of Ecad mRNA (Chapter 2 Figure 4F) and protein (Chapter 2 
Figure 4G). Moreover, TGFβ-treated P-EMT cells that had lost M-ECAD also lacked I-
ECAD, contrasting with the marked cytoplasmic ECAD re-localization observed when 
such cells undergo EMT in the absence of TGFβ (Chapter 2 Figure 4H). Thus, cells that 
use protein relocalization to lose their epithelial phenotype under standard culture 
conditions remain competent to employ classically-defined transcription dependent 
mechanisms when confronted with an exogenous (and overriding) growth factor signal 




EMT subtypes exhibit distinct modes of tumor cell migration 
Metastasis is a multi-step process that begins with cellular invasion and bloodstream 
entry. This process is often conceptualized as the end result of EMT leading to the 
dissemination of single tumor cells (Brabletz, 2012; Lamouille et al, 2014; Nieto et al, 
2016b; Savagner, 2015). However, evidence in several cancer types suggest that 
metastases can also arise from the collective migration and colonization of tumor cells 
(Aceto et al, 2014; Cheung & Ewald, 2016; Friedl et al, 2012; Maddipati & Stanger, 2015; 
Haeger et al, 2015; Labernadie et al, 2017) and may not require E-cadherin loss (Liu et 
al, 2014). To determine whether different EMT programs affect the mode of cell migration 
during metastasis, we generated tumor spheres from C- and P-EMT cell lines, embedded 
them in Matrigel, and performed dynamic imaging to examine invasive behavior in real 
time. In the C-EMT spheres, we observed spindle-like protrusions at the edges of the 
primary cell mass and the invasion of single cells (Chapter 2 Figure 5A and Movie S1 in 
(Aiello et al, 2017)). In P-EMT spheres, by contrast, tumor cells retained cell-cell contacts 
and invaded as a collective group, with multicellular clusters delaminating from the primary 
cell mass (Chapter 2 Figure 5B and Movie S2 in (Aiello et al, 2017)). Importantly, while P-
EMT cell lines exhibited both modes of escape from the primary cell mass (budding 
clusters and single cells), invasion in C-EMT cell lines was primarily by single cells. 
To assess whether these different patterns of cell migration impacted tumor cell 
entry into the bloodstream, we performed orthotopic implantation into the pancreas of 
NOD.SCID mice and examined the blood for evidence of circulating tumor cells (CTCs). 
When tumors were derived from a C-EMT cell line, >95% of the CTCs were present as 
single-cells (Chapter 2 Figure 5C,D). By contrast, when tumors were derived from a P-
EMT cell line, >50% of CTCs existed as tumor cell clusters (Chapter 2 Figure 5C,D). To 
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determine whether the persistence of ECAD protein in cell lines undergoing P-EMT might 
contribute to the prevalence of cell clusters, we stained CTCs and CTC clusters for ECAD. 
In contrast to single CTCs arising from C-EMT tumors, which lacked E-cadherin protein 
altogether, tumor cell clusters arising from P-EMT tumors retained staining for ECAD at 
points of cell-cell contact but not on the cluster surface (Chapter 2 Figure 5E). Overall, 
these data suggest that EMT subtype influences the mode of cell migration, with the P-
EMT subtype exhibiting both single cell and collective migration and C-EMT subtype 
exhibiting primarily a single-cell invasion phenotype. 
 
C- and P-EMT subtypes are conserved across multiple human cancer cell lines 
Our finding that a majority of murine pancreatic tumors utilize a post-transcriptional 
program to shed their epithelial phenotype prompted us to ask whether human cancer 
cells also employ distinct EMT programs. By cross-referencing our EMT subtype gene list 
to expression data from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al, 2012), 
we stratified several human pancreatic cancer cell lines as C-EMT or P-EMT. As expected 
from our mouse studies, human PDAC cell lines associated with the previously-described 
quasi-mesenchymal signature (Collisson et al, 2011) were predicted to have 
characteristics of C-EMT whereas cell lines associated with a classical signature were 
predicted to have characteristics of P-EMT (Chapter 2 Figure S7A). To determine whether 
these classifications were associated with functional differences, we used M-ECAD 
staining to sort two human PDAC cell lines predicted to have a C-EMT phenotype 
(MIAPACA2 and PANC1) and three human PDAC cell lines predicted to have a P-EMT 
phenotype (BXPC3, CAPAN2, and HPAC) and examined the sorted populations for Ecad 
mRNA and/or M-ECAD vs.I-ECAD. Human PDAC cell lines carrying a C-EMT signature 
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exhibited loss of Ecad mRNA and no intracellular ECAD protein upon loss of membranous 
ECAD (Chapter 2 Figure 6A,B). By contrast, human PDAC cell lines exhibiting a P-EMT 
signature retained Ecad mRNA despite loss of membranous ECAD (Chapter 2 Figure 6A), 
and a high percentage of M-ECAD-negative cells from these lines were positive for I-
ECAD (Chapter 2 Figure 6B). These data suggest that human tumor cells belonging to the 
quasi-mesenchymal/squamous/ basal subtype of PDAC utilize transcriptionally-
dominated programs to lose their epithelial phenotype during EMT while those belonging 
to the classical/ pancreatic progenitor/ADEX subtype rely on protein re-localization to lose 
their epithelial phenotype during EMT. 
We next sought to assess whether other cancer types utilize these distinct EMT 
programs and applied the same strategy of gene expression analysis to stratify a panel of 
human breast cancer (BC) and colorectal cancer (CRC) cell lines into those exhibiting a 
C-EMT signature and those exhibiting a P-EMT signature (Chapter 2 Figure S7B, C). 
Among BC cell lines, the C-EMT signature was present in the basal-like subtype, while 
the P-EMT signature was associated with the luminal A/B and normal-like subtypes (Sørlie 
et al, 2001) (subtype information was not available for the CRC cell lines). To determine 
whether these classifications would accurately predict cell behavior during EMT, we sorted 
M-ECAD+ epithelial and M-ECAD- mesenchymal populations from a subset of these BC 
and CRC cancer cell lines and examined Ecad mRNA and protein localization. Consistent 
with our prior results, BC and CRC cell lines categorized as P-EMT retained Ecad 
transcripts in the M-ECAD- population (Chapter 2 Figure 6C,D) and exhibited 
internalization in cells that were negative for M-ECAD (Chapter 2 Figure 6E,F), while cell 
lines categorized as C-EMT had a complete loss of Ecad mRNA and protein (Chapter 2 
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Figure 6C-F). Taken together, these results provide strong evidence that tumor subtype 



























Summary and Discussion 
 
KPCY tumors reflect the heterogeneity of human PDAC 
We found, using a panel of murine pancreatic tumors, that the KPCY autochthonous 
mouse model exhibits broad histological and molecular diversity, as originally described 
(Hingorani et al, 2005). Surprisingly, we found that these heterogeneous tumors also 
recapitulate the transcriptionally-defined subtypes of human PDAC (Bailey et al, 2016b; 
Collisson et al, 2011; Moffitt et al, 2015). At a global transcriptional level, high-grade 
poorly-differentiated murine tumors resembled human tumors belonging to the quasi-
mesenchymal, basal, and squamous subtypes while low-grade well-differentiated murine 
tumors corresponded to human tumors exhibiting a classical or pancreatic progenitor 
transcriptional signature. Because the human signatures were based on analysis of bulk 
tumors, while our analysis of murine tumors relied on sorted YFP+ cells, these cross-
species associations reflect similarities in the transcriptomes of the cancer cells 
themselves rather than signatures derived from the tumor microenvironment. 
Given that all KPCY tumors carry the same founder mutations in Kras and p53, the 
phenotypic diversity exhibited by KPCY tumors is intriguing. Several possibilities could 
account for this variation. First, it is possible that well-differentiated tumors (which are 
associated with “partial EMT” programs) and poorly-differentiated tumors (which are 
associated with “complete EMT” programs) arise from different cells in the pancreas. 
Several studies have suggested that acinar cells constitute the major cellular source of 
PDAC as the result of an acinar-to-ductal metaplasia (ADM) → pancreatic intraepithelial 
neoplasia (PanIN) → carcinoma sequence (De La O et al, 2008; Guerra et al, 2007; Habbe 
et al, 2008; Kopp et al, 2011). However, the Pdx1-Cre driver used in this model mediates 
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recombination in pancreatic progenitor cells during development, meaning that multiple 
pancreatic lineages are exposed to the effects of mutant Kras and p53. Indeed, non-acinar 
cells, including cells within the ductal lineage, can also give rise to pancreatic tumors 
(Bailey et al, 2014, 2016a; Westphalen et al, 2016). Differences in tumor subtype have 
recently been linked to distinct cells-of-origin in skin cancer (Latil et al, 2017), and it is 
enticing to speculate that a similar phenomenon contributes to the heterogeneity in tumor-
related EMT phenotypes observed here. Alternatively, different oncogenic “hits” may act 
in combination with mutant Kras and p53 to drive tumors into one subtype or another, as 
has been observed in breast cancer (Koboldt et al, 2012). Because the KPCY model 
provides a ready source of tumors belonging to distinct subtypes, future studies detailing 
subtype-specific genetic, genomic, and epigenetic correlates may lead to a better 
understanding of the roots of intertumoral heterogeneity. 
 
Two broadly distinct programs drive EMT in vivo 
In the setting of cancer, EMT has traditionally been viewed as a transcriptionally regulated 
process whereby tumor cells repress epithelial gene transcription and upregulate 
mesenchymal gene transcription (Brabletz, 2012; Lamouille et al, 2014; Nieto et al, 2016b; 
Savagner, 2015; Tam & Weinberg, 2013). Recent work has called attention to the fact that 
EMT can also exist along a spectrum, resulting in a bi-phenotypic partial EMT state 
wherein tumor cells retain both epithelial and mesenchymal programs; importantly, such 
a hybrid state has been proposed to confer a greater ability to metastasize than a fully 
mesenchymal state(Jolly, 2015; Nieto et al, 2016b; Li & Kang, 2016; Lambert et al, 2017). 
Our finding that the majority of murine PDAC tumors and cell lines examined use 
protein re-localization rather than transcriptional repression to subdue the epithelial 
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program provides molecular insight into epithelial-mesenchymal plasticity. These tumors 
exhibit low expression of EMT TFs and co-express epithelial and mesenchymal genes, 
consistent with a partial EMT state. Evidence for partial EMT in human cancer has been 
reported, as single cell analysis of head and neck tumors indicates the existence of an in 
vivo partial EMT program that correlates with increased metastatic potential and differs 
fundamentally from the EMT programs defined in vitro (Puram et al, 2017). Considering 
our observation that loss of the epithelial program is achieved post-transcriptionally in 
several human cancer cell lines, it is enticing to speculate that protein re-localization, 
rather than transcriptional repression, is responsible for the hybrid epithelial-mesenchymal 
phenotypes observed in human carcinoma. 
It remains unclear whether cells that undergo P-EMT are paused in a transitional 
state (i.e. an intermediate stage in a mesenchymal differentiation continuum) or whether 
it represents a final state in its own right. While different tumors appeared to use either 
transcriptional or post-transcriptional programs to lose their phenotype, we found no 
evidence that these two programs co-exist within the same tumor, suggesting that the 
tendency to use either a C- or P-EMT program to undergo a mesenchymal transition is a 
specific and stable feature of an individual tumor. Thus, the P-EMT program described 
here appears to represent the end-manifestation of EMT in many KPCY tumors. 
Nevertheless, we cannot rule out the possibility that tumors exhibiting a P-EMT 
phenotype at the time of analysis might exhibit a C-EMT phenotype at some later time 
point (or vice versa). Consistent with this notion, we found that P-EMT cells execute a C-
EMT program when exposed to TGFb, suggesting that signals within the tumor 
microenvironment may also influence the EMT phenotype. In either event, the equilibrium 
between the epithelial vs. mesenchymal phenotype appears to be subject to tumor cell-
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intrinsic “set-points,” as evidenced by the tendency of pure populations of sorted tumor 
cells to give rise to tumors with the same ratios of M-ECAD+ and M-ECAD- cells as the 
parental population, both in vivo and in vitro. 
P-EMT is associated with the re-localization of ECAD and other epithelial proteins to the 
interior of the cancer cell, clearing its plasma membrane of molecules that facilitate cellular 
adhesion while preserving the capacity to redeploy such proteins to the surface. The 
finding that intracellular ECAD is localized to Rab11+ recycling endosomes is consistent 
with this notion and suggests that P-EMT involves an interruption of the last step in ECAD 
trafficking: the return of the protein to the plasma membrane. These findings regarding 
protein re-localization and epithelial-mesenchymal plasticity are consistent with prior 
studies relating ECAD trafficking to cell motility. ECAD is subject to substantial recycling 
in normal epithelial cells (Brüser & Bogdan, 2017), providing cancer cells with an alternate 
means to efficiently lose and re-establish their epithelial properties (Corallino et al, 2015). 
Indeed, post-transcriptional mechanisms have been shown to mediate EMT-like 
processes during normal embryonic development. During zebrafish epiboly, for example, 
protein endocytosis, rather than transcriptional repression, accounts for the loss of M-
ECAD protein and subsequent increases in cell motility (Song et al, 2013). Similarly, 
mesoderm formation during sea urchin embryogenesis and mesoderm formation during 
mouse gastrulation rely on post-transcriptional mechanisms to downregulate ECAD 
protein (Wu & McClay, 2007; Zohn et al, 2006). Thus, carcinoma cells appear capable of 
repurposing either of two distinct developmental EMT mechanisms – transcriptional 
regulation or protein trafficking – to enhance their motility. 
 
EMT subtype impacts invasion and dissemination 
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Our study also has implications for the mechanism of cellular invasion. Two distinct 
patterns of invasive growth leading to metastases have been described: single cell 
migration leading to dissemination of individual tumor cells, and collective (group) 
migration resulting in multi-cellular circulating tumor cell (CTC) clusters (Cheung & Ewald, 
2016; Friedl et al, 2012; Lambert et al, 2017). We find that both modes of cell migration 
occur in KPCY tumors in a manner that correlates with EMT subtype. In C-EMT tumors, 
where cells that have undergone EMT lack ECAD protein entirely, tumor cells tend to 
invade and disseminate as single cells. In P-EMT tumors, by contrast, dysregulated 
trafficking of ECAD and other epithelial proteins allows tumor cells to retain some 
associative properties, resulting in cell clusters that lack epithelial features on the outer 
surface. The P-EMT program may thus confer tumor cells with invasive properties while 
simultaneously allowing them to retain intercellular cohesions that facilitate collective 
behavior (Cheung et al, 2013; Lambert et al, 2017; Liu et al, 2014; Revenu & Gilmour, 
2009; Westcott et al, 2015). 
In addition, we found that these divergent EMT programs were correlated with 
tumor subtype in several human carcinoma lines. In breast cancer cell lines harboring a 
luminal-A, luminal-B, or normal-like signature, for example, EMT was associated with a 
persistence of ECAD mRNA and a re-localization of ECAD protein inside the cell, features 
of the P-EMT program. Cell lines harboring a basal signature, by contrast, had complete 
loss of ECAD mRNA and protein. These results suggest that the mechanisms by which 
tumors undergo EMT and invasive spread are dictated at least in part by the same broad 
molecular programs that determine their subtypes across a variety of carcinomas. 
These differences in EMT programs are likely to translate into different invasive 
mechanisms. Specifically, tumors associated with a P-EMT program may be predisposed 
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to form CTC clusters, a notion that is consistent with the finding that P-EMT cell lines gave 
rise to CTC clusters more readily than C-EMT cell lines. Our results are also in line with 
the findings of Gampieri et al., who showed that TGFβ signaling in breast cancer cells 
prompted a switch from collective to single cell migration (Giampieri et al, 2009)– a 
phenomenon that we hypothesize is attributable to a switch from a P-EMT to a C-EMT 
program. Considering the observation that tumor cell clusters display enhanced metastatic 
potential compared to single cells (Aceto et al, 2014; Cheung & Ewald, 2016; Maddipati & 
Stanger, 2015),  it is tempting to speculate that tumors exhibiting a P-EMT phenotype 
might exhibit an increased metastatic rate compared to tumors exhibiting a C-EMT 
phenotype. However, the factors governing metastasis and patient survival are complex 
and multifaceted, reflecting the ability of tumor cells to overcome many challenges besides 
invasion. Thus, while these EMT programs are likely to be relevant for the invasive 
mechanisms utilized by a given tumor, the relationships between C-EMT, P-EMT, and 
clinical outcome remain to be defined. Likewise, considering the finding that tumor cells 
with different degrees of epithelial-mesenchymal plasticity are prone to metastasize to 
different sites (Reichert et al, 2018), the extent to which the divergent EMT programs 
described here contribute to metastatic organotropism also remains to be explored. 
Chapter 2 Acknowledgements: A special thanks to Nicole Aiello and Ravikanth 
Maddipati for collection of data and writing this chapter. Thanks to David Balli for 
bioinformatics and statistical analysis. This chapter was published:  Aiello NM*, Maddipati 
R*, Norgard RJ*, et al. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. 
Dev Cell. 2018  
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Materials and Methods 
 
Mouse Strains 
KrasLSL-G12D; p53L/+; Pdx1-cre; Rosa26YFP/YFP (KPCY) mice have been described previously 
(Rhim et al, 2012). Mice were palpated and examined for evidence of morbidity twice per 
week. Tumor-bearing animals were sacrificed when moribund. NOD.SCID mice were used 
for tumor cell injection experiments as KPCY cell lines are of mixed background and would 
be rejected by an immuno-competent animal. Both male and female KPCY and 
NOD/SCID animals were used in this study. Tumors were examined by a GI Pathologist 
(E.E.F.) and categorized as moderately-to-well- or poorly-differentiated based on the 
predominant histology following examination of multiple regions. Mice were housed in 
standard microisolator cages and chow with a 12 hour light cycle. All vertebrate animals 
were maintained and experiments were conducted in compliance with the National 
Institutes of Health guidelines for animal research and approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee. 
 
Cell lines 
Murine PDAC cell lines PD7591 (female), PD798 (male), PD454 (male), PD7242 
(unknown), PD883 (male), PD6910 (female), PD483 (female) and PD3077 (male) were 
derived from primary KPCY tumors. The PD832 (male) cell line was obtained from the 
ascites fluid of KPCX mice (Maddipati & Stanger, 2015). The C- and P-EMT status of all 
cells was confirmed by RT-PCR for Ecad mRNA after sorting as well as and intracellular 
staining for ECAD. Human PDAC cell lines Capan2, HPAC, Bxpc3, and Panc1 were 
provided by Dr. Anil Rustgi, University of Pennsylvania. Human breast cancer cell lines 
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MCF7, BT474 and MDA-MB-453 were provided by Dr. Erica Carpenter, University of 
Pennsylvania. Human breast cancer cell lines MDA-MB-157, MDA-MB-231, MDA-MB-
436, MDA-MB-468 and HCC1937 were provided by Dr. Andy Minn, University of 
Pennsylvania. Human colorectal cancer cell lines DLD1, HCT116 and SW480 were 
provided by Dr. Anil Rustgi, University of Pennsylvania. Human colorectal cancer cell lines 
Hs255T (CRL-7213), Hs675T (CRL-7400) and Hs698T (CRL-7435) were purchased 
directly from ATCC. All human lines provided by previously mentioned investigators were 
originally obtained from ATCC.  Human cell lines were authenticated by the University of 
Arizona Genetics Core. Cell lines were regularly tested for mycoplasma using MycoAlert 
Mycoplasma Detection Kit (Lonza). 
Murine cell lines were cultured in Dulbeccos’ Modified Eagle Medium/F12 medium 
supplemented with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL soybean trypsin inhibitor 
type I (Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS Premix; BD Biosciences), 25 
μg/mL bovine pituitary extract (Gemini Bio-Products), 5 nmol/L 3,3′,5-triiodo-L-thyronine 
(Sigma), 1 μmol/L dexamethasone (Sigma), 100 ng/mL cholera toxin (Sigma), 10 mmol/L 
nicotinamide (Sigma), 5% Nu-serum IV culture supplement (ThermoFisher Scientific), and 
antibiotics (gentamicin 150 μg/mL, Gibco; amphotericin B 0.25 μg/mL, Invitrogen). Human 
cell lines were cultured in 10% Dulbecco’s Modified Eagle Medium supplemented to 10% 
decomplemented fetal bovine serum at 37°C, 5% CO2, 21% O2 and 100% humidity. Cell 








Tissues were fixed in Zn-formalin and embedded in paraffin prior to staining.  Sections 
were deparaffinized, rehydrated and subjected to antigen retrieval. For staining cell lines, 
cells were fixed in 4% paraformaldehyde for 15 mins. For staining, sections and fixed cells 
were blocked in 5% donkey serum for 1 hour at room temperature (RT), incubated with 
primary antibodies for 1 hour at RT, washed, incubated with secondary antibodies for 1 
hour at RT, washed and mounted. Primary antibodies used include goat anti-GFP 
(Abcam), rat anti-Ecadherin (Takara Bio), rabbit anti-Zeb1 (Santa Cruz), rabbit anti-Slug 
(gift of Dr. Joel Habener), rabbit anti-Vimentin (Cell Signaling Technologies), rabbit anti-
Fsp1 (DAKO), rabbit anti-Rab5 (Cell Signaling Technologies), rabbit anti-Rab7 (Cell 
Signaling Technologies), rabbit anti-Rab11 (Cell Signaling Technologies), rabbit anti-
EpCAM (Abcam), rabbit anti-Claudin-7 (Abcam), and rabbit anti-B-catenin (Cell Signaling 
Technologies). Zeb1 required additional tyramide signaling amplification (PerkinElmer). 
Slides were visualized using an Olympus IX71 inverted multicolor fluorescent microscope 
equipped with a DP71 camera. Select slides were also visualized using a Zeiss LSM 710 
confocal microscope with Zen 2011 software. 
 
Flow cytometry 
For surface/intracellular E-cadherin staining of KPCY tumor cell lines, cells were stained 
with rat anti-E-cadherin (Takara Bio, clone M108) at 1:250 and Brilliant Violet 421 goat 
anti-rat (Biolegend) at 1:100 for 15 min. at 4oC in the dark for each step with three washes 
between. Cells were then fixed and permeabilized using Foxp3/Transcription Factor 
Staining Buffer Set (eBioscience) according to the manufacturer’s instructions. Cells were 
then stained with rat anti-E-cadherin again at 1:250 and APC donkey anti-rat (Jackson 
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Immunoresearch) at 1:100 for 15 min. at 4oC in the dark for each step with three washes 
between. Finally, the cells were resuspended in 5% FCS in PBS and analyzed on a BD 
LSR II flow cytometer. 
 
Fluorescence-Activated Cell Sorting (FACS) 
To create a single cell suspension, pancreatic tumor tissue was rinsed in cold, sterile 1X 
PBS before mincing with scissors (approximately 100 chops). The minced pieces were 
then incubated in preheated collagenase with protease inhibitors (2 mg/ml; Sigma) for 20 
min at 37°C. Vigorous vortexing was performed every 5 min during this incubation. The 
dissolved pieces were then poured over a 70 μM cell strainer and large pieces were 
mechanically broken down. The flow through was resuspended in cold DMEM/F12, 
centrifuged, washed once, and kept on ice in the dark. The cells were then stained with 
rat anti-E-cadherin (1:250; Takara Bio, clone M108) for 15 minutes at 4oC in the dark, 
followed by three 5 minute washes in 5% FCS in PBS and incubation with APC donkey 
anti-rat (1:100; Jackson Immunoresearch) prior to FACS (FACSVantage with FACSDiva 
option, BD). 
 
RNA isolation, library construction, and next-generation sequencing 
RNAseq libraries were prepared using the Clontech Ultra low RNA kit – HV, with 12 cycles 
of PCR for cDNA amplification, and the Clontech Low Input Kit for library prep, with 9 
cycles of PCR amplification, following the manufacturer’s protocol. The amplified library 
was purified using AMPure beads, quantified by Qubit and QPCR, and visualized in an 
Agilent Bioanalyzer. The libraries were pooled equimolarly, and loaded on either one rapid 
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run HiSeq 2500 flow cell, onboard clustering protocol, or on HiSeq 2500 high output flow 
cell lanes, as paired 50 nucleotide reads. 
 
Sequencing alignment, differential gene expression and clustering analysis 
The quality of raw reads was assessed using Fastqc (v0.11; Babraham Bioinformatics). 
Reads passing quality control were aligned to the mouse genome version UCSC 
GRCm38/mm10 with STAR (v2.3.1) (Dobin et al, 2013) using default parameters. Total 
reads, with alignment quality of at least 10, mapping to each gene were counted using 
HTseq-count (Anders et al, 2015) and GRCm38/mm10 gene annotation files.  Differential 
gene expression analysis was performed using the R/Bioconductor package DESeq2 
(Love et al, 2014). Genes with Benjamini-Hochberg adjusted P values ≤ 0.1 and absolute 
log2 fold change ≥ 1.0 were considered differentially expressed. As an alternate approach 
to obtain gene and transcript level abundances, transcripts per million (TPM) were 
calculated using RSEM (v1.2.18) (Li & Dewey, 2011) with default parameters. Microarray 
expression data for human pancreatic cancer cell lines were obtained from the Cancer 
Cell Line Encyclopedia (Barretina et al, 2012). 
 
Gene expression Heat Maps and Box Plot Generation 
For unsupervised hierarchical clustering and heat map generation, variance-stabilized 
expression values were clustered using average linkage with distance metric equal to 1 
minus the Pearson correlation coefficient using the 2000 genes with the most variable 
expression levels. To visualize expression of specific genes involved in EMT, the log2 
ratio of normalized TPM values between paired mesenchymal (YFP+/M-Ecad-) and 
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epithelial (YFP+/M-Ecad+) fractions from each individual tumor sample were plotted with 
ggplot2 in R. Markers specific for epithelial cells, mesenchymal cells and EMT 
transcription factors were selected from published literature (Lamouille et al, 2014; Nieto 
et al, 2016b). 
 
Gene Set Enrichment Analysis 
Gene expression signatures from published EMT profiles (Anastassiou et al, 2011; 
Gotzmann et al, 2006; Jechlinger et al, 2003) were obtained from GSEA/MSigDB. Gene 
set lists corresponding to established PDAC subtypes were obtained from original 
publications (Bailey et al, 2016b; Collisson et al, 2011; Moffitt et al, 2015). Statistical tests 
and enrichment association was calculated using Gene Set Enrichment Analysis (GSEA 
v.2.2.0). 
 
RNA isolation and qPCR 
Total RNA was extracted from samples consisting of less than 5 x 105 cells using the 
RNeasy Micro Kit (Qiagen), while samples consisting of greater than 5 x 105 cells were 
subjected to the RNeasy Mini Kit (Qiagen). High Capacity cDNA Reverse Transcription 
Kit (Life Technologies) was used to generate cDNA. qPCR was performed with 
SsoAdvanced SYBR (BioRad) using a CFX384 Real-Time System (BioRad). Transcript 
quantities were determined using the difference of Ct method and values were normalized 
to Gapdh. Primary sequences are listed in Table S3. 
 
Tumor sphere invasion assay 
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Murine PDAC cell lines PD798, PD7591, PD3077, and PD832 were plate at 5000cells/well 
in 96-well ultra-low attachment plate (Corning) media for 2 days to enable sphere 
formation. Equal amounts of matrigel was then added to each well and cells were 
incubated for 3 days at 37°C, 5% CO2, 21% O2 and 100% humidity. Live imaging was 
then performed for 72hrs in a humidified chamber at 37°C, 5% CO2. Imaging was 
performed using the Olympus IX81 microscope with Brightfield/DIC and automated stage 
for imaging multiple stage positions. 
 
Analysis of circulating tumor cells 
Blood was isolated from orthotopic tumor bearing mice via cardiac puncture with a 1-ml 
insulin syringe containing 100ul of 1mg/ml heparin sulfate (Sigma-Aldrich, H3149) to 
prevent coagulation. Fluid was immediately placed in a 100cm gridded plate (BD Falcon) 
containing RBC lysis buffer (BD biosciences). Following 10 minutes of lysis, PBS was 
added to the plate and CTCs were directly visualized on a fluorescent microscope and 
imaged. CTC immunofluorescence was performed by manual isolation of CTCs under 
microscope visualization followed by embedding in matrigel. Cells were then fixed and 
stained for E-cadherin and YFP and visualized by confocal microscopy. 
 
Human Specimens 
De-identified primary PDAC tissue samples were obtained from patients who consented 
to a research autopsy in association with the IRB approved Johns Hopkins Rapid Medical 




QUANTIFICATION AND STATISTICAL ANALYSIS 
Differences between two groups were analyzed by two-tailed Student’s t-test unless 
otherwise noted. All statistical analyses were performed using GraphPad Prism 6 
(GraphPad, La Jolla, CA). 
 
DATA AND SOFTWARE AVAILABILITY STATEMENT 
RNAseq data reported in Chapter 2 Figure 1 and Chapter 2 Supplementary Figure S3 has 
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Chapter 2 Figure 1: Two distinct EMT programs exist among KPCY tumors 
 
(A) Representative image of a KPCY tumor (n=9 mice, 115 fields examined) stained for 
YFP (red) and ECAD (green) (DAPI nuclear counterstain, blue). Arrow: YFP+ tumor 
cells within epithelial structures that are positive for membranous ECAD (M-ECAD). 
Arrowhead: YFP+ tumor cells that have delaminated from epithelial structures and are 
negative for M-ECAD. Scale bar, 25µm 
(B) Strategy for isolating epithelial and mesenchymal tumor cells by fluorescence 
activated cell sorting. 
(C) Heatmap of unsupervised hierarchical clustering of expression of the 2000 most 
variable genes between epithelial and mesenchymal tumor cells from KPCY tumors. 
Tumor IDs are color-coded and listed below the heatmap, with M-ECAD+ (plus) and 
M- ECAD- (minus) fractions indicated. 
(D) Principal components of 2000 most variable genes across all samples. Shape 
represents M-ECAD sorting status (Triangles = M-ECAD+, Circles = M-ECAD-) and 
color represents clustering identity (Orange = Cluster 1, Green = Cluster 2). 
(E) Fold-difference in mRNA levels for Ecad, EpCAM, and Claudin-7 comparing 
mesenchymal (M-ECAD-) and epithelial (M-ECAD+) populations (TPM, transcripts per 
million) in tumors belonging to Cluster 1 (orange) or Cluster 2 (green). 
(F) Heatmap of expression fold change for selected epithelial, mesenchymal, and 
extracellular matrix collagen genes comparing mesenchymal (M-ECAD-) and epithelial 
(M-ECAD+) populations in tumors belonging to Cluster 1 (“C-EMT”) or Cluster 2 (“P- 
EMT”). 
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Chapter 2 Figure 2: P-EMT is characterized by post-transcriptional regulation of the 
epithelial program. 
 
(A) Strategy for assessing E-cad mRNA and protein expression from a panel of KPCY 
tumor cell lines. In total, 3 C-EMT and 5 P-EMT cell lines were used. 
(B) Aggregate data showing differences in E-cad mRNA abundance (by qPCR) comparing 
mesenchymal (M-ECAD-) and epithelial (M-ECAD+) cells from 8 murine PDAC cell 
lines classified as either C-EMT (N=3: PD6910, PD483, PD3077) or P-EMT (N=5: 
PD7591, PD798, PD7242, PD454, PD422). A marked decrease in E-cad mRNA in 
association with EMT is observed in C-EMT cell lines, while no decrease is observed 
in P-EMT cell lines. 
(C) Western blot comparing epithelial protein levels in sorted M-ECAD- (E-) and M- 
ECAD+ (E+) cells from 2 C-EMT and 2 P-EMT PDAC cell lines. 
(D) Strategy for detecting internalized E-cadherin by flow cytometry. 
(E) E-cadherin internalization in murine cell lines was quantified by measuring the 
percentage of cells negative for membranous E-cadherin (M-ECAD-) that were 
positive for intracellular E-cadherin (I-ECAD+). P-EMT cell lines: PD7591, PD798 
(69.8% ± 9.0; mean ± SD). C-EMT cell lines: PD483, PD3077 (0.13% ± 0.1). Each cell 
line was assessed in triplicate. Data are representative of at least two independent 
experiments for each cell line. 
(F-I) Representative confocal 3-D projections of mesenchymal (F,G) and epithelial (H, I) 
tumor cells from P-EMT (F, H) and C-EMT (G, I) KPCY tumors. Sections were stained 
for YFP (red) and ECAD (green) (DAPI nuclear counterstain, blue). 
(J-M) Representative confocal 3-D projections of mesenchymal (J, K) and epithelial (L, M) 
tumor cells from two human primary PDAC tumors. Sections were stained for ECAD 
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(green) (DAPI nuclear counterstain, blue). Mesenchymal tumor cells are outlined for 
clarity. 
(O-Q) Representative confocal 3-D projections of mesenchymal tumor cells from P-EMT 
KPCY tumors stained for ECAD (green), YFP (red), and additional epithelial proteins 
(grey) b-catenin (O), Claudin-7 (P), and EpCAM (Q). 
Bar graph data are presented as mean ± standard deviation (SD) in this and subsequent 
figures. Scale bars, 10µm. Statistical differences were identified by Student’s t-test in this 
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Chapter 2 Figure 3: Intracellular ECAD co-localizes with Rab11+ late recycling vesicles 
 
(A) Representative confocal images of cultured cells from a P-EMT cell line showing a 
colony of cells with epithelial features (left) and a delaminated spindle shaped 
mesenchymal cell (right) stained with ECAD and DAPI. Arrows show membranous 
ECAD staining pattern in epithelial cells while arrowheads show punctate cytoplasmic 
staining pattern in mesenchymal cells 
(B) Relative mRNA expression of Rab11 (marker of late recycling vesicles), Rab5 (marker 
of early endosomes), and Rab7 (marker of late endosomes targeted for lysosomal 
degradation) in P-EMT tumors from Figure 1. (*,p<0.05) 
(C-E) Co-immunofluorescent staining of mesenchymal P-EMT cells (as depicted in (A)) 
with ECAD and Rab5, Rab7, or Rab11. Images representative of data from 20 different 
cells for each experiment. Mean Pearson’s correlation coefficients of colocalization are 
0.18, 0.19, and 0.70 for Rab5, Rab7, and Rab11, respectively. 
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Chapter 2 Figure 4: Features of epithelial plasticity in C-EMT and P-EMT subtypes 
 
 
(A) Kinetics of mesenchymal-to-epithelial transition (MET) in vitro. ECAD negative cells 
(>99% purity) were sorted from P-EMT (7591 and 798) and C-EMT (3077, 483, 832) 
cell lines and cultured for 9 days in standard conditions. At day 6, P-EMT and C-EMT 
cells were 98.07% ± 1.98 (mean ± SD) and 28.49% ± 26.40 M-ECAD+ respectively. 
At day 9, P-EMT and C-EMT cells were 86.75% ± 0.73 and 14.61% ± 11.38 M-ECAD+ 
respectively. Baseline percentage of M-ECAD+ cells prior to sorting for 7591, 798, 
3077, 483, and 832 are 97%, 90%, 47%, 12%, and 6% respectively. Insert in A 
demonstrates stable Ecad mRNA expression in the sorted P-EMT cells from day 0 to 
6. Data representative of two independent experiments with cell lines assessed in 
triplicate. 
(B) Mesenchymal gene expression changes during recovery of the epithelial phenotype 
in P-EMT cells. qPCR for mesenchymal markers Cdh11, Col8a2, Pdgfrb, and Snail 
was measured in sorted M-ECAD- P-EMT cells during 6 days of culture in standard 
conditions. 
(C) Quantification of M-ECAD-expressing YFP+ cells in tumors generated from unsorted 
and M-ECAD-sorted KPCY tumor cell lines. C- and P-EMT cell lines were sorted 
based on membrane ECAD (>99% purity of M-ECAD+ or M-ECAD-) and 1 x 104 cells 
were injected subcutaneously into NOD.SCID mice. The resulting tumors (harvested 
when tumors reached 1 cm diameter) were assessed for ECAD expression in YFP+ 
tumor cells by immunofluorescence staining and manual quantification. Data are 
pooled (mean ± SD) from 5 P-EMT cell lines (PD7591, PD454, PD798, PD7242, 
PD883) and 3 C-EMT lines (PD6910, PD483, PD3077). Unsorted P, 95.0% ± 5.3; P 
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E+, 80.5% ± 25.3; P E-, 76.0% ± 24.5; unsorted C, 22.7% ± 32.0; C E+, 26.7% ± 33.7; 
C E-, 15.4% ± 13.8. 
(D) Schematic summarizing the experimental design and results from (B) 
(E) Representative phase-contrast images of P-EMT KPCY tumor cell lines ± TGFβ 
treatment (10 ng/mL, 5 days). 
(F) qPCR for E-cad mRNA with TGFβ treatment or vehicle-only control (10 ng/mL, 5 days) 
in P-EMT KPCY tumor cell lines. 
(G) Western blot for ECAD protein ± TGFβ treatment in P-EMT KPCY tumor cell lines. 
(H) Quantification of M-ECAD-, I-ECAD+ cells ± TGFβ treatment by flow cytometry. 
PD7591, 67.1% ± 3.3; PD7591 + TGFβ, 16.5% ± 2.1; PD798, 85.6% ± 2.3; PD798 + 
TGFβ, 33.8% ± 2.8. 
All data are representative of two or more independent experiments. *, p<0.05; **, p<0.01; 























































































Chapter 2 Figure 5: EMT subtypes exhibit distinct modes of cell migration and 
dissemination 
 
(A) Time-lapse DIC microscopy of P-EMT 798 cells embedded in matrigel. Collectively 
migrating cells emerge from primary tumor sphere. Representative of n=15 tumor 
spheres from 2 independent experiments 
(B) Time-lapse DIC microscopy of C-EMT 3077 cells embedded in matrigel. Collectively 
migrating cells emerge from primary tumor sphere. Representative of n=18 tumor 
spheres from 2 independent experiments 
(C) Representative bright field and fluorescent images of CTCs detected in the blood 
stream of NOD.SCID mice following orthotopic injection of P-EMT 798 or C-EMT 3077 
cells. Data representative of n=3 NOD.SCID mice per condition 
(D) Comparing percentage of single and cluster CTCs/ml between P-EMT 798 or C- EMT 
3077 orthotopic injections in (C). N=5 NOD.SCID mice from two independent 
experiments. 
(E) Single CTC and cluster CTCs from blood of 3077 and 798 orthotopic mice respectively. 
CTCs are stained for YFP (red), ECAD (green) and DAPI (blue). 
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Chapter 2 Figure 6: Distinct EMT subtypes occur in human pancreas, breast, and 
colorectal cancer cell lines 
 
(A, C, E) Relative Ecad mRNA expression in human PDAC (A), breast cancer (C), and 
colorectal cancer (E) cell lines sorted on membranous E-cadherin. 
(B, D, F) Quantification of M-ECAD-, I-ECAD+ cells within human PDAC (B), breast (D) 
and colorectal (F) cancer cell lines. BXPC3, 39.37 ± 3.1% 3 (mean ± SD), CAPAN2, 
40.33 ± 13.1%, HPAC, 53.93 ± 1.629%, PANC1, 7.47 ± 1.9%, MIAPACA2, 1.567 ± 
0.24%. MDA-MB-157, 0.12% ± 0.03; MDA-MB-231, 2.3% ± 0.30; MDA-MB-436, 0.93% 
± 0.09%; BT747, 83.0 ± 1.3%; MCF7, 83.8 ± 4.7%; HCC1937, 80.6% ± 1.6; MDA-MB- 
468, 61.1% ± 11.3; HS675T, 0.6% ± 0.5; HS698T, 0.7% ± 0.1; DLD1, 31.6% ± 2.9; 
HCT116, 69.0% ± 3.7; SW480, 64.0% ± 3.4. 
Each cell line was assessed in triplicate. Lines represent mean ± SD. Data are 
representative of at least two independent experiments for each cell line. 
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Chapter 2 Figure S1: Epithelial and mesenchymal marker expression in KPCY tumors, 
Related to Chapter 2 Figure 1 
 
(A and B). Representative immunofluorescence images from KPCY tumors demonstrating 
that all YFP+ Claudin7 (top panel) and Epcam (bottom panel) negative cells are also 
ECAD negative. 
(C-F) KPCY tumors stained for YFP (red) and ECAD (green) (DAPI nuclear counterstain, 
blue). (C’-F’) KPCY tumors stained for YFP (red) and ZEB1 (C’), SLUG (D’), VIM (E’), 
FSP1 (F’) in green (DAPI nuclear counterstain, blue). Arrows denote M- ECAD- tumor 
cells expressing mesenchymal markers. Arrowheads denote M-ECAD- tumor cells that 
lack expression of mesenchymal markers. 
(G-J) Quantification of ZEB1 (G), SLUG (H), VIM (I) and FSP1 (J) expression in M- ECAD- 
(white bars) and M-ECAD+ (black bars) tumor cells (n=6 tumors; 3 well- differentiated 
and 3 poorly-differentiated). Bars represent mean ± SD. 



































































































































Chapter 2 Figure S2: RNAseq sample quality control, Related to Figure 1 
 
(A) Representative FACS plots of a KPCY tumor and its corresponding unstained control. 
(B) Representative images of sorted KPCY tumor cells illustrating cell purity. 
(C-D) qPCR for a subset of RNAseq samples for CD45 (C) and YFP (D) to check for non-
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Chapter 2 Figure S3: GSEA confirms EMT within RNAseq samples, Related to Chapter 2 
Figure 1 
 
(A) Sorted epithelial (M-ECAD+) and mesenchymal (M-ECAD-) populations from KPCY 
tumors were separated into C-EMT and P-EMT groups as described in Figures 1-3. 
Gene set enrichment analysis (GSEA) was performed between epithelial and 
mesenchymal fractions within each group versus gene sets of established EMT gene 
signatures. 
(B and C) Boxplot distribution of mRNA abundance of several EMT transcription factors 
comparing C-EMT (n=3) and P-EMT (n=8) tumors. Separate comparisons were made 
using M-ECAD+ cells from each tumor type (B) or M-ECAD- cells from each tumor 
type (C). 



























Chapter 2 Figure S4: KPCY tumors demonstrate distinct histological subtypes 
 
H&E images of 11 KPCY tumors used in the RNAseq analysis. Tumor categorized as C-
EMT exhibited poorly-differentiated histology (A) whereas P-EMT tumors exhibited a 






















































































































































































































































































































































































Chapter 2 Figure S5: Tumor subtype correlates with EMT subtype in KPCY tumors 
 
(A) Unsupervised hierarchical clustering of PDA subtype genes from Collisson et al., 2011. 
(B) Unsupervised hierarchical clustering of PDA subtype genes from Moffitt et al., 2015 
(C) Unsupervised hierarchical clustering of PDA subtype genes from Bailey et al., 2016. 
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Chapter 2 Figure S6: Representative flow plots for surface/intracellular ECAD staining,  
 
(A) Gating strategy and representative flow plots for P-EMT KPCY cell line PD483. First, 
cellular debris was excluded by FSC-A and SSC-A, then a “single cell” gate was 
established using FSC-A and FSC-H. M-ECAD- (440/40 Violet-negative) events were 
selected for analysis of I-ECAD (660/20 Red) positivity. A negative control (secondary 
antibody alone) was used for each cell line to determine the placement of gates. 










































































Chapter 2 Figure S7: Tumor and EMT Subtype classification of cell lines in pancreas, 
breast, and colorectal cancer cell lines, Related to Figure 6 
 
(A) Principal components of human PDAC cell lines present in CCLE stratified based on 
PDAC subtype (Classical or Quasi-mesenchymal-like) and EMT subtype (C- or P-
EMT). 
(B) Principal components of breast cancer cell lines present in CCLE stratified based on 
breast cancer subtype (Basal, Luminal A, Luminal B, or Normal-like) and EMT subtype 
(C- or P-EMT). 
(C) Principal components of colorectal cancer cell lines present in CCLE stratified based 















Table S1. Histology of tumors used for RNAseq, Related to Figure 3 
Case Differentiation EMT subtype 
PD345 Sarcomatoid Complete 
PD2412 Sarcomatoid Complete 
PD2204 Poor Complete 
PD798 Moderate Partial 
PD2329 Moderate Partial 
PD2342 Well Partial 
PD2523 Moderate Partial 
PD2904 Moderate Partial 
PD3003 Well Partial 
PD3090 Well Partial 
PD9210 Moderate Partial 
upp nta a
 
Table S2. Gene set enrichment analysis P-values for KPCY tumors, Related to Figure 3 
Publication Gene set Complete EMT Partial EMT 
Collisson, Nat. Med. 2011 Quasi-mesenchymal PDA P = 0.001 NA 
Collisson, Nat. Med. 2011 Classical NA P = 0.002 
Collisson, Nat. Med. 2011 Exocrine-like NA P = 0.244 
Moffitt, Nat. Gen. 2015 Basal-like P = 0.02 NA 
Moffitt, Nat. Gen. 2015 Classical NA P = 0.001 
Bailey, Nature 2016 Squamous (GP2) P = 0.001 NA 
Bailey, Nature 2016 Squamous (GP3) P = 0.003 NA 




CHAPTER 3: CALCIUM SIGNALING INDUCES A PARTIAL EMT 
 
Brief Introduction 
It is increasingly accepted that carcinoma cells exist along a continuum of hybrid E-M 
states (Jolly et al, 2019; Grigore et al, 2016; Yang et al, 2020; Dongre & Weinberg, 2019). 
As reversible transitions between E and M phenotypes appear to be important at different 
stages of metastatic spread (Ocaña et al, 2012; Tsai et al, 2012; Kröger et al, 2019; Tran 
et al, 2014), carcinoma cells exhibiting such hybrid or partial EMT (P-EMT) states can 
more easily navigate barriers to metastatic spread and may thus possess greater 
metastatic competence (Nieto et al, 2016a; Zhang & Weinberg, 2018). Yet the 
mechanisms by which cells adopt such intermediate states are unknown. 
In the previous chapter, we used an autochthonous model of pancreatic ductal 
adenocarcinoma (PDA), we reported and characterized a P-EMT subtype that is a 
common feature of stochastically-arising pancreatic tumors (Aiello et al, 2018). P-EMT in 
vivo is not associated with transcriptional repression of epithelial genes but rather occurs 
through a non-canonical program characterized by the relocalization of epithelial proteins 
(Aiello et al, 2018). Importantly, this phenomenon is not limited to PDA but also describes 
the molecular events underlying P-EMT in a variety of human carcinomas. 
In this chapter, we investigated the molecular signals underlying this newly 
described P-EMT program. We find that prolonged calcium signaling induces a P-EMT 
phenotype characterized by the internalization of membranous E-cadherin (ECAD) and 
an increase in cellular migration and invasion. These effects are recapitulated by signaling 
through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through 
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downstream activation of calmodulin. These results implicate calcium signaling as a driver 
of a hybrid/partial epithelial-mesenchymal state in carcinoma cells. 
Ca2+ signaling is enriched in P-EMT tumor cells 
For clues regarding the molecular pathways responsible for P-EMT, we examined 
transcriptomic data from our prior in vivo analysis (Aiello et al, 2018). In that study, we 
used flow cytometry for the epithelial protein E-cadherin (ECAD) to isolate tumor cells 
exhibiting an epithelial phenotype (surface ECAD+) or a mesenchymal phenotype (surface 
ECAD-) and performed RNA-seq. This analysis stratified tumors into two “EMT subtypes” 
– those that employed a classical or complete EMT program (C-EMT), involving 
transcriptional repression of epithelial genes, and those that employed an alternative 
partial EMT program (P-EMT) characterized by post-translational internalization of 
epithelial proteins including ECAD (Aiello et al. 2018 and Chapter 3 Fig. S1A, B). 
At a global transcriptional level, both subtypes carried robust EMT signatures 
(Aiello et al, 2018). Hence, our re-analysis focused on pathways that were exclusively 
enriched in P-EMT tumors relative to C-EMT tumors. To this end, we performed gene set 
enrichment analysis (GSEA) of the entire dataset – comparing the ECAD+ and ECAD- cell 
populations of each EMT subtype – and ranked those pathways that were uniquely 
associated with the P-EMT program (Chapter 3 Fig. S1C). Strikingly, 15 of the top 25 P-
EMT-associated gene sets were related to ion transport, especially calcium (Chapter 3 
Fig. 1A, S1C). Likewise, HOMER motif analysis of differentially expressed genes in ECAD- 
vs. ECAD+ cells revealed strong enrichment for Nuclear Factor of Activated T cells 
(NFAT), a calcium regulated transcription factor, only in P-EMT tumors (Chapter 3 Fig. 
1B). As expected, a complementary analysis of C-EMT tumors revealed enrichment for 
pathways related to mRNA binding, DNA/chromatin binding, and SMAD signaling 
73 
 
(Chapter 3 Fig. S1D), and enrichment for binding sites for the EMT-TF Slug-Snai2 
(Chapter 3 Fig. S1E). Based upon these results, we hypothesized that calcium signaling 
may contribute to P-EMT. 
To test this hypothesis, we first asked whether the E-M state of a cell is correlated 
with intracellular calcium concentration ([Ca2+]). We previously demonstrated that in the 
absence of any EMT inducer, carcinoma cells exist in an equilibrium between epithelial 
and mesenchymal states, whereby EMT and its reverse process mesenchymal-to-
epithelial transition (MET) occur spontaneously (Aiello et al, 2018; Yuan et al, 2020). We 
therefore introduced a genetically encoded Ca2+ indicator protein, GCaMP6, into three 
murine PDA cell lines, designated cells as either E or M based upon morphology (see 
Methods), and measured relative levels of fluorescence as a function of cellular state. As 
shown in Chapter 3 Fig. 1C, cells with an E morphology (typically part of a colony; red 
arrows) exhibited low fluorescence levels, while cells with an M morphology (typically 
spindle-like and separated from colonies; yellow arrows) exhibited high fluorescence 
levels. To quantitate this effect, we performed flow cytometry on GCaMP6 expressing 
tumor cells pre-incubated with either 0 mM or 2 mM Ca2+ and then determined E-M status 
by staining cells for surface ECAD expression. Cells grown in 0 mM Ca2+ exhibited 
low/background GCaMP6 fluorescence that was equivalent in ECADLow (mesenchymal) 
and ECADHigh (epithelial) cells. In 2 mM Ca2+, both populations exhibited an increase in 
GCaMP6 fluorescence; however, ECADLow (mesenchymal) cells exhibited significantly 
greater fluorescence (Chapter 3 Fig. 1C). Similar results were obtained with the ratiometric 
Ca2+ indicator Indo-1 (Chapter 3 Fig. 1D). Taken together, these results suggest that 
carcinoma cells with a mesenchymal phenotype have a higher intracellular [Ca2+] 




Ca2+ influx is sufficient to drive a P-EMT phenotype and increased migration and 
invasion 
Altered calcium homeostasis has been described in association with several hallmarks of 
cancer, including proliferation, survival, migration, metastasis, and C-EMT under certain 
contexts, (Stewart et al, 2015; Monteith et al, 2017; Davis et al, 2014). We therefore sought 
to determine whether the observed association between intracellular Ca2+ and EMT was 
correlative or whether Ca2+ influx could directly influence a P-EMT state. To this end, we 
treated a panel of murine PDA carcinoma cell lines with either vehicle (DMSO), TGFb (a 
potent EMT inducer), or ionomycin, a calcium ionophore that promotes Ca2+ influx 
(Chapter 3 Fig. S2A). Because sustained elevations in intracellular [Ca2+] are toxic to 
normal cells (Roderick & Cook, 2008), we first confirmed that the treatment did not reduce 
the viability of our carcinoma cells (Chapter 3 Fig. S2B). 
Next, we examined the effects on cell morphology following treatment with these agents. 
As expected, TGFb-treated cells adopted a spindle-like morphology and complete loss of 
ECAD staining, consistent with an EMT (Chapter 3 Fig. 2A, bottom row). Ionomycin 
treatment also led to significant changes in cell morphology; however, cells retained 
expression of ECAD (Chapter 3 Fig. 2A, middle panel). Notably, ECAD was found in the 
cytoplasm of ionomycin-treated cells, as compared to the predominant membrane staining 
observed in vehicle-treated cells (Chapter 3 Fig. 2A, compare middle and top rows). This 
loss of membrane staining was confirmed by flow cytometry, which revealed a significant 
reduction of surface ECAD (Chapter 3 Fig. 2B). Next, we performed a time course 
experiment, collecting protein and mRNA samples at 24h intervals following treatment with 
ionomycin or TGFb. As expected, TGFb treatment resulted in a rapid decrease of ECAD 
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at both the protein and mRNA level (Chapter 3 Fig. 2C (Top)). By contrast, cells treated 
with ionomycin exhibited no change in ECAD mRNA or protein (whole cell lysate), while 
vimentin, a mesenchymal marker, was upregulated at the protein level following both 
treatments (Chapter 3 Fig. 2C (Bottom)). 
To examine whether Ca2+-induced P-EMT is generalizable to human cancer cells, we 
treated human lung (HCC827), breast (MCF7), and PDA (Capan2) carcinoma lines with 
either ionomycin or TGFb. While both agents prompted striking morphological changes 
and a decrease in surface ECAD levels (Chapter 3 Fig. S2C, S2D), ionomycin-treated 
cells exhibited no change in ECAD mRNA and an increase in VIM mRNA (Chapter 3 Fig. 
S2E), consistent with our results using murine lines. Of note, P-EMT in human cells 
occurred more rapidly with ionomycin than TGFb. Specifically, robust changes in cellular 
phenotype and surface ECAD were observed after only 48h of ionomycin treatment, while 
comparable changes following TGFb treatment were not observed before day 10 (Chapter 
3 Fig. S2C). 
Increases in migration and invasion are hallmarks of EMT. To determine whether 
increased intracellular [Ca2+] prompts cells to move, we performed live cell imaging 
following treatment with TGFb, ionomycin, or vehicle. Cells treated with ionomycin 
exhibited a 1.7-fold increase in movement, as compared to a 2.4-fold increase following 
TGFb treatment (Chapter 3 Fig. 2D). To study invasion, we performed a Boyden chamber 
transwell migration assay and measured cellular mobility through Matrigel. Ionomycin 
treatment led to a significant increase in cellular invasion (Chapter 3 Fig. 2D). Taken 
together, these results indicate that carcinoma cells treated with ionomycin exhibit multiple 
phenotypic characteristics of P-EMT: (i) adoption of a mesenchymal morphology, (ii) 
internalization of ECAD protein without change in corresponding mRNA levels, (iii) 
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acquisition of mesenchymal protein expression, and (iv) an increase in migratory and 
invasive properties. 
 
Ionomycin treatment induces mesenchymal gene transcription without repressing 
epithelial gene transcription 
Classically, EMT has been associated with the simultaneous repression of epithelial genes 
and induction of mesenchymal genes. We reported previously that while loss of the 
epithelial program occurs post-transcriptionally in P-EMT, the induction of mesenchymal 
genes at the mRNA level is comparable in P-EMT and C-EMT (Aiello et al, 2018). To 
obtain a global picture of changes in gene expression associated with increased 
intracellular [Ca2+], we treated murine PDA cell lines with vehicle, ionomycin, or TGFb for 
48 hours and performed RNA-sequencing (Chapter 3 Fig. 3A). By principal component 
analysis (PCA), TGFb-treated samples were widely separated from vehicle- and 
ionomycin-treated samples, suggesting that ionomycin treatment brought about 
comparatively fewer transcriptional differences (Chapter 3 Fig. S3A). Next, we examined 
the abundance of specific epithelial and mesenchymal transcripts previously implicated in 
EMT. As expected, TGFb treatment led to a robust downregulation of mRNAs for epithelial 
genes such as ECAD, EpCAM, and epithelial cytokeratins, while ionomycin treatment had 
little effect on the abundance of these epithelial transcripts (Chapter 3 Fig. 3A, Chapter 3 
Fig. S3B). Consistent with our previous in vivo findings regarding P-EMT and C-EMT, both 
ionomycin and TGFb treatment resulted in an upregulation of mesenchymal-related 
transcripts (Chapter 3 Fig. 3A), and GSEA confirmed that the transcriptomes of ionomycin-
treated cells were highly enriched for EMT signatures (Chapter 3 Fig. 3B). As expected, 
calcium-related signatures were strongly enriched following ionomycin treatment, whereas 
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these signatures were not enriched following TGFb treatment (Chapter 3 Fig. 3C). We 
then compiled lists of genes that were differentially expressed between ECAD+ and 
ECAD- cells from our in vivo analysis and compared them to the genes whose mRNAs 
changed following TGFb or ionomycin treatment in vitro. TGFb treated samples were 
strongly enriched for the C-EMT signature, whereas ionomycin treated samples were 
strongly enriched for the P-EMT signature (Chapter 3 Fig. 3D). Finally, a multinomial 
logistic regression (MLR)-based quantitative EMT metric (Chakraborty et al, 2020) 
revealed that TGFb-treated cells exhibited a more mesenchymal state relative to those 
treated with DMSO or ionomycin (Chapter 3 Fig. S3C). Thus, TGFb treatment 
recapitulates the transcriptional changes associated with C-EMT programs in vivo, while 
ionomycin treatment recapitulates the transcriptional changes associated with P-EMT 
programs in vivo. 
To investigate changes in protein abundance accompanying these divergent EMT 
programs, we examined tumor-derived exosomes as a window into the proteome. We 
collected exosomes from three cell lines after 72h of treatment with vehicle, ionomycin or 
TGFb and performed mass spectrometry, capturing approximately 2700 proteins (Chapter 
3 Fig. S3D). The three treatments resulted in highly distinctive proteomes as visualized by 
PCA (Chapter 3 Fig. 3SE). Consistent with our mRNA results, TGFb treatment depleted 
epithelial proteins from tumor-derived exosomes, whereas ionomycin had little effect on 
the abundance of these proteins (Chapter 3 Fig. S3F, G). These results confirm that the 




GPCR signaling through Gaq induces P-EMT 
Many signals could potentially drive a P-EMT by mobilizing intracellular Ca2+. We 
hypothesized that G protein coupled receptors (GPCRs) – particularly those that utilize a 
Gaq subunit, which mobilizes Ca2+ following receptor engagement – might play such a 
role, as GPCRs are frequently overexpressed in cancer (Dorsam & Gutkind, 2007; Bar-
Shavit et al, 2016). To test this hypothesis, we employed a synthetic ligand system in 
which GPCR-Gaq signaling can be induced with the experimentally derived drug 
clozapine-N-oxide (CNO) (Armbruster et al, 2007; Vaqué et al, 2013; Conklin et al, 2008). 
We generated two murine PDA lines overexpressing Gaq-GPCR Designer Receptors 
Exclusively Activated by Designer Drugs (DREADD), an engineered receptor that 
mobilizes Ca2+ following addition of CNO (Chapter 3 Fig. 4A, top). Treatment with CNO 
resulted in a change in cell morphology and loss of surface ECAD, recapitulating the 
phenotypes observed with ionomycin (Chapter 3 Fig. 4B). Of note, a transient calcium 
spike, as elicited by ATP, was not sufficient to cause this phenotype (Chapter 3 Fig. 4A, 
bottom), suggesting that sustained but not transient Ca2+ mobilization is required for 
induction of P-EMT. 
 
Calcineurin (CaN) is dispensable for calcium-induced P-EMT 
An increase in intracellular [Ca2+] results in the activation of several downstream 
mediators, including the transcription factor NFAT, the adaptor protein calmodulin, and 
calcium-activated protein kinases. Based on our HOMER motif analysis (Chapter 3 Fig. 
1B), we initially hypothesized that the calcium responsive transcription factor NFAT might 
be responsible for the P-EMT phenotype. In support of such a hypothesis, several in vitro 
and in vivo studies have reported a role for NFAT in tumor development, migration, and 
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EMT (Baumgart et al, 2014; Singh et al, 2015; Mancini & Toker, 2009; Subbalakshmi et 
al, 2020). To test this hypothesis, we inactivated the NFAT regulator calcineurin (CaN), 
which is required for the activity of nearly all NFAT family members (NFAT1-4) (Crabtree 
& Olson, 2002; Heit et al, 2006). To this end, we deleted the calcineurin B (CnB) regulatory 
subunit in two PDA cell lines (Chapter 3 Fig. S4A) and used the pGL3-NFAT Luciferase 
reporter, which contains 3x NFAT binding sequences upstream of a luciferase reporter, to 
confirm that CnB KO cells lacked detectable NFAT activity following ionomycin treatment 
(Chapter 3 Fig. S4B). Nevertheless, CnB KO cells treated with ionomycin continued to 
exhibit a P-EMT phenotype (Chapter 3 Fig. 4C and data not shown), indicating that CaN 
and NFAT activity are dispensable for Ca2+-induced P-EMT. 
 
Calmodulin (CaM) acts downstream of Ca2+ mobilization to induce P-EMT 
We next considered calmodulin (CaM), which acts as a multifunctional calcium binding 
protein upstream of calcineurin and NFAT. When calcium binds to the EF hands of 
calmodulin, a conformational shift allows calmodulin to interact with and regulate a variety 
of kinases, phosphatases, and other signaling proteins (Villalobo & Berchtold, 2020). 
Because the mammalian genome contains three dispersed CaM genes, whose functions 
are essential for cell viability, genetic targeting of CaM is challenging. Consequently, we 
tested the ability of the CaM antagonist W7 to inhibit P-EMT (see Methods). Pretreatment 
of cells with W7 for 24h blocked ionomycin-induced P-EMT, as measured by loss of 
surface ECAD (Chapter 3 Fig. 4D). Moreover, W7 treatment alone resulted in increased 
surface ECAD expression (Chapter 3 Fig. 4D). These results indicate that CaM is 




Summary and Discussion 
While EMT has long been associated with tumor cell migration and chemoresistance, 
recent studies have pointed to the importance of a hybrid E-M state – P-EMT – as this 
state exhibits greater plasticity and metastatic potential (Nieto et al, 2016a; Zhang & 
Weinberg, 2018). Ca2+ signaling is known to play a role in cellular migration and cancer 
progression (Davis et al, 2014; Monteith et al, 2017; Azimi & Monteith, 2016) and a 
requirement for Ca2+ mobilization has previously been reported in hypoxia- or EGF-
induced EMT in breast cancer (Davis et al, 2014; Monteith et al, 2017; Azimi & Monteith, 
2016).Here, using an unbiased approach based on in vivo observations, we show that 
Ca2+ mobilization induces a stable P-EMT characterized by the re-localization of epithelial 
proteins and increased invasion and migration. Given that our in vitro findings recapitulate 
the cellular phenotypes observed in authochthonous tumors (Aiello et al, 2018), we 
conclude extracellular signals resulting in increased Ca2+ flux are at least one mechanism 
by which tumor cells achieve a partial EMT state. 
These findings raise several questions. First, which GPCR(s) are responsible for 
EMT in native tumors, and what are their cognate ligands? The mammalian genome 
contains hundreds of GPCRs, many of which are orphan receptors. We identified 90 
GPCRs that are differentially expressed between P-EMT and C-EMT tumors in vivo 
(Chapter 3 Fig. S5A), a number that is impractical to study sequentially. This issue 
highlights a broader problem in the EMT field, which is that the physiologic inducers of 
EMT in vivo remain ill-defined. Consequently, it is possible (or even likely) that multiple 
signals act in combination within the tumor microenvironment to achieve critical thresholds 
of intracellular calcium, TGFb pathway activation, and/or other EMT mediators. A second 
question concerns the mechanism by which elevated intracellular [Ca2+] alters the 
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epithelial program. Our data indicate that Ca2+- induced EMT requires calmodulin, a 
calcium binding protein that interacts with hundreds of cellular proteins. This complexity 
poses a challenge for the elucidation of a simple molecular pathway, as multiple 
calmodulin binding partners may be involved in the cellular processes underlying epithelial 
plasticity. Finally, our findings raise the possibility that Ca2+ mobilization plays a role in 
EMT in other contexts, such as embryonic development, as is the case for the canonical 
EMT programs driven by epithelial gene repression. 
In summary, our data suggest a model wherein activation of a Gaq associated 
GPCR mobilizes calcium, which in turn acts through calmodulin to prompt changes in gene 
expression, the cytoskeleton, and protein trafficking, resulting in a stable, hybrid E-M state 
(Chapter 3 Fig. S4C). As the Ca2+-mediated effects described here are not limited to 
murine PDA but are also observed in human cancer cells, this P-EMT program is likely to 
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elucidating the mechanism downstream of calcium.   
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Materials and Methods 
Cell lines 
Murine PDA cell lines PD7591 (female), PD798 (male), PD483 (female), PD3077 (male), 
PD454 (male), PD883 (male) were derived from primary KPCY tumors of mixed genetic 
background. All human cell lines (Capan2, MCF7, HCC827) were obtained originally from 
ATCC. Cell lines were regularly tested for mycoplasma using MycoAlert Mycoplasma 
Detection Kit (Lonza). Murine cell lines were cultured in Dulbecco’s Modified Eagle 
Medium/F12 medium supplemented with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL 
soybean trypsin inhibitor type I (Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS 
Premix; BD Biosciences), 25 µg/mL bovine pituitary extract (Gemini Bio-Products), 5 
nmol/L 3,3′,5-triiodo-L-thyronine (Sigma), 1 µmol/L dexamethasone (Sigma), 100 ng/mL 
cholera toxin (Sigma), 10 mmol/L nicotinamide (Sigma), 5% Nu-serum IV culture 
supplement (ThermoFisher Scientific), and antibiotics (gentamicin 150 µg/mL, Gibco; 
amphotericin B 0.25 µg/mL, Invitrogen). Human PDA and breast cell lines were cultured 
in Dulbecco’s Modified Eagle Medium supplemented to 10% decomplemented fetal 
bovine serum and 1% penicillin/streptomycin. Human lung cell lines were cultured in RPMI 
1640 supplemented to 10% decomplemented fetal bovine serum with 1% 
penicillin/streptomycin. All lines were cultured at 37°C, 5% CO2, 21% O2 and 100% 
humidity. Cell lines were maintained and passaged according to ATCC recommended 
procedures. 
 
Drugs and ligands 
Mouse (Cell Signaling Technology (CST) 5231LC) or human (CST 8915LC) TGFb was 
resuspended in 20mM Citrate pH 3.0 per instructions. Ionomycin calcium salt (CST 
9995S) was resuspended in DMSO per instructions. W7-HCl (Santa Cruz sc-201501) was 
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resuspended in DMSO per instructions. All solutions were used as indicated in text or 
figure legends. 
 
Flow cytometry and Fluorescence-Activated Cell Sorting (FACS) 
For detailed protocol see references(Aiello et al, 2018; Norgard & Stanger, 2021). Briefly, 
for ECAD flow cytometry, cells were dissociated to single cells with Hanks Enzyme Free 
Cell Dissociation Solution (EMD Millipore). Cells were washed in staining solution (HBSS 
with 5% FBS and DNase I (Sigma) and stained with anti-ECAD (BioLegend 147308 or 
147319) or isotype control (BioLegend 400418 or 400430) at 1:100 in staining solution on 
ice for 30 min. Cells were washed 3X in staining solution, filtered through a 70 µM strainer, 
and counterstained with DAPI prior to flow cytometry on a LSR II or FACSJazz, BD. Flowjo 
software was used for analysis. For more information see 
 
Lentivirus production and transduction 
Transfection of 293Ts for lentivirus production was performed using Opti-MEM I (GIBCO), 
DNA (expression plasmid, psPAX2, and pVSVg mixed in a 4:2:1 ratio), and 
polyethylenimine (PEI, Polysciences) at a 3:1 ratio with total DNA. Recipient cells were 
transduced with filtered, unconcentrated viral supernatant in the presence of 8 μg/mL 
polybrene. Puromycin antibiotic selection at 5-10 μg/mL was applied for at least 72 hours. 
 
RNA Isolation, real-time quantitative PCR (RT-qPCR) 
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RNA was prepared from cultured tumor cells using RNeasy Mini Kit (Qiagen) or 
NucleoSpin RNA (Takara). For RT-qPCR, cDNA was generated using High- capacity 
cDNA Reverse Transcription Kit (Life Technologies). RT-qPCR analysis was performed 
with SsoAdvanced SYBR (Bio-Rad) using a CFX384 Real-Time System (Bio- Rad). 
Transcript quantities were determined using the difference of Ct method and values were 
normalized to the expression of GAPDH or TBP. Primer sequences are listed in 
Supplementary Table S1. 
 
Plasmid construction and cloning 
GCaMP6 (a gift from Bruce Freedman) was cloned into pCDH-FHC-EF1 using BamH1 
and Swa1. GCaMP6 was transduced in YFP- tumor cells that were generated by inserting 
sgRNA towards YFP into lentiCRISPR v2, a gift from Feng Zhang (Addgene plasmid # 
52961) using BsmBI. Primers used are listed in Supplementary Table S2. Gaq-DREADD 
lentiviral vector DNA was a kind gift from Dr. Silvio Gutkind. 
 
Measurement of cytosolic Ca2+ flow cytometry by GCaMP6 
Tumor cells expressing GCaMP6 were dissociated with Hanks Enzyme Free Cell 
Dissociation Solution (EMD Millipore). Cells were then stained with anti-ECAD (BioLegend 
147308 or 147319) or isotype control (BioLegend 400418 or 400430) at 1:100 in staining 
solution on ice for 30 minutes. Cells were washed three times in staining solution and then 
placed in either 0mM or 2mM Tyrodes solution on ice. After equilibrium for 1 hour, cells 
were stained with DAPI prior to flow cytometric analysis on BD LSR II flow cytometer. 




Measurement of cytosolic Ca2+ flow cytometry by Indo-1 calcium indicator 
Cells were loaded with Indo-1 at a final concentration of 1.5μM for 45 mins at 37°C in an 
incubator. Cells were washed twice with PBS and dissociated with Hanks Enzyme Free 
Cell Dissociation Solution (EMD Millipore). Cells were then stained with anti-ECAD 
(BioLegend 147308 or 147319) or isotype control (BioLegend 400418 or 400430) at 1:100 
in staining solution on ice for 30 minutes. Cells were washed three times in staining 
solution and then placed in either 0mM or 2mM Tyrodes solution on ice. After equilibrium 
for 1 hour, cells were stained with DAPI prior to flow cytometric analysis on BD LSR II flow 
cytometer. Single cell ratios of bound to unbound was performed using flowjo software. 
 
Measurement of cytosolic Ca2+ changes 
Cytosolic Ca2+ was assessed by plating cells on glass coverslips. Cells were loaded with 
Fura-2 AM (Invitrogen F1221) at 1μM for 30 minutes at 37°C. Time-lapse images were 
recorded (2s interval) using a NikonTi system using a 20x/0.75 NA objective for 
fluorescence at 340 nm excitation/515 nm emission (Ca2+-bound Fura2) and 380nm 
excitation/515 nm emission (Ca2+-free Fura2). ATP, TGFb, CNO, or ionomycin were 
spiked in after equilibration. Data were analyzed with ImageJ and presented as traces of 
mean (bold line) and SEM (error bars) for all data points (time vs fluorescent ratio). 
 
Matrigel invasion assay 
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Transwell inserts (Corning 3464) were coated with matrigel and placed above complete 
DMEM. Cells were serum starved in 0.2% serum DMEM for 24 hours. Cells were seeded 
in serum-free DMEM on top of the matrigel layer and incubated for 24 hours. Transwell 
inserts were removed, washed three times, and fixed in 4% PFA for 15 minutes. Fixed 
matrigel inserts were washed three times, stained with DAPI, and imaged. 
 
Live cell migration 
Cells were seeded on glass coverslips and treated for 24 hours prior to imaging with 
DMSO, Ionomycin (2.5 μM) or TGFb (5ng/ml). Images were recorded every 8 minutes 
using an ImageXpress Micro 4 High Content Imaging Device. IMARIS (Bitplane, Oxford 
Instruments) was used to quantify migration and create movies. 
Cell viability assay 
Cells were plated in a six well dish and treated with DMSO, Ionomycin (2.5 μM), or TGFb 
(5ng/ml) for 48 hours. Etoposide (50μM) was added for 24 hours as a positive control. 
Cells were stained with eBioscience Annexin V Apoptosis Detection Kit APC (88-8007-72) 
according to manufacture instructions. DAPI (1mg/ml) was added prior to analysis by flow 
cytometry. 
 
RNA-seq, GSEA, and HOMER 
RNA samples were extracted using the Qiagen RNeasy or Takara NucleoSpin RNA kit 
following manufacturer’s instructions. RNA was sent out to Novogene for library 
preparation and high-throughput sequencing using Illumina sequencers to generated 
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paired-end results. Raw counts of gene transcripts were obtained using an alignment-
independent tool, Salmon (https://combine-lab.github.io/salmon/), using standard settings. 
The raw count matrix was subsequently imported into R-studio (R version 3.5) and used 
as input file for DESeq2 analysis 
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html) with default settings 
from online software instruction for normalization and differential gene expression analysis. 
Salmon was used to normalize and quantitate gene expression in transcripts-per-million 
(tpm) through quasi-alignment. Differentially expressed genes were used as input for 
principal component analysis (PCA), gene set enrichment analysis (GSEA) 
(https://www.gsea-msigdb.org/gsea/index.jsp) and motif analysis using HOMER 
(http://homer.ucsd.edu/homer/ngs/index.html). Detailed Scripts and parameters used for 
each steps of analysis could be provided by reasonable request to the authors. 
 
Western blot analysis 
Cells were washed with ice cold PBS and lysed in an appropriate amount of RIPA buffer. 
Equal amounts of protein were run in reducing conditions on SDS-PAGE gels and 
transferred to PVDF membrane, blocked in 5% non-fat milk in PBS plus 0.1% Tween-20 
for 1 hour at room temperature. After blocking, membranes were incubated in primary 
antibody diluted in 5% non-fat milk in PBS plus 0.1% Tween-20 overnight at 4°C. After 
PBS-T washes, membranes were incubated with horseradish peroxidase-conjugated 
secondary antibodies (Jackson Immunoresearch) diluted in 5% non-fat milk in PBS plus 
0.1% Tween-20 for 1 hour at room temperature. Primary antibodies used are located in 






Immunofluorescent staining (IF) 
Cells were seeded into 8-well Nunc Lab-Tek II chamber slides (Thermo Scientific) and 
fixed in 4% paraformaldehyde for 15 mins. Fixed cells were blocked and permeabilized in 
PBS with 0.3% Triton-X and 5% donkey serum for 1 hour. After blocking, cells were 
incubated in primary antibody diluted in 5% donkey serum overnight at 4°C. After PBS-T 
washes, cells were incubated in fluorescently-conjugated secondary antibodies, and 
mounted with Aqua Polymount (Polysciences, Inc). Slides were visualized using an 
Olympus IX71 inverted multicolor fluorescent microscope equipped with a DP71 camera. 
Primary antibodies used are located in Supplementary Table S3. 
 
NFAT Reporter Assay 
pGL3-NFAT luciferase (addgene #17870) and pRL-SV40 (Promega E2231) were 
transfected into tumor cells using Lipofectamine 2000 at a ratio of 3:1 for PDAC cells. 
Media was changed after 6 hours. Cells were treated with DMSO, Ionomycin (2.5 μM), or 
TGFb (5ng/ml) for 24 hours. Luciferase activity was analyzed using dual-luciferase 
reporter assay system (Promega E1910) and read on a luminometer. 
 
Exosomes purification, characterization and analyses 
Exosomes were purified by sequential ultracentrifugation, as described previously 
(Hoshino et al, 2015). In brief, cell contamination was removed from 3-4 day cell culture 
supernatant by centrifugation at 500 xg for 10 min. To remove apoptotic bodies and large 
cell debris, the supernatants were then spun at 3,000 xg for 20 min, followed by 
centrifugation at 12,000 xg for 20 min to remove large microvesicles. Finally, exosomes 
were collected by spinning at 100,000 xg for 70min. Exosomes were washed in PBS and 
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pelleted again at 100,000 xg for 70min by ultracentrifugation in a Beckman Coulter Optima 
XE or XPE ultracentrifuge. The final exosomes pellet was resuspended in PBS, and 
protein concentration was measured by BCA (Pierce, Thermo Fisher Scientific). 
Exosomes size and particle number were analyzed using the LM10 or DS500 nanoparticle 
characterization system (NanoSight, Malvern Instruments) equipped with a violet laser 
(405 nm). 
 
Data-dependent analysis of exosomes samples 
Exosomes samples (5ug - adjusted based on BCA measurements) were dried by vacuum 
centrifugation and re-dissolved in 30-50uL 8M Urea/50mM ammonium bicarbonate/10mm 
DTT. Following lysis and reduction, proteins were alkylated using 20 or 30mM 
iodoacetamide (Sigma). Proteins were digested with Endopeptidase Lys C (Wako) in <4M 
urea followed by trypsination (Promega) in <2M Urea. Peptides were desalted and 
concentrated using Empore C18-based solid phase extraction prior to analysis by high 
resolution/high mass accuracy reversed phase (C18) nano-LC-MS/MS. Typically, 30% of 
samples were injected. Peptides were separated on a C18 column (12 cm / 75 µm, 3 µm 
beads, Nikkyo Technologies) at 200 or 300 nl/min with a gradient increasing from 1% 
Buffer B/95% buffer A to 40% buffer B/60% Buffer A in typically 90 or 120 min (buffer A: 
0.1% formic acid, buffer B: 0.1% formic acid in 80% acetonitrile). Mass spectrometers (Q-
Exactive, Q-Exactive Plus, Q-Exactive-HF or Fusion Lumos, Thermo Scientific) were 
operated in data dependent (DDA) positive ion mode. 
 
Proteomic database search 
High resolution/high mass accuracy nano-LC-MS/MS data was processed using 
Proteome Discoverer 1.4.1.14/Mascot 2.5. Mouse data was queried against UniProt’s 
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Complete MOUSE proteome (March, 2020; 55,412 sequences) using the following 
parameters: Enzyme: Trypsin/P, maximum allowed missed cleavage sites: 2, 
monoisotopic precursor mass tolerance: 10 ppm, monoisotopic fragment mass tolerance: 
0.02 Da, dynamic modifications: Oxidation (M), Acetyl (Protein N-term), static modification: 
Carbamidomethyl (C). Percolator was used to calculate peptide False Discovery Rates 
(FDR), which was calculated per file. 1% FDR was applied to each separate LC-MS/MS 
file. For exosomes samples that had been in contact with Fetal Bovine Serum (FBS, 
exemplified by samples that originated from cell culture) an FBS specific database was 
concatenated to the mouse databases when querying the data. 
 
EMT score analysis 
EMT scores for RNA-seq data were calculated using MLR and 76GS EMT scoring 
methods (Chakraborty et al, 2020). The higher the MLR score, the more mesenchymal 
the sample is. The higher the 76GS score, the more epithelial the sample is. 
 
Software 
PRISM software was used for the statistical analysis and data visualization 
(http://www.graphpad.com). ImageJ software (U.S. National Institutes of Health) was used 
for data analysis. The R language and environment for statistical computing and graphics 
(https://www.r-project.org) was utilized in this study for the statistical and bioinformatics 
analysis of RNA-seq. The R packages used for the analysis described in the method 
section were obtained from the Bioconductor (https://www.bioconductor.org) and CRAN 






All sequencing data has been deposited in the Gene Expression Omnibus (GEO): 
GSE157892. 
 
Quantification and Statistical Analysis 
Statistical analysis of multiple comparisons was performed using ANOVA with Tukey’s 
multiple comparison test, and comparisons between two groups were performed using 
Students’ unpaired t-test. All statistical analyses were performed with Graphpad Prism 8. 
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Chapter 3 Figure 1: Ca2+ signaling is enriched in P-EMT cells 
 
(A) Representative calcium signature enriched in P-EMT tumors (comparing ECAD- vs. 
ECAD+ tumor cells). NES, nominal P-value, and FDR are shown. 
(B) HOMER motif analysis comparing P-EMT ECAD- versus ECAD+ tumor cells. The five 
most enriched motifs are shown. 
(C) Representative image of tumor cells transduced with GCaMP6 (LEFT). Yellow arrows 
(mesenchymal cells), red arrows (epithelial cells), scale bar = 50µm. GCaMP6 mean 
fluorescent intensity (MFI) in ECADHIGH or ECADLOW cells cultured in indicated 
medium (0 Ca2+ or 2 Ca2+) for 1h (RIGHT). Representative of 3 independent cell 
lines run in triplicate. Statistical analysis by Student’s unpaired t-test (*, p<0.05; non-
significant (NS); ±SD). 
(D) Flow cytometry analysis of ECADHIGH or ECADLOW cells loaded with Indo-1 and 
cultured in indicated medium (0 Ca2+ or 2 Ca2+) for 1h. Representative of 2 
independent cell lines with n indicating the number of cells analyzed in each group. 
Each experiment was performed in triplicate. Statistical analysis by Student’s unpaired 









Chapter 3 Figure 2   
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Chapter 3 Figure 2: Ca2+ influx is sufficient to drive a P-EMT phenotype and increased 
migration and invasion 
 
(A) Representative 20X brightfield and fluorescent images of YFP+ tumor cells treated for 
72h with vehicle control (DMSO), 2.5µM Ionomycin, or 10ng/ml TGFb and co-stained 
for E- cadherin (Red) and DAPI (Blue). 
(B) Representative flow cytometry analysis of surface ECAD (Left), MFI of surface ECAD 
(Middle), and percentage of surface ECAD negative cells (Right), after treatment with 
DMSO, 2.5µM Ionomycin (IONO), and 10ng/ml TGFb for 72h. Statistical analysis by 
ANOVA (****, p<0.0001; non-significant (NS); ±SD). 
(C) Top: Relative mRNA expression of Ecad after treatment with 2.5µM ionomycin or 
10ng/ml TGFb for denoted time. Bottom: Western blot analysis of total E-cadherin and 
Vimentin protein for denoted time. Experiment was run in duplicate with three different 
cell lines. Statistical analysis by ANOVA (***, p<0.001; non-significant (NS); ±SEM). 
(D) Quantification of live cellular migration over 4h (TOP). N=16 cells per condition. 
Experiment was run in triplicate in two different cell lines. Quantification of transwell 
migration after treatment with DMSO, 2.5µM Ionomycin (IONO), or 10ng/ml TGFb for 
72h (n= 2 cell lines, 3 replicates per cell line with 3 20X images taken per transwell) 
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Chapter 3 Figure 3: Ionomycin treatment induces mesenchymal gene transcription without 
repressing epithelial gene transcription 
 
(A) Schematic for RNA sequencing after EMT induction for 48h. Heatmap illustration of 
EMT related genes in three independent cell lines, sequenced in duplicate, treated 
with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb. 
(B) GSEA of ionomycin versus DMSO (left) or TGFb versus DMSO (right) for EMT 
signatures. NES, nominal P-value, and FDR are shown. 
(C) GSEA of ionomycin versus DMSO (left) or TGFb versus DMSO (right) for calcium 
signatures. NES, nominal P-value, and FDR are shown. 
(D) Leading edge plots showing enrichment of C-EMT gene signatures in TGFb treated 
cells (left) or P-EMT gene signatures in ionomycin (IONO) treated cells (right), based 


































































































































































































Chapter 3 Figure 4: Gaq signaling acts through calmodulin to induce P-EMT 
 
(A) Fura-2 Ca2+ measurements after addition of 5µM CNO (top) or 10µM ATP (bottom) 
in cells expressing a Gaq-DREADD. Blue line indicates average of n=22 cells. ±SD. 
Tracings are representative of experiments performed twice in 2 independent cell lines. 
(B) Representative 20X brightfield images of Gaq-DREADD-expressing cells 48h after 
addition of CNO (LEFT). Scale bar = 100µm. MFI of surface E-cadherin in cells 
expressing a Gaq- DREADD after treatment with DMSO, 5µM CNO, or 2.5µM 
ionomycin (RIGHT). Statistical analysis by ANOVA (**, p<0.01; ±SD). 
(C) MFI of surface E-cadherin in CnB knockout lines after 48h treatment with DMSO, 
2.5µM ionomycin, or 10ng/ml TGFb. Statistical analysis by ANOVA (***, p<0.001; ****, 
p<0.00001; ±SD). 
(D) MFI of surface E-cadherin of cells pretreated with 20µM W7 for 24h and then DMSO, 
2.5µM ionomycin, or 10ng/ml TGFb for 24h. Statistical analysis by ANOVA (**, p<0.01; 
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Chapter 3 Supplemental Figure S1: Enriched pathways in P-EMT and C-EMT 
 
(A) Western blot comparing ECAD in sorted ECAD+ vs. ECAD- cells from two C-EMT and 
three P-EMT murine PDA cell lines. 
(B) qPCR comparing Ecad mRNA in sorted ECAD+ vs. ECAD- cells from a P-EMT (454) 
and C-EMT (483) cell line. Statistical analysis by Student’s unpaired t-test (****, 
p<0.0001; non-significant (NS); ±SEM). 
(C) Left: Bioinformatic schematic for GSEA comparing ECAD- versus ECAD+ tumor cells 
in either P-EMT tumors (n=8) or C-EMT (n=3). Right: GO and KEGG pathways 
upregulated in P-EMT tumors. Normalized enrichment score (NES) for the top 25 
pathways with a false discovery rate (FDR) <0.15 are shown, ordered by FDR. Red 
text indicates pathways of interest. 
(D) Gene ontology (GO) and KEGG pathways upregulated in C-EMT tumors. NES score 
for the top 25 pathways with an FDR<0.15 are shown ordered by FDR value. Red text 
indicates pathways of interest. 
(E) HOMER Motif analysis comparing C-EMT ECAD- tumor cells versus C-EMT ECAD+ 




























































































































































Chapter 3 Supplemental Figure S2: Activation of calcium signaling does not induce cell 
death and promotes EMT in human carcinoma cells 
 
(A) Representative average Fura-2 Ca
2+ 
measurements after addition of 2.5µM 
Ionomycin (purple) or 10ng/ml TGFb (green). Colored line indicates average of n=12 
cells. Black error bars represent SD. 2 cell lines were analyzed. 
(B) Flow cytometry analysis of cellular viability. Viable cells were defined as Annexin-
/DAPI-. Cell lines were treated with DMSO, 2.5µM ionomycin, or 10 ng/ml TGFb for 72 
hours or 50µM etoposide for 24 hours. Statistical analysis by ANOVA with significance 
indicated (****, p<0.0001; error bars indicate SD). 
(C) Representative 20X images of the human lung cancer cell line HCC827 after treatment 
with 7 µM ionomycin for 2 days or 10ng/ml TGFb for 10 days. Scale bars = 100µm 
(D) Mean fluorescent intensity of surface E-cadherin of human pancreatic (Capan2), lung 
(HCC827), or breast (MCF7) carcinoma cell lines following treatment with DMSO, 7 
µM ionomycin for 3 days or 10ng/ml TGFb for 10 days. Statistical analysis by ANOVA 
with significance indicated (****, p<0.0001; error bars indicate SD). 
(E) Representative relative mRNA expression of ECAD and VIM after treatment with 
DMSO, 7 µM ionomycin for 3 days, or 10ng/ml TGFb for 10 days. Statistical analysis 
by ANOVA with significance indicated (*, p<0.05; ***, p<0.001; NS, non-significant; 

















































































Chapter 3 Supplemental Figure S3: Epithelial proteins are conserved in exosomes 
 
(A) Principal component analysis of differentially expressed genes of cell lines treated for 
48 hours with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb. Each cell line per condition 
was sequenced in duplicate. 
(B) Counts per million reads (CPM) of three cell lines pooled together after treatment with 
DMSO, ionomycin (IONO) or TGFb as described in (A). Statistical analysis by ANOVA 
with significance indicated (****, p<0.0001; NS, non-significant; error bars indicate SD). 
(C) EMT scores calculated via MLR and KS methods. Error bars represent SD. *, p < 0.05 
for Students’ two-tailed t-test. N=3. 
(D) Schematic for exosome collection and mass spectrometry after EMT induction for 72 
hours. 
(E) Principal component analysis of proteins contained within exosomes in cell lines 
treated for 72 hours with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb. 3 different cells 
line analyzed per condition. 
(F) Heatmap illustrating representation of EMT-related proteins found within exosomes. 
(G) Relative abundance of E-cadherin protein within exosomes of three cell lines pooled 
together in duplicate treated with DMSO, ionomycin (IONO) or TGFb. Statistical 
analysis by ANOVA with significance indicated (**, p<0.01; NS, non-significant; error 
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Chapter 3 Supplemental Figure S4: Calcineurin activity is dispensable for calcium induced 
EMT 
 
(A) Top: Relative mRNA expression of CnB in two cell lines (PD798 and PD7591) 
comparing Cas9 control cells to CnB knockout (KO). Bottom: Western blot analysis 
showing loss of CnB in KO cells. 
(B) NFAT luciferase activity in Cas9 control and CnB knockout cells after treatment with 
DMSO, 2.5µM ionomycin (IONO), or 10ng/ml TGFb for 24 hours. Statistical analysis 
by ANOVA with significance indicated (**, p<0.01; All other comparisons to DMSO are 
non- significant; error bars indicate SD). 














Chapter 3 Supplemental Figure S5  




Chapter 3 Supplemental Figure S5: GPCRs expressed in C-EMT and P-EMT pancreatic 
tumors 
(A) Heat map illustrating GPCRs differentially expressed between P-EMT and C-EMT   
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Tumor heterogeneity, most commonly studied in a primary disease setting, is a critical 
driver of phenotypic diversity, culminating in metastatic, lethal cancers (Gundem et al, 
2015a; Hunter et al, 2018; McGranahan & Swanton, 2017; Turajlic et al, 2018; Zhao et al, 
2016). In most cancers, prognosis and therapeutic decisions are defined by the presence 
or absence of metastasis. However, tumor heterogeneity is increasingly being questioned 
at the level of metastatic disease, with recent studies in several cancer types suggesting 
that metastasis is not a binary phenotype but rather a disease spectrum ranging from 
oligo- (limited) to polymetastatic (widespread) disease (Foster et al, 2020; Pitroda & 
Weichselbaum, 2019; Weichselbaum & Hellman, 2011). Heterogeneity in the 
manifestation of metastatic disease can guide decisions on use of local regional vs. 
systemic therapies with emerging evidence of its importance in clinical outcome (Deek & 
Tran, 2020; Phillips et al, 2020; Weickhardt et al, 2012). Despite its clinical significance, 
the mechanisms that underlie this spectrum of metastatic states remains unclear and 
largely understudied. 
Pancreatic ductal adenocarcinoma (PDAC) represents a disease entity well suited 
for the study of metastasis, as most PDACs present with metastatic disease that is 
associated with dismal prognosis (Ryan et al, 2014). One barrier to understanding 
metastatic heterogeneity has been a paucity of model systems that capture this natural 
variation and allow for direct assessments of paired primary tumors and metastases in 
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vivo. This has limited our ability to define the factors intrinsic to primary tumors that 
influence the extent of metastatic spread. We previously developed an autochthonous 
model of PDAC – the KPCX model – that employs multiplexed fluorescence-based 
labeling to track the simultaneous development of multiple primary tumor cell lineages and 
follow them as they metastasize (Maddipati & Stanger, 2015). Importantly, this technique 
facilitates confirmation of lineage relationships in vivo, such that primary tumor clones with 
substantial metastatic potential can be distinguished from those having poor metastatic 
potential. 
Here, we show that this system recapitulates the variation in metastatic burden 
found in human PDAC and use it to dissect molecular and cellular features contributing to 
metastatic heterogeneity. We analyzed primary tumors and paired metastases using a 
multi-fluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma 
(PDAC) – a tumor type where most patients present with metastases. Genomic and 
transcriptomic analysis revealed an association between metastatic burden and gene 
amplification or transcriptional upregulation of MYC and its downstream targets. 
Functional experiments showed that MYC promotes metastasis by recruiting tumor 
associated macrophages (TAMs), leading to greater bloodstream intravasation. 
Consistent with these findings, metastatic progression in human PDAC was associated 
with activation of MYC signaling pathways and enrichment for MYC amplifications 
specifically in metastatic patients. Collectively, these results implicate MYC activity as a 
major determinant of metastatic burden in advanced PDAC.
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Metastatic burden is variable in human and murine PDAC 
While the vast majority of PDAC patients have metastases (principally liver and lung), the 
number of metastases is highly variable from patient to patient (Iacobuzio-Donahue et al, 
2009; Yachida & Iacobuzio-Donahue, 2009). Importantly, data regarding metastases have 
largely been obtained at autopsy and thus confounded by varying treatment histories and 
reseeding due to end-stage disease (Gundem et al, 2015b). Thus, we first sought to 
characterize the burden of metastases in treatment-naïve patients. To this end, we 
performed a retrospective analysis of initial CT scans from 55 patients newly diagnosed 
with metastatic (stage IV) PDAC at the University of Pennsylvania (Chapter 4 Fig. 1a). 
The total number of lesions in the lung and liver were counted by examining both coronal 
and sagittal planes for both organs and binned into groups of ten, revealing  a wide 
distribution of metastatic burden (Chapter 4 Fig. 1b). K-means clustering identified two 
metastatic subgroups: a Metlow subgroup (< or = to 10 metastases, 25/55) and a Methigh 
subgroup (>10 metastases, 30/55) (Chapter 4 Fig. 1b, Chapter 4 Fig. S1a). Primary tumor 
size, age, sex, and race were not correlated with differences in metastatic burden (Chapter 
4 Fig. 1c, Chapter 4 Fig. S1b). However, having a greater number of metastases was 
associated with worse overall survival (Chapter 4 Fig. 1d). Thus, even among patients 
with stage IV PDAC, metastatic burden is variable and correlates with clinical outcome. 
We hypothesized that the differences in metastatic burden seen in human PDAC 
may also be present in autochthonous murine models. To test this, we used the KPCXY 
model – in which Cre-mediated recombination triggers expression of mutant KrasG12D and 
p53R172H in the pancreatic epithelium along with YFP and confetti (X) lineage tracers 
(Chapter 4 Fig. 1e, Chapter 4 Methods) – to measure metastatic heterogeneity in a cohort 
of tumor bearing mice. By exploiting the multi-color features of the KPCX model, we 
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previously showed that these mice harbor (on average) 2-5 independent primary tumor 
clones; importantly, the clonal marking of tumors with different fluorophores makes it 
possible to infer the lineages of primary tumors with different metastatic potential 
(Maddipati & Stanger, 2015). In our earlier work with this model, we noted that in most 
tumor-bearing animals – even those with multiple primary tumors – metastasis to the liver 
and lung were driven by a single tumor clone (Chapter 4 Fig. 1e, Chapter 4 Fig. S1c). This 
suggested that tumor cell-intrinsic factors strongly influence the metastatic behavior of a 
tumor, even within a single animal. 
To quantify differences in metastatic burden, we examined a panel of mice with at 
least 2 uniquely labeled fluorescent tumors where most metastases could be attributed to 
a specific tumor on the basis of color (Chapter 4 Fig. 1e, Chapter 4 Fig. S1c). A total of 85 
primary tumors from 30 mice were examined, and gross metastases to the liver and lung 
arising from each tumor were then quantified by stereomicroscopy (Methods). Murine 
PDACs exhibited a wide distribution of metastatic burden, with a pattern resembling that 
of the human disease (Chapter 4 Fig. 1f). Similarly, k-means clustering grouped murine 
samples into a low metastasis subgroup (£10 metastases, 58/85) and a high metastasis 
subgroup (>10 metastases, 27/85), which we similarly refer to as the Metlow and MetHigh 
subgroups, respectively (Chapter 4 Fig. 1f, Chapter 4 Fig. S1d). As with the human 
disease, neither primary tumor size nor tumor cell proliferation correlated with metastatic 
burden (Chapter 4 Fig. 1g, Chapter 4 Fig. S1e). Thus, the KPCXY model recapitulates the 
intertumoral metastatic heterogeneity seen in human PDAC and provides a unique 




Individual tumor lineages in KPCXY mice correspond to clones with distinct 
somatic copy number profiles 
Although primary KPCXY tumors were easily distinguishable based on the expression of 
a distinct fluorophore, each tumor could have arisen via the clonal expansion of a single 
cell or through fusion of multiple tumors which happened to share the same color. Somatic 
copy number alterations (SCNAs) have been shown to provide an unambiguous picture 
of genomic heterogeneity and lineage relationships between primary tumors and matching 
metastases in human disease (Navin et al, 2010). Consequently, we performed copy 
number analysis via genome sequencing on a set of 20 primary tumors, including multi-
regional sampling on a subset of the tumors where sufficient tissue was available (9 
tumors with 2-4 regions sampled per tumor) (Chapter 4 Fig. 2a). Tumors bearing different 
colors exhibited unique DNA copy number profiles, indicating that they arose 
independently (Chapter 4 Fig. 2b, Chapter 4 Fig. S2a) (Baslan et al, 2012). By contrast, 
multi-regional sampling of monochromatic tumors revealed shared copy number 
alterations, indicating that all subregions within a given tumor (defined by color) shared a 
common ancestral lineage (Chapter 4 Fig. 2c, Chapter 4 Fig. S2b). In addition, subregion-
specific alterations were also observed, suggesting that subclonal heterogeneity is also 
present in each tumor (Chapter 4 Fig. 2c, Chapter 4 Fig. S2b). These results suggest that 
the monochromatic tumors observed in KPCXY mice are clonal in origin and continue to 
undergo subclonal evolution during tumor progression. 
To ascertain the lineage relationships between primary tumors and metastases, 
we compared DNA copy number profiles between liver metastases and primary tumors 
within a given mouse. This revealed that primary tumors and metastases of the same color 
shared common DNA copy number profiles across the dataset, confirming on a genetic 
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basis the fluorescence based lineage relationships (Chapter 4 Fig. 2d-f, Chapter 4 Fig. 
S2c). As most lung metastasis were microscopic and difficult to isolate by dissection, they 
were not included in the molecular analysis. Together, these results indicate that the 
lineage history of metastases can be inferred by color and genomic analysis, allowing 
primary tumors with high vs. low metastatic potential to be unambiguously classified. 
 
Genomic and transcriptional analyses identify Myc as a potential driver of 
metastatic phenotypes 
We next sought to examine the molecular differences that distinguish primary tumors with 
high vs. low metastatic potential. We began by examining large scale (mega-base level 
as well as chromosome wide) SCNAs in 20 MetHigh and MetLow primary tumor samples. 
This analysis revealed largely similar genome-wide copy number patterns between Methigh 
and Metlow primary tumors with key PDAC associated genes, such as loss-of-
heterozygosity (LOH) at Cdkn2a/b and Trp53 as well as chromosomal gain of Kras 
occurring at similar frequencies (Chapter 4 Fig. S3a). Thus, KPCXY tumors exhibit 
frequent copy number alterations in canonical PDAC genes, but these alterations do not 
account for the variation in metastatic behavior between Methigh and Metlow tumors. 
We next asked whether other factors (genomic and/or transcriptional) may be 
acting to enhance metastasis in the MetHigh group. Focal amplifications in driver 
oncogenes – Cdk6 and Yap in breast cancer and mutant Kras in PDAC – have been linked 
to the acquisition of metastatic competence (Chan-Seng-Yue et al, 2020; Klotz et al, 2020; 
Mueller et al, 2018; Shih et al, 2020). Consistent with prior studies, we observed focal 
amplicons at genomic regions encoding Cdk6, Yap, and Kras in our tumors (Chapter 4 
Fig. 3a) (Chan-Seng-Yue et al, 2020; Dhanasekaran et al, 2020; Klotz et al, 2020; Mueller 
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et al, 2018; Shih et al, 2020). However, in contrast to these amplifications, which occurred 
at equal frequencies in MetHigh and MetLow tumors, focal high amplitude amplifications in 
Myc were found in 42.8% (3/7) of MetHigh tumors compared to 7.6% (1/13) of MetLow tumors 
(Chapter 4 Fig. 3b). Thus, Myc amplifications are enriched in Methigh tumors. In all cases, 
these amplifications were maintained in paired metastases (Chapter 4 Fig. S3b). In 
addition, RNA-seq analysis demonstrated significantly higher levels of Myc transcripts in 
MetHigh tumors and metastases compared to MetLow tumors (Chapter 4 Fig. 3c); overall, 
Myc was the third-most significantly upregulated gene in MetHigh tumors compared to 
MetLow tumors (Chapter 4 Fig. 3d). Gene set enrichment analysis (GSEA) of the 
differentially expressed genes between MetHigh and MetLow tumors identified MYC and E2F 
signatures as highly enriched, along with other signatures that have been implicated in 
PDAC metastasis including unfolded protein response, oxidative phosphorylation, and 
hypoxia (Chapter 4 Fig. 3e) (Chiou et al, 2017; McDonald et al, 2017; Pommier et al, 
2018). Moreover, MetaCore transcription factor enrichment analysis identified MYC as the 
TF most significantly associated with genes overexpressed in MetHigh tumors (Chapter 4 
Fig. 3f), and Ingenuity Pathway Analysis placed Myc at the center of the interactome 
generated by these differentially expressed genes (Chapter 4 Fig. S4). Collectively, these 
results demonstrate a strong association between a tumor’s metastatic behavior and the 
abundance and/or activity of Myc at the genomic and transcriptional levels. 
Human PDAC can be grouped into two main transcriptomic subtypes – a well-
differentiated classical/exocrine-like/progenitor (classical) subtype and a poorly 
differentiated squamous/quasi-mesenchymal/basal (basal-like) subtype (Bailey et al, 
2016b; Collisson et al, 2011; Moffitt et al, 2015; Cancer Genome Atlas Research Network. 
Electronic address & Cancer Genome Atlas Research, 2017). We found that MetHigh 
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tumors were strongly associated with basal-like PDACs, in line with their more aggressive 
behavior (Chapter 4 Fig. 3g). Likewise, applying murine MetLow and MetHigh signatures (see 
Methods) to human TCGA data predicted a worse survival – indicative of disease 
recurrence – for patients with a MetHigh signature (Chapter 4 Fig. 3h). These data indicate 
that murine MetHigh tumors correspond to the more aggressive subtypes of human PDAC. 
 
A panel of cell lines that preserve the MetLow and MetHigh phenotypes 
To understand the mechanisms underlying these different metastatic properties, we 
generated a panel of cell lines from six MetHigh tumors and five MetLow tumors. Consistent 
with the parent in vivo tumors, Myc gene expression and Myc protein levels were higher 
in the MetHigh lines compared to the MetLow lines (Chapter 4 Fig. 4a-b). SCNA analysis in 
these cells lines found that they retained the majority of the genomic alterations found in 
the matched primary samples, including Myc amplifications (Chapter 4 Fig. S5a-b). 
Furthermore, Myc amplifications were not found in any of the cell lines whose tumors were 
originally characterized as non-Myc amplified, indicating that in vitro culture does not 
select for this specific copy number alteration. Importantly, elevations in Myc mRNA and 
protein were observed in both the Myc amplified and non-amplified MetHigh lines, 
suggesting that elevated Myc expression is a stable phenotype of these cells in culture. 
To investigate the metastatic properties of the MetHigh and MetLow lines in vivo, we 
performed orthotopic implantation of 5 MetHigh and 5 MetLow lines into the pancreas of 
NOD.SCID mice and examined distant organs for evidence of metastasis. Although the 
weights of MetHigh and MetLow tumors were not significantly different (Chapter 4 Fig. S6a), 
MetHigh tumors gave rise to 28-fold more liver and lung metastases compared to MetLow 
tumors (Chapter 4 Fig. 4c). Consistent with the cell line expression differences, the 
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orthotopic MetHigh tumors expressed higher levels of Myc compared to MetLow tumors 
(Chapter 4 Fig. S6b). To further confirm that differences in Myc expression were sufficient 
to drive the metastatic phenotype, we introduced a Myc overexpression construct into 4 
MetLow lines and generated orthotopic tumors (Chapter 4 Fig. S6c). Myc overexpression 
led to a dramatic (22-fold) increase in liver and lung metastases (Chapter 4 Fig. 4d) which 
could not be accounted for by the modest increase in tumor weight (Chapter 4 Fig. S6d). 
Thus, cell lines derived from spontaneously-generated MetHigh and MetLow tumors retain 
their metastatic phenotypes upon implantation. 
 
MYC promotes tumor cell intravasation through the recruitment of tumor 
associated macrophages 
To form distant metastases, cancer cells must navigate a series of events collectively 
referred to as the “metastatic cascade.” These events include (i) intravasation into the 
bloodstream or lymphatics, (ii) survival in the circulation, (iii) extravasation from the vessel, 
and (iv) growth and survival at the distant site (Welch & Hurst, 2019). To determine the 
step(s) at which Myc was exerting its prometastatic effects, we began by measuring the 
number of circulating tumor cells (CTCs) in orthotopically-implanted MetHigh and MetLow 
tumors and in MetLow tumors engineered to overexpress Myc (Myc-OE). Remarkably, 
CTCs arising from MetHigh and Myc-OE tumors were 38-fold and 17-fold more abundant 
than those arising from MetLow tumors (Chapter 4 Fig. 4e), far greater than the 
approximately 2-fold increase in tumor weight resulting from Myc overexpression (Chapter 
4 Fig. S6d). Next, we performed a tail vein metastasis assay, which bypasses the invasion 
step by introducing tumor cells directly into the bloodstream and measuring lung 
metastases. Surprisingly, in contrast to the orthotopic tumor experiment, there was no 
119 
 
difference in the number of metastases between MetHigh and MetLow lines (Chapter 4 Fig. 
4f). Taken together, these data suggest that MetHigh tumors achieve a higher metastatic 
rate principally by promoting cancer cell invasion into the circulation which can be driven 
by increased Myc expression. 
Beyond activation of tumor intrinsic programs, Myc can also affect tumor 
phenotypes by altering the tumor immune microenvironment (TiME) (Kortlever et al, 2017; 
Muthalagu et al, 2020; Sodir et al, 2020). Thus, we sought to determine if differences in 
Myc levels between MetHigh and MetLow tumors were associated with distinct TiMEs. To 
this end, we examined the immune composition of parental primary tumors by staining for 
markers of immune cells previously implicated in metastasis of PDAC and other cancers. 
While MetHigh and MetLow tumors had a similar degree of neutrophil infiltration, MetHigh 
tumors had lower numbers of CD3+ T-Cells and were highly enriched for F4/80+ 
macrophages (Chapter 4 Fig. 5a). In particular, there was an increased abundance of 
macrophages positive for Arg1 (Chapter 4 Fig. 5b), a marker of alternatively activated 
tumor associated macrophages (TAMs) (Jablonski et al, 2015). Thus, compared to MetLow 
tumors, the TiME of MetHigh tumors contains an increased number of TAMs. 
To examine the ability of MetHigh and MetLow tumors to recruit macrophages in our 
system, we co-cultured these cell lines with primary bone marrow derived murine 
macrophages in a transwell migration assay (Dhanasekaran et al, 2020). Compared to 
MetLow lines, MetHigh co-cultures resulted in higher levels of macrophage migration towards 
the tumor cells (Chapter 4 Fig. 5c). Consistent with these in vitro results, orthotopic tumors 
generated from MetHigh cell lines exhibited greater TAM infiltration than those generated 
from MetLow cell lines (Chapter 4 Fig. 5d). Furthermore, MetLow lines overexpressing Myc 
(Myc_OE) gave rise to tumors with greater TAM infiltration compared to controls (Chapter 
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4 Fig 5e). These results demonstrate that MetHigh tumors exhibit enhanced macrophage 
recruitment and implicate Myc expression as a driver of macrophage infiltration. 
The recruitment of macrophages to tumors can occur in response to factors 
secreted by tumor cells. To identify potential mediators of macrophage recruitment by 
MetHigh tumors, we mined our RNAseq data to identify secreted factors that are 
differentially expressed between MetHigh and MetLow tumors (p value <0.01 and logFC >1). 
This resulted in identification of six cytokines/chemokines upregulated in MetHigh tumors 
(Chapter 4 Fig 5f). Importantly,  MYC overexpression in the MetLow cell lines resulted in 
upregulation of these factors as well (Chapter 4 Fig 5g).  Interestingly, each of these 
factors has been previously implicated in regulating macrophage recruitment in pancreatic 
and other cancer types (Hoshino et al, 2015; Steele et al, 2016; Jia et al, 2016; Kodama 
et al, 2020; Miao et al, 2020). These data suggest that multiple Myc-regulated factors likely 
act in concert to induce macrophage recruitment and metastsis. 
To directly test the role of TAMs in metastasis, we generated orthotopic tumors 
from MetLow+Myc_OE lines. After 10 days, we treated mice with a combination of colony 
stimulating factor receptor inhibitor (CSFRi) to inhibit macrophage migration and liposomal 
clodronate (CLD) to ablate tissue resident macrophages (Chapter 4 Fig. 5h). This regimen 
was highly effective at depleting macrophages (Chapter 4 Fig. 5i), consistent with prior 
studies (DeNardo et al, 2009; Zhu et al, 2017, 2014). Macrophage depletion resulted in a 
4-6-fold reduction in metastases (Chapter 4 Fig. 5j), suggesting that MYC enhances 
metastatic spread in part by creating a TAM-rich environment in the primary tumor. While 
previous studies have implicated macrophages in tumor cell infiltration, our work directly 
links this process to the genomic and transcriptional activation of Myc, which occurs 
naturally in our model and is subsequently selected for as a driver of metastasis (Cassetta 
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et al, 2019; Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al, 
2015; Lee et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele 
et al, 2016; Zhu et al, 2014). 
 
Metastasis in human PDAC is associated with MYC gene amplification and elevated 
expression 
Given the finding that genomic and transcriptional variation in Myc was associated with 
metastatic heterogeneity in murine PDAC, we sought to determine whether MYC is 
associated with similar metastatic phenotypes in human PDAC. Since the majority of 
PDAC samples in the ICGC and TCGA are derived from resected stage I/II tumors (Cancer 
Genome Atlas Research Network. Electronic address & Cancer Genome Atlas Research, 
2017), these datasets provide limited insight into the determinants of metastatic burden. 
Consequently, we analyzed data from the COMPASS trial cohort (NCT02750657) which 
is focused on metastatic PDAC patients and utilizes laser capture microdissection (LCM) 
to enrich for tumor cells prior to whole genome sequencing or RNA-seq (Aung et al, 2018; 
Chan-Seng-Yue et al, 2020). By comparing primary tumors and metastases, we found 
that 11.3% (n=17/133) of metastatic tumors were enriched for MYC amplifications 
compared to 1.61% (n=4/244) of resectable disease (Chapter 4 Fig. 6a-b; p=7.6e-5, 
Fishers test). Likewise, advanced tumors (defined as either locally advanced or 
metastatic) were significantly enriched for MYC amplifications (9.22%; n=19/206) 
compared to resectable tumors having no evidence of metastasis at diagnosis (1.04%; 
n=2/192) (Chapter 4 Fig. S7a; p=1.33e-4). As predicted, amplification was associated with 
higher levels of MYC mRNA (Chapter 4 Fig. S7b). MYC amplified tumors did not exhibit 
greater genomic instability compared to non-amplified tumors (Chapter 4 Fig. S7c). 
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Moreover, metastases expressed higher levels of MYC than primary tumors at the mRNA 
level (Chapter 4 Fig. 6c; p=0.00312). These results indicate that MYC amplification and 
transcriptional upregulation are strongly associated with PDAC metastases. 
Next, we examined a separate patient cohort (N=20) in which matched primary 
PDAC tumors and metastases were available for comparison. MYC amplifications were 
common in patients with metastatic disease (35.0%; N=7/20), and these amplifications 
were retained in the matching metastasis (Chapter 4 Fig. S7c), similar to our mouse 
model. The enrichment of MYC amplifications in metastatic samples and the observed 
retention of the amplification when analyzing matched primary/metastasis samples 
suggests that amplification and/or transcriptional upregulation of MYC in primary PDACs 
are selected for and retained during tumor metastatic progression. Consistent with this 
notion, we identified a PDAC patient in whom single cell analysis of a paired primary tumor 
and metastasis revealed enrichment of a MYC amplified subclone in the metastatic lesion 
compared to the primary (Chapter 4 Fig. 6d-e, Chapter 4 Fig. S7d). Collectively, these 
data suggest that enhanced expression and/or genomic amplification of MYC is 
associated with metastatic spread in human PDAC, complementing our findings from the 
mouse model.  
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Summary and Discussion 
Phenotypic variation, the result of inter- and intra-tumoral heterogeneity arising 
during tumor progression,  has made it challenging to understand the molecular 
mechanisms underlying tumor spread (McGranahan & Swanton, 2017; Turajlic et al, 
2019). Consequently, the demonstration that certain genes function as “metastasis 
drivers” – promoting metastasis through mechanisms distinct from their roles in primary 
tumor growth – has proven elusive (Lambert et al, 2017). In this study, we exploited an 
autochthonous PDAC model with varying degrees of metastatic spread to explore the 
molecular basis of naturally-arising variation in metastatic burden. This system revealed 
a strong association between the level of Myc – at either the genomic or transcriptional 
level – and tumor metastasis, a relationship that was also observed in human PDAC 
samples. Myc exerts its pro-metastatic effect at least in part by recruiting pro-invasive 
TAMs, leading to greater tumor cell intravasation into the bloodstream. These activities 
are not directly related to Myc’s well-described role in primary tumor growth (Farrell et al, 
2017; Hessmann et al, 2016; Sodir et al, 2020), as tumors with different levels of Myc 
expression grow at comparable rates despite dramatic differences in metastatic ability. 
Prior work by us and others has examined the genetic events associated with PDAC 
metastasis. In one study, a comparison of matched primary tumors and metastases from 
four patients failed to reveal nonsynonymous mutations in driver oncogenes that 
distinguished primary tumors from metastases (Makohon-Moore et al, 2017). By contrast, 
examination of DNA copy number changes in mouse and human PDAC revealed a 
significant association between increased mutant KRAS gene dosage and metastatic 
progression  (Chan-Seng-Yue et al, 2020; Mueller et al, 2018). While our mouse studies 
did not detect an association between Kras focal amplification and metastatic potential, 
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Kras gains (via entire gain of chromosome 6) were detected with comparable frequency 
in both MetHigh and MetLow tumors, consistent with the ability of both tumor populations to 
metastasize. Interestingly, the MYC_TARGETS geneset represented the most highly 
enriched signature in PDAC patients with KRAS amplifications or major allelic imbalances 
(Chapter 4 Fig. 6f) mirroring the enrichment of this signature in MYC amplified PDAC 
tumors (Chapter 4 Fig. S7f). Signaling through KRAS has long been known to impact MYC 
expression (Dang, 2012; Kortlever et al, 2017; Sodir et al, 2020; Vaseva et al, 2018), and 
thus our results are consistent with a model in which elevated MYC activity – as a result 
of MYC and/or KRAS amplification, or some other mechanism – enhances metastatic 
activity. This interpretation is consistent with recent studies of lung, breast, and prostate 
cancers identifying a link between MYC amplification and brain or bone metastasis 
(Arriaga et al, 2020; Klotz et al, 2020; Shih et al, 2020). 
Although tumor formation in the KPCXY model results from shared founder 
mutations (KrasG12D activation and Trp53 loss) our genomic analysis revealed ongoing 
somatic events during tumor progression, resulting in heterogeneous patterns of genomic 
alterations within a given tumor. Such alterations were largely present at the level of copy 
number gains and losses rather than point mutations or small insertion/deletions. Although 
the complexity of genomic rearrangements varied between tumors, the degree of genome 
instability did not correlate with metastatic burden. Thus, the increase in metastasis 
observed in MetHigh tumors is not a function of overall SCNA burden but is instead specific 
to Myc. 
While subregions within a tumor shared many genomic alterations, consistent with 
a clonal origin, distinct copy number alterations were also present, suggesting ongoing 
subclonal evolution. Clonally related metastases exhibited unique (“private”) alterations; 
125 
 
however most copy number gains and losses were shared with the parent primary tumor 
clone, suggesting that they were present prior to dissemination. In this respect, it is 
noteworthy that MYC amplifications in human PDAC were far more common in 
metastases than primary tumors, including one case in which we were able to trace a 
metastatic lesion directly to a MYC-amplified subclone in the primary tumor. Collectively, 
these results suggest that subclonal MYC amplifications, which have been observed in 
human primary tumors, provide a selective advantage during metastatic progression 
(Baslan et al, 2020; Hayashi et al, 2020). Given that our analysis identified a Myc signature 
in tumor MetHigh clones without Myc amplifications, and MYC amplifications are present in 
only 11% of human PDAC metastases, other mechanisms for the increased expression 
of MYC mRNA in PDAC metastases are likely to exist. 
As one of the best-studied oncogenes, MYC has been associated with multiple tumor-
promoting activities (Dang, 2012). Given MYC’s role in tumor cell growth and proliferation, 
one possible explanation for our results is that MetHigh tumors had an earlier onset and/or 
grew more rapidly, leading to increased metastasis by mass effect. Against this possibility, 
we found that tumor size and proliferation rates showed no correlation with metastatic 
burden. Likewise, our MetHigh and MetLow cell lines exhibited dramatic differences in 
metastatic ability despite giving rise to primary tumors of comparable size, suggesting that 
Myc can have a context dependent role wherein it drives tumor growth in early progression 
and enhances metastatic spread later. Indeed, prior studies have shown that Myc 
overexpression in the pancreas in the context of tumor initiation does not result in PDAC 
but rather insulinomas (Lewis et al, 2003). By contrast, our work provides strong evidence 




Our studies implicate non-cell autonomous mechanisms involving the recruitment 
of tumor associated macrophages (TAMs) as contributors to metastatic heterogeneity. 
The ability of TAMs to promote tumor cell invasion is well-documented (Cassetta et al, 
2019; Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al, 2015; 
Lee et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele et al, 
2016; Zhu et al, 2014), a property that is in agreement with our finding that MetHigh and 
Myc_OE tumors exhibit enhanced vascular intravasation. Furthermore, MYC expression 
in tumor cells is known to shape the makeup of the surrounding immune 
microenvironment, making it more immunosuppressive (Dhanasekaran et al, 2020; 
Kortlever et al, 2017). In line with these observations, we find that MetHigh tumors are 
enriched for alternatively activated TAMs and have decreased T-cell infiltration – features 
that favor metastasis (Cassetta et al, 2019; Cassetta & Pollard, 2020; Chen et al, 2011; 
Ginter et al, 2019; Kitamura et al, 2015; Lee et al, 2018; Linde et al, 2018; Qian et al, 2011; 
Roh-Johnson et al, 2014; Steele et al, 2016; Zhu et al, 2014; Pommier et al, 2018; Li et 
al, 2018). Our data thus support a model wherein stochastically-arising tumor subclones 
with elevated levels of MYC alter the tumor immune microenvironment to facilitate 
intravasation and metastasis. 
While the specific molecular mediator of TAM recruitment is unknown, we 
speculate that MYC acts indirectly. Consistent with this, we identified several 
chemokines/cytokines that were upregulated in MetHigh tumors and could also be induced 
by Myc overexpression. Thus, we hypothesize that multiple secreted factors, as opposed 




Most patients with PDAC develop metastases. Our data show that even within this 
population, the extent of metastatic disease varies widely between patients and impacts 
survival. While many steps are required for tumor cells to metastasize, our data indicate 
that bloodstream invasion may be a rate limiting event for metastasis in PDAC. Our work 
further suggests that in addition to its well-documented cell autonomous role in tumor 
growth, MYC acts non-cell autonomously to promote metastasis. Given that MYC family 
members are focally amplified in 28% of human cancer (Schaub et al, 2018) these results 
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Materials and Methods 
Data and Code Availability 
The datasets generated during this study are available in public databases under the 
accession numbers PRJNA647834, PRJNA646123, and PRJNA646156. Additional 
primary data needed for review or to replicate the findings will be made available on 




All experiments were performed in accordance with the National Institutes of Health 
policies on the use of laboratory animals and approved by the Institutional Animal Care 
and Use Committee of the University of Pennsylvania.   KPCX mice were generated 
through a series of backcrosses as previously described (Maddipati & Stanger, 2015). The 
RosaConfetti (“X”) reporter allele was introduced into mutant strains bearing Pdx1CreER 
(“C”), KrasG12D (“K”), and p53fl/+ (“P”) alleles to obtain Pdx1CreER; KrasG12D; p53fl/+; 
RosaConfetti    (“KPCX”) mice (Maddipati & Stanger, 2015). For most experiments, animals 
were heterozygous for the confetti reporter and also contained the RosaYFP in lieu of the 
second confetti allele to generate “KPCXY” mice. The Yfp reporter was introduced to 
enable fluorescent lineage labeling  of tumors that undergo a “no-color” recombination 
event in the confetti reporter as previously described (Snippert et al, 2010). To induce 
recombination, a suspension of TAM (MP Biomedicals) in corn oil (Sigma Aldrich) was 
administered to pups via lactation following oral gavage of the mother with 6 mg of the 
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drug on post-natal day 0, 1, 2. On average, tumor bearing KPCXY mice were 14-16 weeks 
of age at time of sacrifice. 
 
Cell Lines 
Pancreatic tumors were dissociated into single-cell suspensions through mechanical 
separation and enzymatic digestion as previously described (Rhim et al, 2012). Murine 
PDAC cell lines 471_MetHigh_1, 832_MetHigh_1, 836_MetHigh_1, 850_MetHigh_4, 
852_MetHigh_1, 853 MetHigh_1, 471_MetLow_2, 832_MetLow_2, 842_MetLow_2, 
850_MetLow_1, 852_MetLow_2 were derived from KPCXY mice primary tumors that were 
also evaluated by SCNA and RNAseq (Chapter 4 Fig. 3c and Chapter 4 Fig. S2). Murine 
cell lines were cultured in Dulbeccos’ Modified Eagle Medium/F12 medium supplemented 
with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL soybean trypsin inhibitor type I 
(Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS Premix; BD Biosciences), 25 μg/mL 
bovine pituitary extract (Gemini Bio-Products), 5 nmol/L 3,3′,5-triiodo-L-thyronine (Sigma), 
1 μmol/L dexamethasone (Sigma), 100 ng/mL cholera toxin (Sigma), 10 mmol/L 
nicotinamide (Sigma), 5% Nu-serum IV culture supplement (ThermoFisher Scientific), and 
antibiotics (gentamicin 150 μg/mL, Gibco; amphotericin B 0.25 μg/mL, Invitrogen) at 37°C, 
5% CO2, 21% O2 and 100% humidity. Cell lines were maintained and passaged according 
to ATCC recommended procedures and regularly tested for mycoplasma using MycoAlert 





Multicolor image analysis 
Pancreatic tumors and organs form tumor bearing KCPXY mice were isolated and 
analyzed by fluorescent stereomicroscopy using the Lecia M216FA fluorescent 
microscope with CFP, YFP, and dsRED filters (Chroma). As previously described 
(Maddipati & Stanger, 2015), distinct colorimetric tumor clones in the primary tumor mass 
are defined as an anatomically contiguous region of monochromatic cells that share 
distinct borders with adjacent clones of a different color (Chapter 4 Fig. 1d, Chapter 4 Fig. 
S1c). In order to accurately quantify the contribution of a different colorimetric tumors to 
metastasis we used the following criteria to identify KPCXY mice suitable for analysis: (1) 
presence of at least one metastatic lesion to the liver and/or lung, (2) two or more tumors 
present, (3) each metastatic primary tumor carries a unique fluorescent color, and (4) 
metastatic lesions can be linked to specific tumor based on a shared unique fluorescent 
lineage label.  Using these criteria, we identified a panel of 30 mice with a total of 85 
tumors. Metastasis were quantified by fluorescent stereomicroscopy. Tumor size was 
determined using ImageJ to measure the largest circumference of each fluorescent tumor. 
 
Murine tumor and metastasis sample acquisition 
Pancreatic tumors and associated liver and lung tissues were isolated from tumor bearing 
KPCXY mice. Under fluorescent stereomicroscopy, individual colored tumors were 
identified and biopsied using a 6mm punch biopsy. Initial biopsy was placed in 750ml of 
RNAlater (Sigma Aldrich) for downstream DNA/RNA isolation. Subsequent biopsies were 
submitted for cell line generation and histology. In tumor where sufficient tissue was 
available, additional biopsies were taken from anatomically distinct regions of the tumor 
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to obtain subclonal biopsies for genomic analysis (Fig 2a). From 7 KPCXY mice, we 
obtained biopsies from 20 tumors, 8 of which were amenable to additional sub-regional 
biopsies. Paired primary tumor and metastasis in each mouse were identified by shared 
fluorescent lineage labels. Metastasis were harvested by microdissection under 
fluorescent stereomicroscopy and placed in 500ml of RNAlater for DNA/RNA isolation or 
cell line generation. Remainder of tissue was embedded for histology. In total, 56 
metastases were isolated for genomic analysis. While individual liver metastases were of 
sufficient size for microdissection, lung lesions were microscopic and could not be readily 
isolated for molecular analysis. 
 
Immunofluorescence and histological analysis 
Tissue samples were fixed in 4% paraformaldehyde (EMS) at room temperature for 45 
minutes followed by an overnight incubation in 30% weight/volume sucrose solution 
(Sigma Aldrich). Samples were then embedded in O.C.T. (Tissue-Tek) and frozen on dry 
ice.  Staining was performed on 10  m sections by first blocking with 5% donkey serum 
and 0.1% Tween-20 for 1 h followed by overnight incubation with primary antibody diluted 
in blocking buffer in a humidified chamber. Sections were washed three times in PBS 
containing 0.1% Tween-20. For Immunofluorescence (IF) staining slides were then 
incubated with DAPI (Life Technologies, 1:1000),  and Alexa flour conjugated antibodies 
(Jackson ImmunoResearch).  For immunohistochemistry (IHC), slides were first incubated 
with biotinylated secondary antibodies (Jackson ImmunoResearch) followed by 
development using the ABC HRP and DAB kits per manufactures protocol (Vectorlabs). 
Primary antibodies used were as follows: rat anti-Ki67 (eBioscience, 14-5698-82), rabbit 
anti-c-Myc [Y69] (Abcam, Ab32072),  rabbit anti-CD3 (Invitrogen, PA1-29547),  rabbit anti-
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F4/80 (Novus, NBP2-12506), rat anti-neutrophil (ABCAM, NIMP_R14), and Rabbit Anti-
Arg1 (Cell Signaling, 93668). 
 
Orthotopic, subcutaneous, and Circulating Tumor cell analysis 
Mice were anaesthetized using isoflurane. For orthotopic injections, NOD.SCID mice were 
shaved and their abdomen was sterilized using iodine followed by ethanol. An incision 
was made over the left upper quadrant of the abdomen, and the pancreas was 
exteriorized. 1.0x104 tumor cells in 50 μl sterile PBS were injected into the pancreas via a 
27-gauge 5/8’’ insulin needle. The pancreas was returned to the peritoneal cavity, and the 
peritoneum and overlying skin were closed with 4-0 coated Vicryl violet FS-2 sutures 
(Ethicon). Tumors, lungs, and livers were harvested, weighed, measured, and imaged 4-
6 weeks following implantation. Blood was drawn from tumor-bearing animals via cardiac 
puncture with a 1 mL insulin syringe coated with 0.5M EDTA pH 8.0 (Gibco) to prevent 
coagulation and was immediately placed in a 150mm plate containing 5-10ml RBC lysis 
buffer (BD Biosciences). After 10 min of lysis at room temperature, PBS was added to the 
plate and CTCs were directly visualized on a fluorescent microscope and counted. 
Subcutaneous injections were performed under anesthesia with 1x105 tumor cells in 




Lung metastasis colonization assay 
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1.0x105 tumor cells were injected via tail vein into NOD.SCID mice. After 21 days, lungs 
were fluorescently imaged. The tail vein injection experiment was performed in one 
experiment, 3 mice per group (MetHigh and MetLow) for analysis. Total metastasis counts 
were quantified using fluorescent stereomicroscopy. 
 
Immune flow cytometry analysis 
Subcutaneous tumors following 20-30 days of implantation were chopped into small 
pieces and digested in collagenase (1 mg/mL in DMEM; Sigma-Aldrich) at 37°C for 30 
minutes and filtered through a 70-μM cell strainer. Single-cell suspensions were stained 
with LIVE/DEAD Fixable Aqua (Thermo Scientific L-34966) for 10 minutes on ice, followed 
by antibodies on ice for 30 minutes and washed twice with PBS with 5% FBS for flow 
cytometric analysis. No intracellular staining is needed for this analysis. Cells were then 
analyzed by flow cytometry using BD FACS (BD Biosciences) and FlowJo software 
(Treestar). Antibodies used for the analysis: anti-CD11b PerCP-Cy5.5 (M1/70; BD 
550993), anti-F4/80 APC/Cy7 (BM8; Biolegend 123118), anti-I-A/I-E (MHCII) PE/Cy7 
(M5/114.15.2; Biolegend 107630), anti-Ly-6C BV570 (HK1.4; Biolegend 128030), anti-Ly-
6G V450 (1A8; BD 560603) anti-CD45 AF700 (30-F11; Biolegend 103128), anti-CD206 
APC (C068C2; Biolegend 141708), anti-CD115 (CSF-1R) AF488 (AFS98; Biolegend 
135512). Gating Strategies for immune cells are as follows: Macrophages – 
CD45+CD11b+F4/80+, CSF-1R+ Myeloid cells – CD45+CD11b+CSF1R+, Neutrophils – 
CD45+CD11b+F4/80-Ly6G+. The flow analysis of immune infiltration of MetLow and MetHigh 




Bone marrow derived Macrophage isolation 
Bone marrow immune cells were isolated as shown previously (Liu & Quan, 2015).  2x106 
isolated immune cells were plated in a six well dish in IMDM (Gibco, 12440053) 
supplemented with 10% fetal bovine serum (Gibco), 1% L-glutamine (Corning, 
MT25005CI), 1% Non-essential Amino Acids (Corning, 11140076), 1% Sodium pyruvate 
(Gibco, 11360-070), 0.001% 2-mercaptoethanol (Gibco, 21985023), 1% Penicillin-
Streptomycin (Gibco, 15140163), 20ng/ml recombinant murine M-CSF (PeproTech, 315-
02)  at 37°C, 5% CO2, 21% O2 and 100% humidity. Bone marrow derived macrophages 
(BMDMs) were differentiated for 7 days and used by gentle scraping before 10 days 
 
Macrophage Transwell migration assay 
Macrophage invasion was assessed using a 12 well transwell chamber with 8 mm filter 
inserts (Corning). Growth factor reduced Matrigel (Corning 356231) was diluted 1:1 in PBS 
and plated onto the transwell. Tumor cells were plated to the lower chamber 24 hours 
before addition of bone marrow derived macrophages (BMDMs). 100,000 BMDMs were 
plated in the transwell. After 24 hours, the non-migrated BMDMs and Matrigel were gently 
removed with a swab. Cells in the lower surface (migrated BMDMs) of the membrane were 
fixed in 4% paraformaldehyde (PFA) for 15 mins. DAPI (Invitrogen D21490) was added in 
PBS to the transwells. The membranes were imaged and number of macrophages 
counted in 4 random fields. The experiment was performed in triplicates and was repeated 
twice. 
Macrophage Depletion in vivo 
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10,000 tumor cells were orthotopically injected into the pancreas of NOD.SCID mice. 
Treatments started 10 days after implantation. GW2580, CSF-1R inhibitor (AdooQ 
Bioscience, A11959-200) was dissolved in 0.5% hydroxypropyl methyl cellulose and 0.1% 
Tween and dosed 3 times a week at 160mg/kg by oral gavage. 200ul of Clodronate or 
control liposomes (Liposoma, CP-025-025) was given one time a week by intraperitoneal 
injection. Blood from tail snips was used to analyze depletion. Experimental and control 
mice were euthanized 14 days after treatment start and analyzed for metastasis and 
immune cells by flow cytometry. Control and experimental groups were run in triplicate. 
 
Molecular cloning, Lentivirus generation and transduction 
Murine Myc was cloned into pCDH-EF1-FHC (Addgene plasmid # 64874). The vectors 
were transfected into 293T cells using PEI reagent and packaged into lentivirus for 
transduction. Lentivirus was collected 48 hours after transfection and 0.45um filtered for 
usage. Tumor cells were transduced with packaged virus with 4ug/ml polybrene for 48 
hours. Cells were selected with puromycin for 10 days. Overexpression efficiencies were 
assessed by gene-specific quantitative PCR analysis. 
 
Immunoblotting 
Cells were washed with cold PBS and lysed in RIPA buffer on ice. Lysis was spun down 
at max speed and supernatant was collected. Protein was separated by SDS-PAGE, 
transferred to PVDF membrane, blocked in 5% non-fat milk in PBS plus 0.1% Tween- 20, 
probed with primary antibodies, and detected with horseradish peroxidase- conjugated 
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secondary antibodies (Jackson ImmunoResearch). Primary antibodies used include: anti-
Myc [Y69] (Abcam, ab32072); anti-GAPDH (CST, 2118S) 
 
Real-time PCR 
RNA was prepared from cultured tumor cells using RNeasy Mini Kit (Qiagen). cDNA was 
generated using High-capacity cDNA Reverse Transcription Kit in a 20 ul reaction volume 
and diluted 1:10 for qPCR analysis (Life Technologies). qPCR analysis was performed 
using 1 ul diluted cDNA with biological (2-3) and technical replicates (2- 3) using 
SsoAdvanced SYBR reagent (Bio-Rad) and Bio-Rad qPCR platform, and results were 
normalized to the expression of Gapdh using the Bio-Rad software. Primer sequences 
utilized for qPCR were: mGapdh F- atgttccagtatgactccactcacg, mGapdh R- 
gaagacaccagtagactccacaca, 
mMyc F-  gcatgaggagacaccgccca, mMyc R- ggtttgcctcttctccacaga, mCxcl3 F- 
cagccacactccagccta, mCxcl3 R- cacaacagcccctgtagc, mCxcl2 F- ccaaccaccaggctacagg, 
mCxcl2 R- gcgtcacactcaagctctg, mIl24 F- gagcctgcccaactttttgtg, mIl24 R- 
tgtgttgaagaaagggccagt, mCcl3 F- ccaagtcttctcagcgccata, mCcl3 R- 
gatgaattggccgtggaatctt, mCcl4 F- tgctcgtggctgccttct, mCcl4 R- ctgccgggaggtgtaagaga, 




DNA and RNA isolation and purification 
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Tumor and metastasis biopsy samples were stored in RNAlater (Sigma Aldrich) prior to 
processing. Bulk tissues were homogenized in triazol (ThermoFisher) and followed by 
phase separation with 0.2ml chloroform per 1ml of Triazol. Aqueous phase was isolated 
and RNA extracted with RNAeasy Mini Kit (Quiagen) per manufactures protocol. To 
extract DNA, the remainder of the solution following removal of aqueous phase was mixed 
with 300ul of Back extraction buffer (4M Guanidine Thiocyanate, 50mM Sodium Citrate 
dihydrate, 1M Tris free base, and molecular grade water. All reagents from Sigma Aldrich) 
per 1ml of triazol. Solution was incubated on a shaker for 10 min followed by centrifugation 
for 30 minutes at 12000xg at room temperature. Aqueous solution was isolated and 0.4ml 
of Isopropanol was added followed by centrifugation for 15 minutes at 12000xg at 4C. The 
DNA pellet was then washed with 70% Ethanol. 
 
Analysis of RNA-seq, Differential gene expression, GSEA, and molecular subtype. 
RNA sequencing was performed on bulk tumor and metastasis samples from 7 KPCX 
mice resulting in 66 samples for analysis (Primary tumor with subregional biopsies and 
metastasis). RNA purity and integrity were verified on the Agilent Tapestation prior to 
library construction followed by paired-end 75bp sequencing on an Illumina HiSeq 4000 
high-throughput sequencer. Alignment of fastq files was performed with STAR aligner 
v2.5.2b using mm10 as the reference genome (Dobin et al, 2013). Gene level expression 
data in terms of expected counts and FPKM was obtained using RSEM v1.2.28 (Li & 
Dewey, 2011). Low expressing genes were removed using cutoff of 100 for count and 10 
for FKPM. For primary tumor clones where subregional biopsies were taken, count data 
for the tumor was obtained by merging expression data of the subclone count data using 
the mean value. This resulted in a total of 54 samples for downstream analysis (MetLow = 
138 
 
13, MetHigh = 7, and Metastasis = 34). For differential expression analysis, count data was 
normalized using the voom function in the limma R-package followed by batch correction 
using the ComBat R-package (Ritchie et al, 2015; Wang et al, 2017). Then limma was 
used to perform differential expression between MetHigh, MetLow, and metastasis. Boxplots 
of log2 FPKM values for genes were generated using the ggplot2 R-package. To generate 
volcano plots, differential expression data comparing MetLow and MetHigh clones was 
plotted using ggplot2 with log base 2-fold change from MetLow compared to MetHigh tumors 
of each gene was plotted on the x-axis and the adjusted p-values plotted on the Y axis. 
Genes with adjusted p-values less than 0.01 and absolute log2 fold change >1 were 
highlighted. Differentially expressed genes were used as input for GSEA MSigDB geneset 
enrichment analysis (Mootha et al, 2003; Subramanian et al, 2005). Transcription factor 
enrichment on all differentially expressed genes was performed using the Metacore 
software package (https://clarivate.com/products/metacore/, Clarivate Analytics, London, 
UK). Network analysis was performed on all differentially expressed genes using ingenuity 
pathway analysis software (www.ingenuity.com, Ingenuity Systems Inc., Redwood City, 
CA). Molecular subtype classification using the Bailey, Moffitt, and Collision (Bailey et al, 
2016b; Collisson et al, 2011; Moffitt et al, 2015) signature was performed on each sample 
by subtracting the sum of normalized expression for genes corresponding to specific 
classes within a particular molecular signature. We then took the maximum score 
observed across each class and assigned to the samples. Heatmaps were generated 
using differentially expressed genes with adjusted p-value <0.05 and absolute LogFC >1. 
 
Survival analysis of TCGA data 
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TCGA PAAD expression and patient and sample level clinical data was downloaded from 
cBioportal (http://www.cbioportal.org/) (Cerami et al, 2012; Gao et al, 2013). Samples 
were filtered to those classified as pancreatic adenocarcinoma and having available 
expression data (162 of 186 samples). To develop a signature gene list associated with 
the MetHigh phenotype, we filtered differentially expressed genes between MetHigh and 
MetLow tumors using an adjusted p-value <0.05 and absolute logFC >0.58 resulting in a 
set of genes that are upregulated or downregulated in the MetHigh tumors (736 Up and 
1036 down). To calculate a signature score for each TCGA PAAD sample, we first z-score 
normalized the TCGA PAAD expression data and then subtracted the sum of all 
downregulated gene expression from the sum of all upregulated gene expression values. 
We divided the signature score into high and low strata using a cutoff score >0. Kaplan-
Meier analysis was done to compare survival between the two groups. 
 
Human Stage IV pancreatic tumor and metastasis imaging analysis 
CT scans were obtained from patients with metastatic PDAC undergoing treatment at the 
University of Pennsylvania (IRB protocol #822028). Patients were filtered to include only 
those with CT-scan imaging of the abdomen and chest with IV contrast at the time of 
diagnosis and prior to any treatment and found to have Stage IV disease. In total, 55 
patients were included. CT images for each patient were reviewed and metastatic lesions 
in liver and lung were counted. All metastases were examined in multiple planes to ensure 
accurate assessment. Tumor area was pulled from the initial radiologist report and 
measured at the largest diameter. Cut-off for high and low metastasis groups was 




Human pancreatic cancer patient sample acquisition with genomic and RNA-seq 
analysis 
Sample acquisition resulted from patients recruited as part of the International Cancer 
Genome Consortium (ICGC) Pancreatic Cancer Ductal Adenocarcinoma Canadian 
sequencing initiative or the COMPASS trial as previously described (Connor et al, 2017). 
Tissue samples were collected at the University Health Network (Toronto), Sunnybrook 
Health Sciences Centre (Toronto), Kingston General Hospital (Kingston), McGill 
University (Montreal), Mayo Clinic (Rochester), or Massachusetts General Hospital 
(Boston) with patient informed consent and approval from Institutional Review or Research 
Ethics Boards. Whole Genome Sequencing and RNA Sequencing was performed on fresh 
frozen tumor tissue samples which were enriched for tumor content by laser capture 
microdissection (LCM). Whole genome sequencing (WGS) and RNAseq were performed 
at the Ontario Institute of Cancer Research as described previously (Connor et al, 2017) 
DNA Read Alignment and MYC Copy Number Variations were performed on paired end 
whole genome sequencing reads aligned to human reference genome hg19 using BWA 
0.6.2 (Li & Durbin, 2009). PCR duplicates were marked with Picard 1.90. Tumor cellularity, 
ploidy, and copy number segments were derived using an in-house algorithm CELLULOID 
(Notta et al, 2016). RNA reads were aligned to human reference genome hg38 and to 
transcriptome Ensemble v84 using STAR v2.5.2a (Dobin et al, 2013). Duplicate reads 
were marked with Picard 1.121. Raw counts were obtained using HTSeq 0.6.1(Anders et 
al, 2015). Differential gene expression analysis was performed with DESeq2 v.1.14.1 
(Love et al, 2014).  using default settings. Briefly, RNA HTSeq count data was imported 
to generate a dispersion estimate and a generalized linear model. Wald statistical test was 
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used to compare gene expression of MYC amplified to non-amplified cases. Gene set 
enrichment analysis was performed using genes ranked based on the P value and sign of 
the log2 fold change from differential gene expression analysis. Gene set enrichment 
analysis was run using GSEA Preranked 4.0.2 with default settings against hallmark gene 
sets (Subramanian et al, 2005). Statistical Analyses included pairwise comparisons of 
quantitative variables performed using Wilcoxon rank sum test. All tests were two-sided. 
Analyses were carried out in R 3.3.0. 
 
Somatic Copy Number Analysis in murine tumors 
DNA purified from dissected murine tumors was processed for Illumina library preparation 
and sequencing using standard protocols. In brief, isolated DNA (between 100-100ng in 
total) was sonicated on a Covaris instrument. Sonicated DNA was then end-repaired and 
ligated to TruSeq dual-index library adaptors. Index libraries were subsequently enriched 
by 10 cycles of PCR amplification followed by pooling and multiplex sequencing targeting 
a coverage of roughly 2 million reads per sample (Baslan et al, 2015). For data processing 
and copy number inference, sequencing data was processed as previously described with 
mouse genomic bins computed in a manner similar to human bins (Baslan et al, 2012).  In 
brief, sequencing reads were mapped to the mouse reference genome built mm9. 
Sequencing reads were indexed, sorted, with PCR duplicates removed. Uniquely mapped 
reads were counted in each bin and normalized for GC content using lowess smoothing. 
Normalized read count data were then segmented using Circular Binary Segmentation 
(CBS) (Venkatraman & Olshen, 2007) with the profiles centered around a mean of 1. 
Chromosomal segments with variance that is above or below the mean where called as 
gains or deletions, respectively. A threshold of 0.2 was used. For hierarchal clustering and 
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lineage reconstruction, an analysis based on copy number values and alteration 
breakpoints, in a genome-wide manner, was employed. 
 
Bulk and single cell analysis of matched primary and metastasis from human tissue 
For 20 patients, tissue sections from flash frozen samples were processed for bulk DNA 
purification using Qiagen DNeasy Blood and Tissue kit. Purified DNA was processed as 
described above for multiplex sequencing. A coverage of 2 million sequencing reads was 
similarly targeted. For a single case, matched pancreatic primary and liver metastasis 
tissue was retrieved and processed for single-nuclei isolation as previously described 
(Baslan et al, 2012). Single-nuclei were sorted based on DNA content form both diploid 
and polyploid populations of each tissue. Approximately 100 nuclei per tissue sample was 
amplified using WGA4 kit (Sigma-Aldrich) with the resulting Whole Genome Amplified 
(WGA) DNA processed for TruSeq Indexed sequencing library preparation as described 
above. Sequencing data was processed as described above with the exception that a 
least squares fitting algorithm was used to calculate absolute integer copy number (Baslan 
et al, 2015). 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical analysis used is indicated in each figure where relevant. All statistical analyses 
were performed with Graphpad Prism 8 (GraphPad). K-means clustering and Survival 
analysis were carried out in R 3.3.0. Error bars show standard deviation (SD) or standard 
error of the mean (SEM) shown as indicated in the legend and p<0.05 was considered 
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statistically significant. * indicates p<0.05; **, p<0.005; ***, p<0.0001, unless otherwise 
indicated. ns denotes not significant. 
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Chapter 4 Figures and Figure Legends 
 
Chapter 4 Figure 1   
145 
 
Chapter 4 Figure 1: Advanced pancreatic tumors exhibit intertumoral differences in their 
propensity for metastasis 
 
(A) CT imaging of human PDAC liver metastasis demonstrating heterogeneity in 
metastatic burden in Stage IV disease. Arrowheads indicate solitary metastasis in the 
top panel and selected metastases in the bottom panel 
(B) Density plot and histogram showing the distribution of total (liver and lung) metastases 
enumerated from CT scans of human Stage IV PDAC at the time of diagnosis (N=55). 
Values above each histogram bar represent the number of patients in each group. The 
vertical dotted line (red) represents the cutoff between MetLow tumors (£ 10 mets) and 
MetHigh tumors (>10 mets) determined by k-means clustering. 
(C) Quantification of tumor area (based on tumor dimensions from largest cross-sectional 
plane on imaging) comparing MetLow and MetHigh cases from the cohort in (b). 
(D) Overall survival analysis of the cohort in (b). 
(E) Top: Schematic view of the KPCXY model, showing multiple primary tumors 
distinguishable by color arising in the pancreas with matched metastases in the liver. 
Bottom: Representative fluorescent stereomicroscopic images showing a YFP+ tumor 
adjoining a CFP+ tumor in the pancreas (left) and liver metastases derived from the 
CFP+ tumor in the same animal (right). 
(F) Density plot and histogram showing the distribution of total (liver and lung) metastases 
enumerated at autopsy of KPCXY mice. Values above each histogram bar represent 
the number of tumors giving rise to the indicated number of metastases, based on 
color (N=85 tumors from 30 KPCXY mice). The vertical dotted line (red) represents 
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the cutoff between MetLow tumors (£ 10 mets, N=58) and MetHigh tumors (>10 mets, 
N=28) determined by k-means clustering. 
(G) Quantification of tumor area comparing MetLow and MetHigh tumors from the cohort 
in (f). 
Statistical analysis by Student’s unpaired t-test with p-values indicated (ns, not significant). 
Box- whisker plots in (c) and (f) indicate mean and interquartile range. Scale bar (e) = 




Chapter 4 Figure 2   
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Chapter 4 Figure 2: Somatic copy number alteration analysis confirms fluorescence-based 
lineage relationships and reveals genetic heterogeneity in in paired primary pancreatic 
tumors and liver metastasis 
 
(A) Schematic representation of KPCXY pancreatic tumor and matching liver metastasis 
with multi- region sampling for copy number sequence analysis. 
(B) Representative genome-wide copy number profiles of MetHigh (CFP+ fluorescence) 
and MetLow (YFP+ fluorescence) tumors from mouse 832 (m832) as depicted in Fig 
1e. Gray shading denotes alterations that are unique to the MetHigh (CFP+) tumor. Y-
axis illustrate normalized read count values (low-ratio) which are directly proportional 
to genome copy number at a given chromosomal location. The copy number profiles 
are centered around a mean of 1 with gains and deletions called for segments with 
values higher and lower than the mean, respectively (Methods). 
(C) Representative genome-wide copy number profiles of three sub-sampled tissue 
regions of the MetHigh (CFP+) primary tumor from m832. Gray shading denotes 
alterations that are found heterogeneously from multi-region sequencing of the primary 
tumor. 
(D) Genome-wide heatmap with hierarchal clustering based on copy number alterations 
of matched primary and metastatic samples profiled from m832. 
(E) Representative genome-wide copy number profiles of fluorescently matched primary 
and metastatic tissue from two profiled mice (m832-left panel and m836-right panel) 
illustrating the shared clonal genetic lineage. 
(F) Zoom-in chromosomal views of copy number alterations with distinguishing breakpoint 
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Chapter 4 Figure 3: The MetHigh phenotype is associated with focal, high amplitude Myc 
amplifications and elevated expression 
 
(A) Schematic representation of focal amplifications identified in profiled primary tumors. 
Vertical gray line denotes the location of amplicon and likely driver gene 
(B) (Left) Zoomed in schematic representation of three identified Myc amplicons in 
MetHigh tumors illustrating the focal and high-amplitude nature of the event. Each 
event (amplicon) is illustrated by a different colored segment line. The shared amplified 
region between the different amplicons is denoted by the chromosomal cytoband top 
of panel and illustrated in UCSC genome browser view (Right) with RefSeq Genes, 
including Myc, illustrated. 
(C) Box-and-whisker plot showing Myc mRNA levels in MetHigh tumors (N=7) and paired 
metastases (N=34) compared to MetLow tumors (N=13). 
(D) Volcano plot illustrating genes meeting cutoffs for differential expression (logfold-
change >1, Padj <0.05) between MetHigh and MetLow tumors (N=20 tumors used in 
the comparison). Genes upregulated in MetHigh tumors are highlighted in green, and 
genes upregulated in MetLow tumors are highlighted in red. 
(E) Top ten Hallmark Gene Sets identified as enriched in MetHigh tumors compared to 
MetLow tumors using all DEGs (adj. p < 0.05). 
(F) Top five transcription factor binding sites enriched in DEG in MetHigh tumors 
compared to MetLow tumors (adj. p< 0.05) identified by Metacore prediction software. 
(G) Heatmap showing unsupervised clustering of differentially expressed genes (logfold-
change >1, Padj <0.05) between MetHigh and MetLow tumors (N=20) and their 
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association with PDAC transcriptional subtypes previously reported by Collison(42), 
Moffitt(15), and Bailey(16). 
(H) Kaplan-Meier analysis showing overall survival of PDAC patients in the TCGA cohort 
stratified into those with a MetHigh signature (red line) versus those with a MetLow 
signature (blue line). Signature based on DEGs with absolute logfold-change > 0.58 
and Padj <0.05 (736 up and 1036 down regulated genes) 
Statistical analysis in (c) was performed by Wilcoxon test (*, p=3.9x10-4; **, p=5.3x10-5). 
Box and whiskers represent median mRNA expression and interquartile range. Statistical 

















































































































































































































Chapter 4 Figure 4: Myc regulates metastasis by enhancing tumor cell intravasation 
 
(A) Bar graph showing Myc mRNA levels in cell lines derived from MetHigh and MetLow 
tumors, normalized to Gapdh. N= 6 MetHigh and 5 MetLow cell lines 
(B) Western blot showing corresponding MYC protein levels in cell lines derived from 
MetHigh and MetLow tumors described in (a). 
(C) Representative fluorescent images of primary tumors and associated liver and lung 
metastasis following orthotopic transplantation of the cell lines in (a) and (b) into 
NOD.SCID mice. The bar graph shows the total number of metastases (liver and lung) 
counted following orthotopic transplantation of 5 MetLow cell lines or 5 MetHigh cell 
lines (pooled data from N=49 mice in total). 
(D) Representative fluorescent image of primary tumors, liver, and lung metastases 
following orthotopic transplantation of MetLow cell lines that were stably transduced 
with either a Myc overexpression construct (Myc-OE) or empty vector (EV). The bar 
graph shows the total number of metastases (liver and lung) counted following 
orthotopic transplantations of Myc-OE or EV cells. Data were pooled from 4 
independent MetLow lines transduced with either the MYC-OE or EV construct 
transplanted into 12 NOD.SCID (for the Myc-OE cells) or 10 NOD.SCID mice (for the 
EV cells). 
(E) Quantification of circulating tumor cells (CTCs) in arterial blood derived from the 
orthotopic tumors depicted in (c) (N=27 mice examined) and d (N= 12 mice examined). 
(F) Representative fluorescent images of lung metastasis following tail vein injection of 
cell lines derived from the MetLow and MetHigh primary tumor clones. The bar graph 
shows the total number of lung metastases counted following tail vein injection of 5 
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MetLow cell lines or 5 MetHigh cell lines (pooled data from N= 36 mice in total). 
 
Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.0152; **, 
p = 0.013; ***, p= 0.0008; **** p < 0.0001; ns, not significant). Error bars indicate SEM (c-









Chapter 4 Figure 5: Myc recruits pro-metastatic macrophages to the TME 
 
(A-B) Representative immunofluorescence images (top) and quantification (bottom) of 
T-cells (CD3+), Neutrophils (anti-neutrophil antibody+), macrophages (F4/80)+, and 
Arg1+ macrophages in primary KPCXY tumors categorized as MetLow or MetHigh 
(N=3 mice for each subgroup and 4-5 random fields of view analyzed). 
(C) Representative immunofluorescence images (left) and quantification (right) of 
macrophages that have migrated across a transwell filter following co-culture with 
MetHigh or MetLow tumor cells (N= 2 MetLow and 2 MetHigh cell lines used, 3 
replicates per cell line with 3 20X images taken per transwell; each dot represents 
quantification of an independent image). 
(D) Quantification of tumor infiltrating macrophages (as a percentage of total CD45+ cells) 
in MetLow or MetHigh subcutaneous tumors assessed by flow cytometry (N=5 
MetHigh cell lines and 3 MetLow cell lines; 2 NOD.SCID mice examined per cell line 
with 2 tumors per mouse; each dot represents an independent tumor). 
(E) Quantification of tumor infiltrating macrophages (as a percentage of total CD45+ cells) 
in Myc- OE or control (EV) subcutaneous tumors assessed by flow cytometry (N=2 
Myc-OE cell lines and 2 EV cell lines; 2 NOD.SCID mice examined per cell line with 2 
tumors per mouse; each dot represents an independent tumor). 
(F) Differentially expressed chemokines/cytokines with elevated expression (logfold-
change >1, Padj <0.01) between MetHigh and MetLow tumors (as described in Fig 3d) 
(G) Bar graph showing fold change in chemokines/cytokine mRNA levels listed in (f) 
comparing Myc-OE to EV cell lines. Data representative of 2 independent cell lines. 
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(H) Schematic outline of the macrophage depletion experiment. Mice were orthotopically 
implanted with Myc-OE cell lines (N=2 independent cell lines) and after 10d were 
treated with a combination of CSFR inhibitor (GW2580) and liposomal clodronate 
(CLD) or vehicle. Metastases were quantified 14d later. 
(I) Representative flow cytometry dot plots showing relative abundance of 
CSFR1+CD11b+ macrophages in the circulation following treatment with 
GW2580+CLD or vehicle. 
(J) Quantification of total metastases (liver and lung) following the macrophage depletion 
strategy outlined in (h) (N=6 control mice and N=7 GW2580+CLD mice; each dot 
represents an independent mouse). 
 
Statistical analysis by Student’s unpaired t-test with significance indicated (*, p<0.05; **, 
p<0.005; ***, p<0.0001; ns, not significant). Error bars indicate SEM (a-e, h). Scale bars = 










Chapter 4 Figure 6: MYC amplification and enhanced transcriptional activity are 
associated with metastasis in human PDAC 
 
(A) Bar graph showing the relative frequencies of MYC amplifications in primary PDAC 
tumors and metastases from the COMPASS cohort. 
(B) Representative plot of chromosome 8 from a metastatic tumor with MYC amplification. 
Orientation of breakpoint junctions from intra-chromosomal rearrangements indicated 
by TH, HT, HH, and TT where T = tail (3’ end of fragment) and H = head (5’ end of 
fragment). 
(C) Box-and-whisker plot showing MYC mRNA levels (FPKM) in primary PDAC tumors 
and metastases. 
(D) Representative genome-wide absolute copy number plots of single cells retrieved from 
a primary (top panel) and its matched metastasis (lower panel) illustrating acquisition 
of focal MYC amplification in the metastatic lesion. 
(E) Heatmap depiction of cancer single cells sequenced from a matched primary PDAC 
and its liver metastasis. Color codes indicate absolute copy number in single-cells. 
Top bar plot depicts tissue site from where single-cells were retrieved. 
(F) Gene set enrichment analysis of tumors with a major imbalance of mutant KRAS 
(compared to those with no major imbalance) in the COMPASS cohort. 
 









































































) Race  White (48)  Black (1)
  Asian (2)
  Hispanic (2) 
Age  MetLow (66.52 +/- 8.9)
  MetHigh (66.33 +/- 10)
Sex  Male (29; MetLow-13, MetHigh -16)























Extended Data Figure 1: Classifying metastatic burden in human and murine advanced PDA. (a) K-means clustering 
of human PDAC metastasis counts demonstrating two distinct clusters with MetLow ≤10 and MetHigh >10 total (liver and lung) 
metast sis. n=55 patients. (b) Demographics (age of diagnosis, sex, and race) of the patients analyzed in Fig. 1a-d and 
Extended Data Fig. 1a. (c) Top: Representative stereomicroscopic fluorescent image showing multiple primary tumors 
(RFP+, YFP+, and CFP+) in the pancreas with matched metastases in the liver and lung. Liver and lung metastases are 
derived primarily from the YFP+ tumor. (d) K-means clustering of murine PDAC metastasis counts demonstrating two 
distinct clusters that are defined as having high or low metastatic burden. MetLow ≤10 and MetHigh >10 total (liver and lung) 
metastasis, n=85 tumor clones. (e) Ki67 staining in primary MetLow and MetHigh tumors with representative IF images (left) 
and counts (right). Data from n=3 MetLow and n=3 MetHigh primary tumors and 4-5 random fields of view. Statistical analysis 
by students unpaired t-test with significance indicated (ns, not significant). Error bars indicating SEM. Scale bar 1mm for 
Extended Data Fig. 1c and 50um for Extended Data Fig. 1e.
Extended Data Figure 1
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Chapter 4 Supplementary Fig. 1: Classifying metastatic burden in human and murine 
advanced PDA. 
 
(A) K-means clustering of human PDAC metastasis counts demonstrating two distinct 
clusters with MetLow ≤10 and MetHigh >10 total (liver and lung) metastasis. n=55 
patients. 
(B) Demographics (age of diagnosis, sex, and race) of the patients analyzed in Fig. 1a-d 
and Extended Data Fig. 1a. 
(C) Top: Representative stereomicroscopic fluorescent image showing multiple primary 
tumors (RFP+, YFP+, and CFP+) in the pancreas with matched metastases in the liver 
and lung. Liver and lung metastases are derived primarily from the YFP+ tumor. 
(D) K-means clustering of murine PDAC metastasis counts demonstrating two distinct 
clusters that are defined as having high or low metastatic burden. MetLow ≤10 and 
MetHigh >10 total (liver and lung) metastasis, n=85 tumor clones. 
(E) Ki67 staining in primary MetLow and MetHigh tumors with representative IF images 
(left) and counts (right). Data from n=3 MetLow and n=3 MetHigh primary tumors and 
4-5 random fields of view. 
Statistical analysis by students unpaired t-test with significance indicated (ns, not 
significant). Error bars indicating SEM. Scale bar 1mm for Extended Data Fig. 1c and 









Chapter 4 Supplementary Fig. 2: Copy number alteration analysis reveals lineage 
relationships and genetic heterogeneity of fluorescently labeled primary PDACs and their 
matching metastasis. 
 
(A) Overlay genome-wide copy number profiles of different fluorescently labeled (CFP and 
RFP) primary tumors from mouse 842 (m842 - top panel) and mouse 836 (m836 - 
bottom panel) illustrating differing rearrangement profiles. 
(B) Overlay genome-wide copy number profiles of tumors where multi-region sampling 
was performed. Top panel illustrates three CFP sub-samples from CFP tumor mass 
from m842. Bottom panel illustrates three YFP sub-samples from a YFP tumor mass 
from m836. 
(C) Genome-wide heatmap with hierarchal clustering based on copy number alterations 
of matched primary and metastatic samples profiled from m471 (top panel) and m842 
(bottom panel). Color codes for Fluorescence label, primary/metastatic designation, 








































































Extended Data Figure 3
Extended Data Figure 3: Global patterns of large scale copy number alterations do not differ between MetHigh and 
MetLow clones, while Myc amplifications are maintained in metastatic lesions. (a) Genome-wide frequency plot 
illustration of large scale copy number events found in all primary tumors  (left panel) and in MetHigh (right panel) primary 
tumors. Alterations in Cdkn2a, Kras, and Trp53 are noted on the plots. (b) Genome-wide copy number profiles of matching 
MetHigh primary tumors (left panels) and paired liver metastases (right panels) from different examined mice. Myc 
amplifications are noted on profiles.
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Chapter 4 Supplementary Fig. 3: Global patterns of large scale copy number alterations 
do not differ between MetHigh and MetLow clones, while Myc amplifications are 
maintained in metastatic lesions. 
 
(A) Genome-wide frequency plot illustration of large scale copy number events found in 
all primary tumors (left panel) and in MetHigh (right panel) primary tumors. Alterations 
in Cdkn2a, Kras, and Trp53 are noted on the plots. 
(B) Genome-wide copy number profiles of matching MetHigh primary tumors (left panels) 
and paired liver metastases (right panels) from different examined mice. Myc 






Chapter 4 Supplementary Fig. 4: Ingenuity pathway analysis of the MetHigh transcriptome. 
 
Extended Data Figure 4
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Chapter 4 Supplementary Fig. 5: Established MetHigh / MetLow cell lines maintain their 
overall genomic profile and do not select for Myc amplification during in vitro culture. 
 
(A) Schematic representation of genome wide copy number profile of matching primary 
tumor and cell lines samples illustrating the maintenance of their overall copy number 
pattern. 
(B) Representative genome-wide copy number profiles of matching primary tumors and 
cell line samples for a MetHigh tumor from m836 (YFP+) and MetLow tumor from m842 



































































Extended Data Figure 6
Extended Data Figure 6: Tumor weight and Myc expression in orthotopic primary tumors primary and Myc 
overexpressing cell lines. (a) Tumor weight in grams of MetLow and MetHigh cell line derived orthotopic tumors in 
Figure 4c-d. Weight from n= 4 MetLow and 5 MetHigh cell lines. (b) Representative IHC staining of MetLow and MetHigh 
orthotopic tumors from Figure 4c-d. (c)  Myc gene expression in MetLow_Myc-OE relative to MetLow_EV cell lines 
in Figure 4e-f. (d) Tumor weight in grams of MetLow_EV and MetLow_Myc-OE cell line derived orthotopic tumors in 
Figure 4e-f. Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.007; ns, not significant). 
Error bar indictes SEM (panels a,c,d). Scale bar 50mm (panel b).
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Chapter 4 Supplementary Fig. 6: Tumor weight and Myc expression in orthotopic primary 
tumors primary and Myc overexpressing cell lines. 
 
(A) Tumor weight in grams of MetLow and MetHigh cell line derived orthotopic tumors in 
Figure 4c-d. Weight from n= 4 MetLow and 5 MetHigh cell lines. 
(B) Representative IHC staining of MetLow and MetHigh orthotopic tumors from Figure 
4c-d. 
(C) Myc gene expression in MetLow_Myc-OE relative to MetLow_EV cell lines in Figure 
4e-f. 
(D) Tumor weight in grams of MetLow_EV and MetLow_Myc-OE cell line derived 
orthotopic tumors in Figure 4e-f. 
Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.007; ns, 
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Genome Instability in Metastatic PDAC













Genome instability in metastatic PDAC
Wilcox p value = 0.51 (ns)
c
Extended Data Figure 7: MYC amplifications are enriched in metastatic human PDA. (a) Bar graph showing the 
relative frequencies of MYC amplifications in resected and advanced PDAC tumors from the COMPASS cohort.
(b) MYC expression in non-MYC ampl fied and MYC amplified tumors in the COMPASS cohort. (c) Measurement of
total structural variant burden in non-MYC amplified and MYC amplified tumors in the COMPASS cohort. (d) Genome-
wide relative copy number profiles of two patients with matched primary PDAC (left) and liver metastasis (right).
(e) Heatmap depiction of Myc, CDKN5A, TP53, and SMAD4 copy number alteration in cancer single cells sequenced 
from a matched primary PDAC and its liver metastasis depicted in Fig. 6e. Color codes indicate absolute copy number 
in single-cells. Top bar plot depicts tissue site from which single-cells were retrieved. (f) Gene set enrichment analysis 
of MYC amplified tumors (compared to non-amplified tumors) in the COMPASS cohort.
Extended Data Figure 7
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Chapter 4 Supplementary Fig. 7: MYC amplifications are enriched in metastatic human 
PDA 
 
(A) Bar graph showing the relative frequencies of MYC amplifications in resected and 
advanced PDAC tumors from the COMPASS cohort. 
(B) MYC expression in non-MYC amplified and MYC amplified tumors in the COMPASS 
cohort. 
(C) Measurement of total structural variant burden in non-MYC amplified and MYC 
amplified tumors in the COMPASS cohort. 
(D) Genome- wide relative copy number profiles of two patients with matched primary 
PDAC (left) and liver metastasis (right). 
(E) Heatmap depiction of Myc, CDKN5A, TP53, and SMAD4 copy number alteration in 
cancer single cells sequenced from a matched primary PDAC and its liver metastasis 
depicted in Fig. 6e. Color codes indicate absolute copy number in single-cells. Top bar 
plot depicts tissue site from which single-cells were retrieved. 
(F) Gene set enrichment analysis of MYC amplified tumors (compared to non-amplified 






CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
Insights into the regulation of epithelial plasticity in vivo 
While EMT has been widely studied in cancer, it is considered one of the pivotal 
processes during embryogenesis and organogenesis. Elizabeth Hay, who first described 
EMT, noted that that major differences between EMT in embryogenesis versus EMT in 
cancer is the transition from subtle, highly controlled movements, to aggressive and 
uncontrolled movements that resonate well with cancers in other aspects (proliferation, 
death evasion, etc). In either scenario, the transition from the static epithelial state to a 
more motile mesenchymal state is met with immense protein reprogramming that occurs 
through a concurrent downregulation of epithelial genes and an upregulation of 
mesenchymal genes. While disruption of any of the pathways involved in EMT/MET 
process during development results in disorders of varying severity, understanding how 
cancers hijack EMT may have therapeutic implications to hinder cancer progression. 
EMT in cancer was first described and studied in vitro (Hay, 1995). There were 
initial concerns that EMT was only observed in experimental, mainly cell culture conditions, 
and not in human tumors (Tarin, 2005; Ledford, 2011). It was highly likely that studying 
EMT in a dish fails to recapitulate the complex in vivo environment that tumor cells 
experience creating an artificial induction of EMT. Furthermore, the debate of whether 
EMT even exists in vivo has been a long-standing argument. The identification of EMT 
tumor cells in vivo remains a challenge due to the high resemblance of an EMT tumor cell 
to that of a stromal/fibroblast cell. But histopathological analysis of the invasive fronts of 
tumors revealed tumor cells that exist in an EMT phenotype, amidst desmoplastic stroma, 
suggesting that tumor cells exist and also that EMT induction may promote the cell 
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invasion and dissemination (Brabletz et al, 2001; Huang et al, 2012). But still, the isolation 
to characterize tumor cells in vivo has been challenging. With the advent of lineage labeled 
genetic engineered mouse models, we are now able to isolate and trace tumor cells in an 
EMT state attempting to answer pertinent questions. 
The use of these mouse models has been increasing relevant in understanding 
the molecular mechanisms that drive EMT in vivo. As noted previously in the introduction, 
recent studies have investigated the role of EMT-TFs in cancer which have led to 
conflicting results (Stemmler et al, 2019). Deletion of either SNAIL1 or TWIST1 in a 
spontaneous mouse model of PDAC had minimal effect on metastasis, whereas ZEB1 
ablation in a similar model drastically reduced colonization, invasion, and metastasis 
(Zheng et al, 2015; Krebs et al, 2017). But, depletion of SNAIL or TWIST in the PyMT 
breast cancer model was capable of reducing metastasis formation(Xu et al, 2017; Ni et 
al, 2016). These studies suggest that that tissue- and context-dependent differences 
dictate the molecular mechanisms underlying EMT in a given tumor. However, in all of 
these studies, while metastasis was affected, it was never entirely hindered, suggesting 
that some other mechanism may be responsible for tumor cell metastasis. 
Here, we used a lineage labeled mouse model of PDAC to isolate tumor cells that 
are in a de novo EMT state revealing that the majority of PDAC tumors use protein re-
localization rather than transcriptional repression to subdue the epithelial program(Aiello 
et al, 2018). These tumors exhibit low expression of EMT-TFs, suggesting that they may 
play a minimal role, and co-express epithelial and mesenchymal genes, consistent with a 
P-EMT state. This post-transcriptional program, although not typically discussed as a 
potential mechanism for EMT in cancer, is indeed seen in several instances during 
development (Song et al, 2013; Wu & McClay, 2007; Zohn et al, 2006), suggesting that 
175 
 
both transcriptional and posttranscriptional mechanisms may play distinct roles in tumor 
progression under certain circumstances. 
One of the most pondered questions of the P-EMT state is regarding its longevity. 
Is the P-EMT state just a tumor cell paused in a transitional state (i.e. an intermediate 
state along a mesenchymal differentiation continuum) or does it represent a final state in 
its own right? Is it just a mixed population composed of epithelial and mesenchymal cells? 
Is it a population of mostly transitioning cells? Several recent theoretical and mouse 
studies have predicted that a partial EMT state can exist at a single level (Pastushenko et 
al, 2018; Puram et al, 2018; Jolly et al, 2016). Indeed, we have no evidence that the P-
EMT program and the C-EMT program co-exist within the same PDAC tumor, suggesting 
that the tendency to use one program over the other is a stable entity of an individual 
tumor (see Chapter 2, Figure S4). Yet, to further understand the stability of this state, the 
molecular mechanisms dictating this P-EMT state need to be explored. 
In Chapter 3, we investigated potential mediators regulating the partial EMT 
phenotype seen in vivo. Here, we identified Ca2+ mobilization as an inducer of a stable P-
EMT state characterized by the re-localization of epithelial proteins along with increased 
migration and invasion, mirroring the phenotype seen in vivo (Figure 1). Mechanistically, 
upon calcium influx, calmodulin becomes activated and we found that this P-EMT 
phenotype is dependent on its activation. Future studies will attempt to identify the precise 
mechanism and targets of calmodulin. New studies have implicated Ca2+/calmodulin-
dependent protein kinases (CAMK) as a regulator of P-EMT (Pastushenko et al, 2020). 
This is directly downstream of calmodulin and a likely candidate in our system which future 
studies will interrogate.  Collectively, this data suggests that at one mechanism by which 
tumor cells can achieve a partial EMT phenotype is by extracellular signals that result in 
increased Ca2+ influx. These findings raise several questions. 
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First, what ligands and cognate receptors are responsible for the P-EMT 
phenotype. In our study, we have evidence that GPCR signaling activation results in P-
EMT. However, there are over 800 GPCRs in humans of which anyone of them can be 
responsible. Using our sequencing results, we have narrowed that list down to about 90 
GPCRs that are differentially expressed between P-EMT and C-EMT in vivo, a number 
that is still impractical to study sequentially. We can reason based on our results, that this 
GPCR must couple with a Gaq subunit to activate signaling. However, while some 
receptors are well known to couple with the Gaq subunit, the structural determinants of 
receptor specificity for most GPCRs are not completely understood. Although we have 
identified GPCR signaling as one potential avenue for calcium influx and the P-EMT 
phenotype, it is highly probable that other signaling pathways in cancer such as 
neurotransmitter receptors (Schuller & Al-Wadei, 2010) that are known to induce calcium 
signaling may also be capable of inducing a P-EMT. Yet, this issue highlights a broader 
problem in the EMT field which is what physiological inducers invoke EMT in vivo. A 
plethora of developmental growth factors (Wnt, TGFb, EGF, HGF) and 
microenvironmental stimulus (hypoxia, matrix stiffness) have been shown to induce EMT 
in vitro (Lamouille et al, 2014). Which of these ligands is responsible within the tumor 
microenvironment remains ill-defined. As with the receptors, it is again possible or more 
likely, that multiple factors act in combination to achieve critical thresholds of the 
necessary signal. 
 
Partial EMT: The best of both worlds? 
The idea of a tumor cell invoking a partial EMT state is rather intriguing. In theory, 
it would allow tumor cells to utilize traits that are advantageous to both epithelial and 
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mesenchymal cells giving it advantages in metastasis, chemoresistance, and immune 
evasion. 
To metastasize tumor cells must detach from the primary tumor and invade 
surrounding or distant tissues. Broadly speaking, there are two major modes of invasion: 
single cell migration and collective migration. And depending on the environmental stimuli, 
cancer cells are thought to be capable to switch between these two invasion strategies 
(Clark & Vignjevic, 2015). In collective migration, cancer cells retain cell-cell adhesions 
and display as a group of cells or cluster. These tumor cells that metastasize in a collective 
fashion display enhanced metastatic potential compared to single cells. In a 3D 
assessment of many types of cancers, it was found that single cell migration was almost 
nonexistent (<0.0003%) suggesting that collective migration as the predominant 
mechanism used in these cancers (Bronsert et al, 2014). In this thesis, we find that both 
modes of cell migration occur and this correlates well with EMT subtype (P-EMT = 
collective migration, C-EMT = single cell migration). In accordance with the 3D 
assessment (Bronsert et al, 2014), we find that the majority of tumors exist in a P-EMT 
state and exhibit collective migration. These tumor cells that exist in a P-EMT retain their 
epithelial proteins allowing them the ability re-express these proteins when necessary 
endowing them with the ability to form clusters. In contrast, C-EMT tumor cells are 
completely devoid of surface E-cadherin and other epithelial proteins, inhibiting the ability 
to form tumor clusters. It is tempting to speculate based on this that disruption or breaking 
of these clusters in circulation or prior to formation may lead to therapeutic benefit in 
patients. 
Over many decades of work, a central theme of EMT has been in its role in 
chemoresistance (Nieto et al, 2016a). In response to therapeutic pressures, tumor cells 
may activate EMT and thus inhibit proliferation or upregulate drug efflux machinery for 
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example, to acquire resistance. Recent work in mouse models has suggested that EMT-
TFs may play a large role in this acquired resistance(Zheng et al, 2015; Fischer et al, 2015; 
Wang et al, 2016). However, in some circumstances this dogma may not hold true. Several 
studies have suggested that selective sensitivities may exist when tumor cells exist in an 
epithelial subtype/state versus tumor cells in a mesenchymal subtype/state (Genovese et 
al, 2017; Collisson et al, 2011). This scenario, aligns with the notion that being in a P-EMT 
may be superior to combat therapeutic agents. Similarly, to therapeutic resistance, recent 
findings have led to increased interest in how EMT might contribute to immune escape 
(Terry et al, 2017). We can again speculate that being in a P-EMT may be the perfect 
cover for tumor cells to escape from immune detection while maintaining abilities 
necessary for progression, another avenue worth exploring. 
In summary, all of these observations indicate a primary requisite for the 
development of targeted treatment modalities suppressing EMT and the partial EMT 
phenotype. While this is merited, there are several drawbacks that should be emphasized: 
1) Tumor cells have different resistances in epithelial or mesenchymal states and targeting 
one state may leave the other state behind, 2) reversal of EMT may counteract the benefits 
of inhibiting EMT since cells in the epithelial state have been found to proliferate and 
colonize distant sites more and 3) inhibition of EMT would have minimal impact on 
baseline disease burden, leaving already metastatic foci present. Thus, more than one 
agent would have to be used to combat the effects of cells in a variety of stages. To this 
end, future work should investigate pharmacological agents that are capable of targeting 
specific EMT states: epithelial, mesenchymal, and P-EMT states. In this thesis, we have 
found a method to stably induce both the P-EMT (calcium influx) and C-EMT (TGFb 
treatment). Using these principles, we propose a high throughput pharmacological screen 
to extend our own findings and determine compounds that could effectively lead to 
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eradication of specific EMT states. Through these studies, we aim to find and then design 
combinations that would eradicate all cell populations reducing tumor burden and 
subsequent metastatic events. 
 
The existence of metastatic drivers 
The presence of plasticity, intratumoral heterogeneity, and intertumoral 
heterogeneity has made it increasing challenging to understand mechanisms behind 
tumor spread. As tumors develop they successively accumulate genetic alterations that 
drive tumor progression. Based on this, one would postulate that the occurrence of 
metastasis would depend on the acquisition of yet some other mutation empowering tumor 
cells with the ability of metastasis. However, after many years and many studies, no single 
mutation has been identified that are characteristically associated with progression to 
metastatic disease. In fact, even large-scale genome sequencing studies have yet to 
uncover recurrent genetic mutations that can explain metastasis (Lambert et al, 2017).  
This has shaped the field to believe that the development of metastasis is not entirely 
driven by a single somatic mutation and that other factors play a pioneering role. 
In our study, we utilized the KPCXY mouse model of PDAC, which exhibited 
varying degrees of metastatic spread to interrogate the molecular mechanisms driving 
metastasis in naturally arising tumors. This system revealed a strong association between 
the level of MYC at both the genome and transcriptome level and tumor metastasis. MYC 
exerts its pro-metastatic effect, in part, by recruiting tumor associated macrophages that 
influenced tumor cell metastasis (Figure 2). Depletion of macrophages from the circulation 
and the primary tumor nearly completely inhibited metastasis in our system. 
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These results raise several questions that challenge the notion that genetic drivers 
of metastasis do not exist. The first obvious question is whether genetic drivers do exist? 
As indicated, several studies have attempted to uncover genetic drivers to no avail. A 
recent study in pancreatic cancer compared matched primary and metastasis from four 
patients yet failed to reveal mutations in driver oncogenes (Makohon-Moore et al, 2017). 
But the existence of primary tumor heterogeneity may be an explanation for this. To clarify, 
in our mouse model, we observed that primary tumors are composed of several (up to 5) 
different subclones. If a biopsy was taken from a non-metastatic clone and compared to a 
metastatic lesion, no similarities would be concluded, illustrating the power of our model 
and the potential relevance of our findings. It is noteworthy that MYC amplifications were 
far more common in metastases than primary tumors, including the one instance where 
we were able to trace a metastatic lesion directly to a MYC amplified subclone. The more 
likely scenario is that genetic drivers do indeed exist but non-genetic drivers (i.e. 
epigenetic and transcriptional changes) are present and potentially even more common. 
An increase in MYC transcripts, regardless of whether this was the result of an 
amplification or an increase in transcription, resulted in increased metastasis. 
Our studies implicate non-cell autonomous mechanisms involving the recruitment 
of tumor associated macrophages (TAMs) as contributors to metastatic heterogeneity. 
The ability of TAMs to promote tumor cell invasion is well described (Cassetta et al, 2019; 
Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al, 2015; Lee 
et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele et al, 2016; 
Zhu et al, 2014), in concordance with our finding that metastatic high tumors and MYC 
overexpression have increased macrophages present. It is also well known that MYC 
plays a specific role in both tumor cell intrinsic (i.e. proliferation and cell cycle) and non-
intrinsic properties, as many studies have shown that it can shape the makeup of the tumor 
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microenvironment. While the specific recruitment factor for TAMs is unknown (and likely 
diverse), we can speculate that MYC either directly or indirectly regulates the upregulation 
of this factor or potential combination of factors. Follow up experiments will attempt to 
identify the genes that MYC directly controls and what factors are necessary for 
macrophage recruitment. 
Surprisingly, metastatic high tumor clones failed to show any indication of EMT. 
Although not entirely unexpected this further adds to the literature that suggests EMT is 
not the only method of metastatic spread in tumors. Therefore, understanding many 
aspects of tumor biology – plasticity and heterogeneity – are crucial to designing initial 







My thesis work sought to investigate the molecular underpinnings of epithelial 
plasticity and tumor cell heterogeneity leading to metastasis. These projects were built 
upon by observations in genetic engineered mouse models of PDAC. Following the 
dogma-shifting finding that EMT occurred frequently and early in PDAC, we utilized our 
mouse model of pancreatic cancer to investigate the divergent mechanisms of EMT in 
vivo. Notably, the lineage tracing marker, YFP, allowed us distinguish and isolate tumor 
cells that have undergone EMT from normal stromal cells that infiltrated into primary 
tumors, a technique that had not been previously employed to study EMT. We then 
followed up on our initial characterization and identification of a P-EMT phenotype present 
in the majority of PDAC tumors, and used GSEA and HOMER motif analysis to initially 
hypothesize that calcium signaling is an underlying molecular mechanism that regulates 
P-EMT. The identified signaling axis thorough calmodulin may serve as a therapeutically 
tractable avenue to inhibit P-EMT. This research strategy could be utilized in many other 
scenarios: other tumors (breast, colon, ovarian, etc) to identify if redundant or non-
redundant pathways exist for EMT or other types of tumor cell plasticity (refer to Yuan et 
al, 2019). 
In chapter 4, we utilized a related genetic mouse model of PDAC that utilized a 
multi-color confetti allele instead of a YFP lineage label to investigate tumor cell 
heterogeneity in PDAC. This allowed for the identification of tumor cell subpopulations 
with high or low metastatic capability. The lineage label again allowed for the isolation and 
characterization of these two populations and further molecular studies to identify 
metastatic drivers in PDAC. While chapters 2 and 3 focused on tumor cell intrinsic 
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mechanisms of tumor cell invasion, in chapter 4 we found that MYC amplification or 
transcriptional upregulation resulted in a rewiring of the tumor microenvironment and non-
cell autonomous recruitment of tumor associated macrophages led to greater bloodstream 
intravasation and metastasis. Given that MYC family members are amplified in many 
different cancers, these results have broad implications for metastasis in tumor types other 
than PDAC. 
Collectively, these studies highlight the power and utilization of lineage labels in 
cancer models to understand several aspects of tumor biology. Understanding both 
epithelial plasticity and heterogeneity are dire being the downfall of many cancer patients 
before and during treatments. While PDAC mouse models were exclusively used in this 
thesis, we have confirmed many results in human cells, patients, and other tumor types, 




Chapter 5 Figures and Figure Legends 
 
 
Figure 1 (Chapter 5): Graphical abstract of classical or complete C-EMT versus partial 





Figure 2 (Chapter 5): Using the KPCXY mouse model of PDAC, we found a strong 
association between the level of MYC at both the genome and transcriptome level and 
tumor metastasis. MYC exerts its pro-metastatic effect, in part, by recruiting tumor 














Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely 
A, Engstrom A, Zhu H, et al (2014) Circulating tumor cell clusters are oligoclonal 
precursors of breast cancer metastasis. Cell 158: 1110–1122 
Aiello NM, Maddipati R, Balli D, Norgard R, Li J, Yaun S, Yamazoe T, Black T, Sahmoud 
A, Bar-Sagi D, et al (2017) Tumor Subtype influences epithelial plastiticy and mode 
of cell migration. (under Rev 
Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, 
Sahmoud A, Furth EE, et al (2018) EMT Subtype Influences Epithelial Plasticity and 
Mode of Cell Migration. Dev Cell 45: 681-695.e4 
Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ & Kandel 
JJ (2011) Human cancer cells express Slug-based epithelial-mesenchymal 
transition gene expression signature obtained in vivo. BMC Cancer 
Anders S, Pyl PT & Huber W (2015) HTSeq-A Python framework to work with high-
throughput sequencing data. Bioinformatics 
Armbruster BN, Li X, Pausch MH, Herlitze S & Roth BL (2007) Evolving the lock to fit the 
key to create a family of G protein-coupled receptors potently activated by an inert 
ligand. Proc Natl Acad Sci 104: 5163–5168 
Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, 
Marcom PK, George DJ & Garcia-Blanco MA (2011) Circulating Tumor Cells from 
Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and 
Mesenchymal Markers. Mol Cancer Res 9: 997–1007 
Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, 
Rodriguez A, Coleman I, et al (2020) A MYC and RAS co-activation signature in 
187 
 
localized prostate cancer drives bone metastasis and castration resistance. Nat 
Cancer 1: 1082–1096 
Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, 
Liang SB, Chadwick D, Zhang A, et al (2018) Genomics-Driven Precision Medicine 
for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin 
Cancer Res 24: 1344–1354 
Azimi I & Monteith GR (2016) Plasma membrane ion channels and epithelial to 
mesenchymal transition in cancer cells. Endocr Relat Cancer doi:10.1530/ERC-16-
0334 [PREPRINT] 
Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha 
PJ, Bardeesy N, Matsui W, et al (2014) DCLK1 marks a morphologically distinct 
subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. 
Gastroenterology 
Bailey JM, Hendley AM, Lafaro KJ, Pruski MA, Jones NC, Alsina J, Younes M, Maitra A, 
McAllister F, Iacobuzio-Donahue CA, et al (2016a) P53 mutations cooperate with 
oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. 
Oncogene 35: 4282–4288 
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, 
Colaprico A, Wendl MC, Kim J, Reardon B, et al (2018) Comprehensive 
Characterization of Cancer Driver Genes and Mutations. Cell 
Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, 
Bruxner TJC, Quinn MC, et al (2016b) Genomic analyses identify molecular 
subtypes of pancreatic cancer. Nature 531: 47–52 
Bar-Shavit R, Maoz M, Kancharla A, Nag J, Agranovich D, Grisaru-Granovsky S & 
Uziely B (2016) G Protein-Coupled Receptors in Cancer. Int J Mol Sci 17: 1320 
188 
 
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, 
Lehár J, Kryukov G V., Sonkin D, et al (2012) The Cancer Cell Line Encyclopedia 
enables predictive modelling of anticancer drug sensitivity. Nature 
Baslan T, Kendall J, Rodgers L, Cox H, Riggs M, Stepansky A, Troge J, Ravi K, 
Esposito D, Lakshmi B, et al (2012) Genome-wide copy number analysis of single 
cells. Nat Protoc 
Baslan T, Kendall J, Volyanskyy K, McNamara K, Cox H, D’Italia S, Ambrosio F, Riggs 
M, Rodgers L, Leotta A, et al (2020) Novel insights into breast cancer copy number 
genetic heterogeneity revealed by single-cell genome sequencing. Elife 9 
Baslan T, Kendall J, Ward B, Cox H, Leotta A, Rodgers L, Riggs M, D’Italia S, Sun G, 
Yong M, et al (2015) Optimizing sparse sequencing of single cells for highly 
multiplex copy number profiling. Genome Res 25: 714–724 
Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J & García De Herreros  
a (2000) The transcription factor snail is a repressor of E-cadherin gene expression 
in epithelial tumour cells. Nat Cell Biol 2: 84–89 
Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, 
Esposito I, Heßmann E, et al (2014) Inflammation-Induced NFATc1-STAT3 
transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer 
Discov 4: 688–701 
Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, Donaher JL, 
Reinhardt F, Chaffer CL, Keckesova Z, et al (2017) Integrin-β4 identifies cancer 
stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc Natl 
Acad Sci U S A 




Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R & 
Kirchner T (2001) Variable β-catenin expression in colorectal cancers indicates 
tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 
Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, 
Kohler I, Bausch D, Hoeppner J, et al (2014) Cancer cell invasion and EMT marker 
expression: a three-dimensional study of the human cancer-host interface. J Pathol 
De Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, 
Shafi S, Murugaesu N, Rowan AJ, et al (2014) Spatial and temporal diversity in 
genomic instability processes defines lung cancer evolution. Science (80- ) 
Brüser L & Bogdan S (2017) Adherens junctions on the move—membrane trafficking of 
E-cadherin. Cold Spring Harb Perspect Biol 
Campbell K, Whissell G, Franch-Marro X, Batlle E & Casanova J (2011) Specific GATA 
Factors Act as Conserved Inducers of an Endodermal-EMT. Dev Cell 21: 1051–
1061 
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, 
Morsberger LA, Latimer C, McLaren S, Lin ML, et al (2010) The patterns and 
dynamics of genomic instability in metastatic pancreatic cancer. Nature 
Cancer Genome Atlas Research Network. Electronic address  andrew aguirre dfci 
harvard edu & Cancer Genome Atlas Research N (2017) Integrated Genomic 
Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32: 185-203 
e13 
Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, Del Barrio MG, Portillo F 
& Nieto MA (2000) The transcription factor Snail controls epithelial-mesenchymal 
transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83 
Carter SL, Eklund AC, Kohane IS, Harris LN & Szallasi Z (2006) A signature of 
190 
 
chromosomal instability inferred from gene expression profiles predicts clinical 
outcome in multiple human cancers. Nat Genet 
Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong 
DYH, Cotechini T, Anur P, Lin EY, et al (2019) Human Tumor-Associated 
Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific 
Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell 35: 588-602 
e10 
Cassetta L & Pollard JW (2020) Tumor-associated macrophages. Curr Biol 30: R246–
R248 
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, 
Heuer ML, Larsson E, et al (2012) The cBio Cancer Genomics Portal: An open 
platform for exploring multidimensional cancer genomics data. Cancer Discov 
Chakraborty P, George JT, Tripathi S, Levine H & Jolly MK (2020) Comparative Study of 
Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal 
Spectrum. Front Bioeng Biotechnol 8 
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O’Kane GM, Connor AA, 
Denroche RE, Grant RC, McLeod J, et al (2020) Transcription phenotypes of 
pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet 
52: 231–240 
Chen Q, Zhang XH & Massague J (2011) Macrophage binding to receptor VCAM-1 
transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 
20: 538–549 
Cheung KJ & Ewald AJ (2016) A collective route to metastasis: Seeding by tumor cell 
clusters. Science (80- ) doi:10.1126/science.aaf6546 [PREPRINT] 
Cheung KJ, Gabrielson E, Werb Z & Ewald AJ (2013) Collective invasion in breast 
191 
 
cancer requires a conserved basal epithelial program. Cell 
Chiou SH, Risca VI, Wang GX, Yang D, Gruner BM, Kathiria AS, Ma RK, Vaka D, Chu 
P, Kozak M, et al (2017) BLIMP1 induces transient metastatic heterogeneity in 
pancreatic cancer. Cancer Discov 
Clark AG & Vignjevic DM (2015) Modes of cancer cell invasion and the role of the 
microenvironment. Curr Opin Cell Biol doi:10.1016/j.ceb.2015.06.004 [PREPRINT] 
Cleary AS, Leonard TL, Gestl SA & Gunther EJ (2014) Tumour cell heterogeneity 
maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 
Collisson EA, Bailey P, Chang DK & Biankin A V. (2019) Molecular subtypes of 
pancreatic cancer. Nat Rev Gastroenterol Hepatol doi:10.1038/s41575-019-0109-y 
[PREPRINT] 
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim 
GE, Jakkula L, et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their 
differing responses to therapy. Nat Med 17: 500–3 
Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier J-
M, Chang WC, Pei Y, McCarthy KD, et al (2008) Engineering GPCR signaling 
pathways with RASSLs. Nat Methods 5: 673–678 
Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, 
Wilson GW, Chan-Seng-Yue MA, Borozan I, et al (2017) Association of Distinct 
Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic 
Ductal Adenocarcinoma. JAMA Oncol 3: 774–783 
Corallino S, Malabarba MG, Zobel M, Di Fiore PP & Scita G (2015) Epithelial-to-
mesenchymal plasticity harnesses endocytic circuitries. Front Oncol 
Crabtree GR & Olson EN (2002) NFAT Signaling. Cell 109: S67–S79 
Dagogo-Jack I & Shaw AT (2018) Tumour heterogeneity and resistance to cancer 
192 
 
therapies. Nat Rev Clin Oncol doi:10.1038/nrclinonc.2017.166 [PREPRINT] 
Dang C V (2012) MYC on the path to cancer. Cell 149: 22–35 
Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW, Goodhill GJ, Thompson 
EW, Roberts-Thomson SJ & Monteith GR (2014) Induction of epithelial-
mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. 
Oncogene 
Deek MP & Tran PT (2020) Oligometastatic and Oligoprogression Disease and Local 
Therapies in Prostate Cancer. Cancer J (United States) 
doi:10.1097/PPO.0000000000000432 [PREPRINT] 
Delva E & Kowalczyk AP (2009) Regulation of cadherin trafficking. Traffic 
doi:10.1111/j.1600-0854.2008.00862.x [PREPRINT] 
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N & Coussens LM 
(2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by 
enhancing protumor properties of macrophages. Cancer Cell 16: 91–102 
Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Anand Rajan KD, 
Lai I, Gabay M, Tong L, et al (2020) MYC and twist1 cooperate to drive metastasis 
by eliciting crosstalk between cancer and innate immunity. Elife 
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M & 
Gingeras TR (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 
Dongre A & Weinberg RA (2019) New insights into the mechanisms of epithelial–
mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20: 69–
84 
Dorsam RT & Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev 
Cancer 7: 79–94 
Farmer H, McCabe H, Lord CJ, Tutt AHJ, Johnson DA, Richardson TB, Santarosa M, 
193 
 
Dillon KJ, Hickson I, Knights C, et al (2005) Targeting the DNA repair defect in 
BRCA mutant cells as a therapeutic strategy. Nature 
Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, 
Heiser LM, Morton JP, et al (2017) MYC regulates ductal-neuroendocrine lineage 
plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and 
chemoresistance. Nat Commun 8: 1728 
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, Choi H, El Rayes T, Ryu S, 
Troeger J, et al (2015) Epithelial-to-mesenchymal transition is not required for lung 
metastasis but contributes to chemoresistance. Nature 527: 472–476 
Foster CC, Pitroda SP & Weichselbaum RR (2020) Definition, Biology, and History of 
Oligometastatic and Oligoprogressive Disease. Cancer J (United States) 
doi:10.1097/PPO.0000000000000434 [PREPRINT] 
Friedl P, Locker J, Sahai E & Segall JE (2012) Classifying collective cancer cell invasion. 
Nat Cell Biol doi:10.1038/ncb2548 [PREPRINT] 
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, 
Sinha R, Larsson E, et al (2013) Integrative analysis of complex cancer genomics 
and clinical profiles using the cBioPortal. Sci Signal 
Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli 
R, Pettazzoni P, et al (2017) Synthetic vulnerabilities of mesenchymal 
subpopulations in pancreatic cancer. Nature 542: 362–366 
Giampieri S, Manning C, Hooper S, Jones L, Hill CS & Sahai E (2009) Localized and 
reversible TGFβ signalling switches breast cancer cells from cohesive to single cell 
motility. Nat Cell Biol 
Ginter PS, Karagiannis GS, Entenberg D, Lin Y, Condeelis J, Jones JG & Oktay MH 
(2019) Tumor Microenvironment of Metastasis (TMEM) Doorways Are Restricted to 
194 
 
the Blood Vessel Endothelium in Both Primary Breast Cancers and Their Lymph 
Node Metastases. Cancers (Basel) 11 
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park J-O, 
Hochhauser D, Arnold D, Oh D-Y, et al (2019)  Maintenance Olaparib for Germline 
BRCA -Mutated Metastatic Pancreatic Cancer . N Engl J Med 
Gotzmann J, Fischer ANM, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner 
T, Weith A, Beug H, et al (2006) A crucial function of PDGF in TGF-β-mediated 
cancer progression of hepatocytes. Oncogene 
Grigore A, Jolly M, Jia D, Farach-Carson M & Levine H (2016) Tumor Budding: The 
Name is EMT. Partial EMT. J Clin Med 5: 51 
Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang 
YH, Moreno D, Mosqueda M, et al (2018) In vivo screening identifies GATAD2B as 
a metastasis driver in KRAS-driven lung cancer. Nat Commun 
Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, 
Dubus P, Sandgren EP & Barbacid M (2007) Chronic Pancreatitis Is Essential for 
Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult 
Mice. Cancer Cell 
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, 
Brewer DS, Kallio HM, Hognas G, Annala M, et al (2015a) The evolutionary history 
of lethal metastatic prostate cancer. Nature 520: 353–357 
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, 
Brewer DS, Kallio HML, Hognas G, Annala M, et al (2015b) The evolutionary 
history of lethal metastatic prostate cancer. Nature 520: 353–357 
Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, 
Konieczny SF, Leach SD, et al (2008) Spontaneous induction of murine pancreatic 
195 
 
intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult 
mice. Proc Natl Acad Sci 105: 18913–18918 
Haeger A, Wolf K, Zegers MM & Friedl P (2015) Collective cell migration: Guidance 
principles and hierarchies. Trends Cell Biol doi:10.1016/j.tcb.2015.06.003 
[PREPRINT] 
Hanahan D & Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 
646–674 doi:10.1016/j.cell.2011.02.013 [PREPRINT] 
Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian BZ, Oktay MH, Pollard JW, 
Jones JG & Condeelis JS (2015) Real-time imaging reveals local, transient vascular 
permeability, and tumor cell intravasation stimulated by TIE2himacrophage–derived 
VEGFA. Cancer Discov 5: 932–943 
Hay ED (1995) An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 
154: 8–20 
Hayashi A, Yavas A, McIntyre CA, Ho YJ, Erakky A, Wong W, Varghese AM, Melchor 
JP, Overholtzer M, O’Reilly EM, et al (2020) Genetic and clinical correlates of 
entosis in pancreatic ductal adenocarcinoma. Mod Pathol 
Heit JJ, Apelqvist ÅA, Gu X, Winslow MM, Neilson JR, Crabtree GR & Kim SK (2006) 
Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function. Nature 
443: 345–349 
Hessmann E, Schneider G, Ellenrieder V & Siveke JT (2016) MYC in pancreatic cancer: 
novel mechanistic insights and their translation into therapeutic strategies. 
Oncogene 35: 1609–1618 
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, 
Chang S & Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote 
chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in 
196 
 
mice. Cancer Cell 7: 469–483 
Hirano M, Hashimoto S, Yonemura S, Sabe H & Aizawa S (2008) EPB41L5 functions to 
post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal 
transition. J Cell Biol 182: 1217–1230 
Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, Molina 
H, Kohsaka S, Di Giannatale A, Ceder S, et al (2015) Tumour exosome integrins 
determine organotropic metastasis. Nature 527: 329–335 
Huang RY-J, Guilford P & Thiery JP (2012) Early events in cell adhesion and polarity 
during epithelial-mesenchymal transition. J Cell Sci 125: 4417–4422 
Hunter KW, Amin R, Deasy S, Ha NH & Wakefield L (2018) Genetic insights into the 
morass of metastatic heterogeneity. Nat Rev Cancer 18: 211–223 
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, 
Wang Z, Keller JW, Banerjee P, et al (2009) DPC4 gene status of the primary 
carcinoma correlates with patterns of failure in patients with pancreatic cancer. J 
Clin Oncol 27: 1806–1813 
Ireton RC, Davis MA, Van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis 
PZ, Matrisian L, Bundy LM, Sealy L, et al (2002) A novel role for p120 catenin in E-
cadherin function. J Cell Biol 
Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez 
S & Guerau-de-Arellano M (2015) Novel Markers to Delineate Murine M1 and M2 
Macrophages. PLoS One 10: e0145342 
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, 
Shafi S, Johnson DH, Mitter R, Rosenthal R, et al (2017) Tracking the Evolution of 
Non–Small-Cell Lung Cancer. N Engl J Med 
Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith 
197 
 
A, Beug H & Kraut N (2003) Expression profiling of epithelial plasticity in tumor 
progression. Oncogene 
Jia Y, Ji K, Ji J, Hao C, Ye L, Sanders AJ & Jiang WG (2016) Il24 and its receptors 
regulate growth and migration of pancreatic cancer cells and are potential 
biomarkers for il24 molecular therapy. Anticancer Res 
Jolly MK (2015) Implications of the Hybrid Epithelial/Mesenchymal Phenotype in 
Metastasis. Front Oncol 5 
Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, 
Bapat SA, Rangarajan A & Levine H (2019) Hybrid epithelial/mesenchymal 
phenotypes promote metastasis and therapy resistance across carcinomas. 
Pharmacol Ther 194: 161–184 
Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, 
Ben-Jacob E & Levine H (2016) Stability of the hybrid epithelial/mesenchymal 
phenotype. Oncotarget 7: 27067–27084 
Jolly MK, Ware KE, Gilja S, Somarelli JA & Levine H (2017) EMT and MET: necessary 
or permissive for metastasis? Mol Oncol doi:10.1002/1878-0261.12083 
[PREPRINT] 
Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J & Pollard JW 
(2015) CCL2-induced chemokine cascade promotes breast cancer metastasis by 
enhancing retention of metastasis-associated macrophages. J Exp Med 212: 1043–
1059 
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin A V., Neale RE, Tempero 
M, Tuveson DA, Hruban RH, et al (2016) Pancreatic cancer. Nat Rev Dis Prim 2: 
16022 
Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, Restrepo-Vassalli S, Wang A, 
198 
 
Izadian N, MacKay M, et al (2020) Circulating Tumor Cells Exhibit Metastatic 
Tropism and Reveal Brain Metastasis Drivers. Cancer Discov 10: 86–103 
Klymkowsky MW & Savagner P (2009) Epithelial-mesenchymal transition: A cancer 
researcher’s conceptual friend and foe. Am J Pathol 174: 1588–1593 
doi:10.2353/ajpath.2009.080545 [PREPRINT] 
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton 
LL, Dooling DJ, Ding L, Mardis ER, et al (2012) Comprehensive molecular portraits 
of human breast tumours. Nature 
Kodama T, Koma Y ichiro, Arai N, Kido A, Urakawa N, Nishio M, Shigeoka M & 
Yokozaki H (2020) CCL3–CCR5 axis contributes to progression of esophageal 
squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK 
pathways. Lab Investig 
Kopp JL, Dubois CL, Schaffer AE, Hao E, Shih HP, Seymour PA, Ma J & Sander M 
(2011) Sox9+ ductal cells are multipotent progenitors throughout development but 
do not produce new endocrine cells in the normal or injured adult pancreas. 
Development 
Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, 
Littlewood TD & Evan GI (2017) Myc Cooperates with Ras by Programming 
Inflammation and Immune Suppression. Cell 171: 1301-1315 e14 
Krebs AM, Mitschke J, Losada ML, Schmalhofer O, Boerries M, Busch H, Boettcher M, 
Mougiakakos D, Reichardt W, Bronsert P, et al (2017) The EMT-activator Zeb1 is a 
key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell 
Biol 19: 518–529 
Kröger C, Afeyan A, Mraz J, Eaton EN, Reinhardt F, Khodor YL, Thiru P, Bierie B, Ye X, 
Burge CB, et al (2019) Acquisition of a hybrid E/M state is essential for 
199 
 
tumorigenicity of basal breast cancer cells. Proc Natl Acad Sci 116: 7353–7362 
De La O J-P, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB & Murtaugh LC 
(2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial 
neoplasia. Proc Natl Acad Sci 105: 18907–18912 
Labernadie A, Kato T, Brugués A, Serra-Picamal X, Derzsi S, Arwert E, Weston A, 
González-Tarragó V, Elosegui-Artola A, Albertazzi L, et al (2017) A mechanically 
active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive 
cancer cell invasion. Nat Cell Biol 
Lambert AW, Pattabiraman DR & Weinberg RA (2017) Emerging Biological Principles of 
Metastasis. Cell doi:10.1016/j.cell.2016.11.037 [PREPRINT] 
Lamouille S, Xu J & Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal 
transition. Nat Rev Mol Cell Biol 15: 178–96 
Latil M, Nassar D, Beck B, Boumahdi S, Wang L, Brisebarre A, Dubois C, Nkusi E, 
Lenglez S, Checinska A, et al (2017) Cell-Type-Specific Chromatin States 
Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial 
to Mesenchymal Transition. Cell Stem Cell 20: 191-204.e5 
Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC & Farace F (2011) 
Detection of circulating tumour cells with a hybrid (epithelial/ mesenchymal) 
phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105: 
1338–1341 
Ledford H (2011) Cancer theory faces doubts. Nature 472: 273–273 
Lee CC, Lin JC, Hwang WL, Kuo YJ, Chen HK, Tai SK, Lin CC & Yang MH (2018) 
Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate 
metastatic colonization. Nat Commun 9: 3763 
Lee JD, Silva-Gagliardi NF, Tepass U, McGlade CJ & Anderson K V. (2007) The FERM 
200 
 
protein Epb4.1l5 is required for organization of the neural plate and for the 
epithelial-mesenchymal transition at the primitive streak of the mouse embryo. 
Development 134: 2007–2016 
Lewis BC, Klimstra DS & Varmus HE (2003) The c-myc and PyMT oncogenes induce 
different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev 
17: 3127–3138 
Li B & Dewey CN (2011) RSEM: Accurate transcript quantification from RNA-Seq data 
with or without a reference genome. BMC Bioinformatics 
Li H & Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 25: 1754–1760 
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, 
Rech AJ, et al (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of 
Immune Cell Infiltration and Response to Immunotherapy. Immunity 
Li W & Kang Y (2016) Probing the Fifty Shades of EMT in Metastasis. Trends in Cancer 
doi:10.1016/j.trecan.2016.01.001 [PREPRINT] 
Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, Harper K, 
Tardio E, Reyes Torres I, Jones J, et al (2018) Macrophages orchestrate breast 
cancer early dissemination and metastasis. Nat Commun 9: 21 
Liu X, Huang H, Remmers N & Hollingsworth MA (2014) Loss of E-cadherin and 
epithelial to mesenchymal transition is not required for cell motility in tissues or for 
metastasis. Tissue Barriers 
Liu X & Quan N (2015) Immune Cell Isolation from Mouse Femur Bone Marrow. Bio 
Protoc 5 
Love MI, Huber W & Anders S (2014) Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol 
201 
 
Maddipati R & Stanger BZ (2015) Pancreatic cancer metastases harbor evidence of 
polyclonality. Cancer Discov 5: 1086–1097 
Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, Chatterjee K, Wong 
F, Jiao Y, Kohutek ZA, et al (2017) Limited heterogeneity of known driver gene 
mutations among the metastases of individual patients with pancreatic cancer. Nat 
Genet 49: 358–366 
Mancini M & Toker A (2009) NFAT proteins: emerging roles in cancer progression. Nat 
Rev Cancer 9: 810–820 
McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, 
Carrer A, Salz TH, Natsume S, et al (2017) Epigenomic reprogramming during 
pancreatic cancer progression links anabolic glucose metabolism to distant 
metastasis. Nat Genet 49: 367–376 
McGranahan N & Swanton C (2017) Clonal Heterogeneity and Tumor Evolution: Past, 
Present, and the Future. Cell 168: 613–628 
Mehlen P & Puisieux A (2006) Metastasis: A question of life or death. Nat Rev Cancer 
doi:10.1038/nrc1886 [PREPRINT] 
Miao L, Qi J, Zhao Q, Wu QN, Wei DL, Wei XL, Liu J, Chen J, Zeng ZL, Ju HQ, et al 
(2020) Targeting the STING pathway in tumor-associated macrophages regulates 
innate immune sensing of gastric cancer cells. Theranostics 
Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, Rashid NU, 
Williams LA, Eaton SC, Chung AH, et al (2015) Virtual microdissection identifies 
distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. 
Nat Genet 47: 1168–1178 
Monteith GR, Prevarskaya N & Roberts-Thomson SJ (2017) The calcium–cancer 
signalling nexus. Nat Rev Cancer 17: 373–380 
202 
 
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, 
Carlsson E, Ridderstrale M, Laurila E, et al (2003) PGC-1alpha-responsive genes 
involved in oxidative phosphorylation are coordinately downregulated in human 
diabetes. Nat Genet 34: 267–273 
Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz 
B, Ollinger R, Zwiebel M, Strong A, et al (2018) Evolutionary routes and KRAS 
dosage define pancreatic cancer phenotypes. Nature 554: 62–68 
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, Laing 
S, Kruspig B, Upstill-Goddard R, Shaw R, et al (2020) Repression of the Type I 
Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in 
Pancreatic Ductal Adenocarcinoma. Cancer Discov 
Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, Riggs M, Eberling Y, Troge 
J, Grubor V, et al (2010) Inferring tumor progression from genomic heterogeneity. 
Genome Res 20: 68–80 
Ni T, Li XY, Lu N, An T, Liu ZP, Fu R, Lv WC, Zhang YW, Xu XJ, Grant Rowe R, et al 
(2016) Snail1-dependent p53 repression regulates expansion and activity of 
tumour-initiating cells in breast cancer. Nat Cell Biol 
Nieto MA, Huang RY-J, Jackson RA & Thiery JP (2016a) EMT: 2016. Cell 166: 21–45 
Nieto MA, Huang RYYJ, Jackson RAA & Thiery JPP (2016b) EMT: 2016. Cell 
doi:10.1016/j.cell.2016.06.028 [PREPRINT] 
Norgard RJ & Stanger BZ (2021) Isolation and Identification of EMT Subtypes BT  - The 
Epithelial-to Mesenchymal Transition: Methods and Protocols. In, Campbell K & 
Theveneau E (eds) pp 315–326. New York, NY: Springer US 
Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, 
Liang SB, Brown AM, Kim JC, et al (2016) A renewed model of pancreatic cancer 
203 
 
evolution based on genomic rearrangement patterns. Nature 538: 378–382 
Nowell PC (1976) The clonal evolution of tumor cell populations. Science (80- ) 
Ocaña OH, Córcoles R, Fabra Á, Moreno-Bueno G, Acloque H, Vega S, Barrallo-
Gimeno A, Cano A & Nieto MA (2012) Metastatic Colonization Requires the 
Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. Cancer Cell 22: 
709–724 
Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van 
Keymeulen A, Brown D, Moers V, Lemaire S, et al (2018) Identification of the 
tumour transition states occurring during EMT. Nature 
Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, Impens F, Van 
Haver D, Opitz M, Thery M, et al (2020) Fat1 deletion promotes hybrid EMT state, 
tumour stemness and metastasis. Nature 
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, 
Gorin MA, Deville C, et al (2020) Outcomes of Observation vs Stereotactic Ablative 
Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized 
Clinical Trial. JAMA Oncol 
Pieters T, Van Roy F & Van Hengel J (2012) Functions of p120ctn isoforms in cell-cell 
adhesion and intracellular signaling. Front Biosci 
Pitroda SP & Weichselbaum RR (2019) Integrated molecular and clinical staging defines 
the spectrum of metastatic cancer. Nat Rev Clin Oncol doi:10.1038/s41571-019-
0220-6 [PREPRINT] 
Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, Auffray C, 
Albrengues J, Egeblad M, Iacobuzio-Donahue CA, et al (2018) Unresolved 
endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer 
metastases. Science (80- ) 360 
204 
 
Puram S V., Parikh AS & Tirosh I (2018) Single cell RNA-seq highlights a role for a 
partial EMT in head and neck cancer. Mol Cell Oncol 
Puram S V., Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, 
Mroz EA, Emerick KS, et al (2017) Single-Cell Transcriptomic Analysis of Primary 
and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell 171: 1611-
1624.e24 
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA & 
Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour 
metastasis. Nature 475: 222–225 
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM & Matrisian LM (2014) 
Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, 
liver, and pancreas cancers in the united states. Cancer Res 74: 2913–2921 
doi:10.1158/0008-5472.CAN-14-0155 [PREPRINT] 
Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro 
I & Potapenko T (2009) Myc is a metastasis gene for non-small-cell lung cancer. 
PLoS One 
Reichert M, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati 
R, Rhim AD, Schlitter AM, et al (2018) Regulation of Epithelial Plasticity Determines 
Metastatic Organotropism in Pancreatic Cancer. Dev Cell 
Revenu C & Gilmour D (2009) EMT 2.0: shaping epithelia through collective migration. 
Curr Opin Genet Dev doi:10.1016/j.gde.2009.04.007 [PREPRINT] 
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, 
Rustgi AK, Vonderheide RH, et al (2012) EMT and dissemination precede 
pancreatic tumor formation. Cell 148: 349–361 
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W & Smyth GK (2015) limma powers 
205 
 
differential expression analyses for RNA-sequencing and microarray studies. 
Nucleic Acids Res 43: e47 
Roderick HL & Cook SJ (2008) Ca2+ signalling checkpoints in cancer: remodelling Ca2+ 
for cancer cell proliferation and survival. Nat Rev Cancer 8: 361–375 
Roh-Johnson M, Bravo-Cordero JJ, Patsialou A, Sharma VP, Guo P, Liu H, Hodgson L 
& Condeelis J (2014) Macrophage contact induces RhoA GTPase signaling to 
trigger tumor cell intravasation. Oncogene 33: 4203–4212 
Ryan DP, Hong TS & Bardeesy N (2014) Pancreatic Adenocarcinoma. N Engl J Med 35: 
353–354 
Savagner P (2001) Leaving the neighborhood: Molecular mechanisms involved during 
epithelial-mesenchymal transition. BioEssays doi:10.1002/bies.1132 [PREPRINT] 
Savagner P (2015) Epithelial-mesenchymal transitions: From cell plasticity to concept 
elasticity. In Current Topics in Developmental Biology 
Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, 
Zhang X, Ventura A, Liu Y, et al (2018) Pan-cancer Alterations of the MYC 
Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6: 
282-300 e2 
Schuller HM & Al-Wadei HA (2010) Neurotransmitter receptors as central regulators of 
pancreatic cancer. Future Oncol doi:10.2217/fon.09.171 [PREPRINT] 
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, 
D’Andrea MR, Chukwueke U, et al (2020) Genomic characterization of human brain 
metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet 52: 
371–377 
Singh SK, Chen N-M, Hessmann E, Siveke J, Lahmann M, Singh G, Voelker N, Vogt S, 
Esposito I, Schmidt A, et al (2015) Antithetical NFATc1-Sox2 and p53-miR200 
206 
 
signaling networks govern pancreatic cancer cell plasticity. EMBO J 34: 517–30 
Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, 
Barker N, Klein AM, van Rheenen J, Simons BD, et al (2010) Intestinal crypt 
homeostasis results from neutral competition between symmetrically dividing Lgr5 
stem cells. Cell 143: 134–144 
Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, Anastasiou 
P, Swigart LB, Soucek L, Arends MJ, et al (2020) MYC Instructs and Maintains 
Pancreatic Adenocarcinoma Phenotype. Cancer Discov 10: 588–607 
Song S, Eckerle S, Onichtchouk D, Marrs JA, Nitschke R & Driever W (2013) Pou5f1-
Dependent EGF Expression Controls E-Cadherin Endocytosis, Cell Adhesion, and 
Zebrafish Epiboly Movements. Dev Cell 24: 486–507 
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van 
De Rijn M, Jeffrey SS, et al (2001) Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 
Stairs DB, Bayne LJ, Rhoades B, Vega ME, Waldron TJ, Kalabis J, Klein-Szanto A, Lee 
JS, Katz JP, Diehl JA, et al (2011) Deletion of p120-Catenin Results in a Tumor 
Microenvironment with Inflammation and Cancer that Establishes It as a Tumor 
Suppressor Gene. Cancer Cell 
Steeg PS (2006) Tumor metastasis: Mechanistic insights and clinical challenges. Nat 
Med doi:10.1038/nm1469 [PREPRINT] 
Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson 
S, McDaid K, Wilson Z, et al (2016) CXCR2 Inhibition Profoundly Suppresses 
Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. 
Cancer Cell 29: 832–845 
Stemmler MP, Eccles RL, Brabletz S & Brabletz T (2019) Non-redundant functions of 
207 
 
EMT transcription factors. Nat Cell Biol doi:10.1038/s41556-018-0196-y 
[PREPRINT] 
Stewart TA, Yapa KTDS & Monteith GR (2015) Altered calcium signaling in cancer cells. 
Biochim Biophys Acta - Biomembr 1848: 2502–2511 
Subbalakshmi AR, Kundnani D, Biswas K, Ghosh A, Hanash SM, Tripathi SC & Jolly MK 
(2020) NFATc Acts as a Non-Canonical Phenotypic Stability Factor for a Hybrid 
Epithelial/Mesenchymal Phenotype   . Front Oncol   10: 1794 
(https://www.frontiersin.org/article/10.3389/fonc.2020.553342) [PREPRINT] 
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich 
A, Pomeroy SL, Golub TR, Lander ES, et al (2005) Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci U S A 102: 15545–15550 
Tam WL & Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in 
cancer. Nat Med 19: 1438–49 
Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 
65: 5996–6000 doi:10.1158/0008-5472.CAN-05-0699 [PREPRINT] 
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP & Chouaib S 
(2017) New insights into the role of EMT in tumor immune escape. Mol Oncol 
doi:10.1002/1878-0261.12093 [PREPRINT] 
Tran HD, Luitel K, Kim M, Zhang K, Longmore GD & Tran DD (2014) Transient SNAIL1 
expression is necessary for metastatic competence in breast cancer. Cancer Res 
74: 6330–6340 
Tsai JH, Donaher JL, Murphy DA, Chau S & Yang J (2012) Spatiotemporal Regulation of 
Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma 
Metastasis. Cancer Cell 22: 725–736 
208 
 
Turajlic S, Sottoriva A, Graham T & Swanton C (2019) Resolving genetic heterogeneity 
in cancer. Nat Rev Genet 20: 404–416 
Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O’Brien T, Larkin 
J, Horswell S, et al (2018) Tracking Cancer Evolution Reveals Constrained Routes 
to Metastases: TRACERx Renal. Cell 173: 581-594 e12 
Vaqué JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant 
A, Seeger MA, Ksander BR, Teramoto H, et al (2013) A Genome-wide RNAi 
Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic 
Signals Initiated by G Protein-Coupled Receptors. Mol Cell 49: 94–108 
Vaseva A V, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, 
Gautam P, Bryant KL, Pearce KH, et al (2018) KRAS Suppression-Induced 
Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. 
Cancer Cell 34: 807-822 e7 
Venkatraman ES & Olshen AB (2007) A faster circular binary segmentation algorithm for 
the analysis of array CGH data. Bioinformatics 23: 657–663 
Villalobo A & Berchtold MW (2020) The Role of Calmodulin in Tumor Cell Migration, 
Invasiveness, and Metastasis. Int J Mol Sci 21: 765 
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, 
Nones K, Quek K, et al (2015) Whole genomes redefine the mutational landscape 
of pancreatic cancer. Nature 518: 495–501 
Wang J, Wei Q, Wang X, Tang S, Liu H, Zhang F, Mohammed MK, Huang J, Guo D, Lu 
M, et al (2016) Transition to resistance: An unexpected role of the EMT in cancer 
chemoresistance. Genes Dis doi:10.1016/j.gendis.2016.01.002 [PREPRINT] 
Wang M, Huang J, Liu Y, Ma L, Potash JB & Han S (2017) COMBAT: A Combined 
Association Test for Genes Using Summary Statistics. Genetics 207: 883–891 
209 
 
Wculek SK & Malanchi I (2015) Neutrophils support lung colonization of metastasis-
initiating breast cancer cells. Nature 
Weichselbaum RR & Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 
doi:10.1038/nrclinonc.2011.44 [PREPRINT] 
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, 
Kavanagh BD, Doebele RC, et al (2012) Local ablative therapy of oligoprogressive 
disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted 
non-small-cell lung cancer. J Thorac Oncol 
Welch DR & Hurst DR (2019) Defining the Hallmarks of Metastasis. Cancer Res: 3011–
3028 
Westcott JM, Prechtl AM, Maine EA, Dang TT, Esparza MA, Sun H, Zhou Y, Xie Y & 
Pearson GW (2015) An epigenetically distinct breast cancer cell subpopulation 
promotes collective invasion. J Clin Invest 
Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, 
Ormanns S, Nagar K, Tailor Y, et al (2016) Dclk1 Defines Quiescent Pancreatic 
Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell 
Stem Cell 
Wolfer A & Ramaswamy S (2011) MYC and metastasis. Cancer Res doi:10.1158/0008-
5472.CAN-10-3776 [PREPRINT] 
Wu SY & McClay DR (2007) The Snail repressor is required for PMC ingression in the 
sea urchin embryo. Development 
Xu J, Lamouille S & Derynck R (2009) TGF-Β-induced epithelial to mesenchymal 
transition. Cell Res 19: 156–172 doi:10.1038/cr.2009.5 [PREPRINT] 
Xu Y, Lee DK, Feng Z, Xu Y, Bu W, Li Y, Liao L & Xu J (2017) Breast tumor cell-specific 
knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis 
210 
 
in mice. Proc Natl Acad Sci U S A 
Yachida S & Iacobuzio-Donahue CA (2009) The pathology and genetics of metastatic 
pancreatic cancer. Arch Pathol Lab Med 133: 413–422 
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, 
Casanova J, Christofori G, et al (2020) Guidelines and definitions for research on 
epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 21: 341–352 
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, 
Gitelman I, Richardson A & Weinberg RA (2004) Twist, a master regulator of 
morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927–939 
Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E & Weinberg RA (2015) 
Distinct EMT programs control normal mammary stem cells and tumour-initiating 
cells. Nature 525: 256–260 
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells 
MN, Shah AM, et al (2013) Circulating breast tumor cells exhibit dynamic changes 
in epithelial and mesenchymal composition. Science (80- ) 339: 580–584 
Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu N V., Yamazoe T, Lin JH, Merrell 
AJ, Sela Y, Thomas SK, et al (2020) Global Regulation of the Histone Mark 
H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer 
Discov 10: 854–871 
Yuan S, Norgard RJ & Stanger BZ (2019) Cellular Plasticity in Cancer. Cancer Discov 9: 
837–851 
Zavadil J & Böttinger EP (2005) TGF-β and epithelial-to-mesenchymal transitions. 
Oncogene doi:10.1038/sj.onc.1208927 [PREPRINT] 
Zhang Y & Weinberg RA (2018) Epithelial-to-mesenchymal transition in cancer: 
complexity and opportunities. Front Med 12: 361–373 
211 
 
Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL 
& Townsend JP (2016) Early and multiple origins of metastatic lineages within 
primary tumors. Proc Natl Acad Sci U S A 113: 2140–2145 
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu C-C, LeBleu VS & 
Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis 
but induces chemoresistance in pancreatic cancer. Nature 527: 525–530 
Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, 
Bearden AR, Lavine KJ, et al (2017) Tissue-Resident Macrophages in Pancreatic 
Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote 
Tumor Progression. Immunity 47: 323-338 e6 
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, 
Goedegebuure SP, Linehan DC & DeNardo DG (2014) CSF1/CSF1R blockade 
reprograms tumor-infiltrating macrophages and improves response to T-cell 
checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74: 5057–
5069 
Zohn IE, Li Y, Skolnik EY, Anderson K V., Han J & Niswander L (2006) p38 and a p38-
Interacting Protein Are Critical for Downregulation of E-Cadherin during Mouse 







The following manuscripts are discussed in this thesis: 
 
Yuan S*, Norgard RJ*, and Stanger BZ. Cellular Plasticity in Cancer. Cancer Discovery. 2018. 
 
Aiello NM*, Maddipati R*, Norgard RJ*, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, 
Furth EE, Bar-Sagi D, Stanger BZ. EMT Subtype Influences Epithelial Plasticity and Mode of Cell 
Migration. Dev Cell. 2018 
 
Norgard RJ*, Pitarresi JR*, Maddipati R, Aiello-Couzo NM, Balli D, Li J, Yamazoe T, Wengyn MD, 
Millstein ID, Folkert IW, Rosario-Berrios DN, Payne R, Berrt CT, Fend X, Sun K, Cioffi M, 
Chakraborty P, Jolly MK, Gutkind JS, Lyden D, Freedman BD, Foskett JK, Rustgi AK, Stanger BZ. 
Calcium signaling induces a partial EMT. In revision EMBO reports. 2021. 
 
Maddipati R*, Norgard RJ*, Baslan T*, Rathi KS, Zhang A, Ramen P, Wengyn MD, Yamazoe T, 
Li J, Balli D, LaRiviere MJ, Folkert IW, Millstein ID, Bermeo J, Carpenter EL, Lowe S, Iacobuzio-
Donahue C, Notta F, Stanger BZ. Metastatic proclivity in pancreas cancer is governed by Myc 
mediated regulation to the tumor immune microenvironment. In submission Cancer Cell. 2021. 
 
Norgard RJ, Stanger BZ. Isolation and Identification of EMT Subtypes. In: Campbell K., 
Theveneau E. (eds) The Epithelial-to Mesenchymal Transition. Methods in Molecular Biology, 
vol 2179. 2021. 
 
* Co-first authors 
